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SUMMARY 
 
Elastic fibres are important components of the extracellular matrices, being composed 
of an elastin core and fibrillin-microfibrils around the periphery. Elastic fibre formation is a 
complex developmentally regulated process whereby fibrillin-microfibrils act as templates 
for the deposition of elastin. Additional matrix macromolecules, including fibulin-4, fibulin-5 
and as yet unidentified heparan sulphate proteoglycans (HSPGs), have also been identified as 
playing important roles in this process.  
  Fibrillins-1, -2, -3 and latent transforming growth factor-β binding protein (LTBP)-1, 
-2, -3, -4, associated components of fibrillin-microfibrils, make up a superfamily of 
extracellular matrix proteins. Fibrillins and LTBPs share a high degree of structural similarity 
since they both have rod-like structures of tandem EGF-like 6-cysteine repeats interspersed 
with unique 8-cysteine motifs. LTBP-1, -3 and -4 covalently bind TGF-β and target and store 
the latent growth factor in the matrix. Unlike the other LTBPs, LTBP-2 does not bind latent 
TGF-β and its function is poorly understood. LTBP-2 has been shown to bind fibulin-5, an 
elastin-binding protein and through this interaction it may target tropoelastin-fibulin-5 
complexes on to fibrillin-1-microfibrils during elastic fibre assembly. In order to understand 
more about the role of LTBP-2 in the assembly of elastic fibres and to identify other novel 
functions, this study involved screening for potential molecular interactions of LTBP-2 with 
other matrix components, particularly heparin/HSPGs. In elastic tissues HSPGs are found on 
cell surfaces as syndecans and glypicans and in basement membranes as perlecan. 
  Full length human recombinant LTBP-2 (rLTBP-2) was expressed in 293 EBNA cells 
using a modified pCEP-4 vector and purified by nickel affinity chromatography. Upon 
validation of the purified protein using western blots, solid phase binding assays were used to 
screen for interaction between rLTBP-2 and heparin. Heparin serves as a useful model for 
heparan sulphate; due to the lack of adherence of heparin to microtitre plates heparin-BSA 
conjugate was synthesised and purified for the binding assays. Recombinant LTBP-2 was 
found to interact with heparin-BSA conjugates using an established solid phase binding assay. 
The binding was blocked by the addition of heparin (but not chondroitin sulphate) to the 
liquid phase, confirming the specificity of the interaction. Furthermore, the binding was 
blocked by the addition of 5mM EDTA and 5mM EGTA, showing that the interaction was 
cation (calcium) dependent. An apparent Kd of 14.5±3.7nM was calculated from non-linear 
regression analysis of the LTBP-2-heparin binding curve, indicating a strong affinity. To 
identify the location of the heparin binding site(s) on LTBP-2, expression constructs were 
produced encoding three fragments of LTBP-2, i.e. rLTBP-2NT(H), rLTBP-2C(H) and 
rLTBP-2CT(H), corresponding to the N-terminal, central and C-terminal regions of the  
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molecule. Good yields of rLTBP-2C(H) were obtained using the pCEP4-293-EBNA system, 
and rLTBP-2CT(H) was previously expressed and purified by members of the Gibson 
laboratory. However, difficulties were encountered with the rLTBP-2NT(H) expression 
construct and no LTBP-2NT(H) was available during the candidature. The central fragment 
LTBP-2C(H), (but not the C-terminal fragment  LTBP-2CT(H)), was found to bind heparin. 
However, the apparent Kd of 52.2±6.9nM was significantly higher than that for full length 
LTBP-2, indicating that LTBP-2C(H) had relatively lower heparin-binding affinity. This 
result suggested that an additional heparin binding site(s) is present in the N-terminal region 
of the molecule. 
It was considered that the true tissue ligand(s) for LTBP-2 would be a HSPG rather 
than heparin. Therefore, LTBP-2 was screened for interaction with HSPGs, recombinant 
syndecans-2 and -4, and endothelial cell-derived perlecan. Interestingly, LTBP-2 bound 
strongly to r-syndecan-4 but not r-syndecan-2 even though both molecules were produced in 
the same mammalian cell system and had been screened for binding to HS-binding growth 
factor, fibroblast growth factor-2. This finding indicates that LTBP-2 does not interact with 
all HS and must recognise specific microstructures within the heparan sulphate chains. It 
appears that syndecan-4 is now a strong candidate as mediator of LTBP-2-cell signalling. 
LTBP-2 was also found to specifically interact with perlecan in a cation-dependent, heparin-
inhibitable manner. Confocal immunohistochemical studies using foetal human aorta showed 
that LTBP-2 and perlecan generally had distinct distribution patterns within the medial layer, 
located on fibrillin-microfibrils and basement membranes respectively. However, there were 
small but widespread regions of LTBP-2-perlecan colocalisation which showed a similar 
pattern to the fibrillin-1-perlecan colocalisation. Thus it would appear that LTBP-2 is present 
at microfibril-basement membrane interfaces and may be involved in stabilising the 
interaction between these two structural elements of the matrix. This concept needs to be 
confirmed at the ultrastructural level. The interaction of LTBP-2 with perlecan during 
embryonic development is also worthy of investigation. 
  In parallel studies, a proteomic approach was used to identify other matrix binding 
proteins for LTBP-2. This was carried out in parallel with another matrix protein of poorly 
defined function, transforming growth factor-beta-inducible gene-h3 (βig-h3). Recombinant 
LTBP-2 and βig-h3 coupled to sepharose were used as bait proteins to screen complex 
mixtures of matrix proteins from the elastic tissue nuchal ligament and basement membrane 
preparation Matrigel. Initial studies showed that non-specific background binding to these 
proteins was a major problem. In efforts to overcome this difficulty, binding conditions were 
varied with limited success. A two-dimensional gel approach was used to fractionate and 
compare proteins binding to LTBP-2 with those binding to βig-h3. The differentially- 
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displayed protein spots were to be identified by mass spectrometry. However, complications 
in comparing the patterns on two separate gels made identification of candidate spots 
challenging. Finally, CyDye DIGE fluor dyes were used to fractionate proteins binding to 
LTBP-2 and βig-h3 on the same gel, but unfortunately this work could not be completed in 
the time frame of the candidature.  
  




1.1 Extracellular Matrix 
The extracellular matrix (ECM) is a complex structural entity that surrounds and 
supports cells that are found within tissues. This ECM is composed of collagens (Wess, 2005), 
elastin (Mithieux and Weiss, 2005), proteoglycans (PGs) (Hocking et al., 1998) and 
glycoproteins (Mark, 2002) that include fibrillins, fibronectin, laminins, as well as 
thrombospondin, tenascin and vitronectin. These components are organised into a meshwork 
that provides mechanical strength and elasticity to mammalian tissues and also creates a 
structural framework for cell adhesion and migration. In addition, there are also specialised 
extracellular matrices that can create barriers for cell penetration and also filtration of 
macromolecules (Hocking et al., 1998). The ECM is not an inert structure; it is an 
environment in which there is extensive interplay between the resident cells, structural 
proteins, growth factors and cytokines and numerous cell surface receptors. It has been shown 
that there is signalling of one form or another that operates in a bi-directional manner in the 
ECM and examples of this occur in both normal and disease processes (Hocking et al., 1998). 
 
1.1.1 Collagens 
Collagens are major components of the ECM, and the most abundant proteins found in 
the body. There are at least 26 different types of collagens described in vertebrates thus far 
that have distinct properties in the matrix. Structurally, collagens are triple helical structures 
formed by three extended protein chains that wrap around one another. The sequence of these 
protein chains consists predominately of repeats of G-X-Y (Ottani et al., 2002), where the 
first position of the repeat is glycine, and the second and third positions of the repeat can be 
any residues but are frequently proline and hydroxyproline (Kielty, 2002).  
Fibrous collagens are synthesised as precursor proteins called procollagens. The 
procollagen begins to assemble in the endoplasmic reticulum and golgi complexes of 
fibroblasts cells and some epithelial cells, where they undergo numerous modifications. For 
example, the specific proline residues in the procollagen molecule are hydroxylated by prolyl-
4-hydroxylase and prolyl-3-hydroxylase, and the specific lysine residues are hydroxylated by 
lysyl hydroxylase. Glycosylation of the hydroxylysine residues within the triple helix also 
occurs by two enzymes in the rough endoplasmic reticulum (Kielty, 2002). 
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Following the completion of this process, the procollagens are secreted into the 
extracellular space where they undergo further modification before the collagen molecules 
polymerise to form collagen fibrils (Kielty, 2002). 
Collagens are major components of skin, ligament, bone, cartilage, tendon, lung and 
teeth. The most distinctive characteristic feature of collagen is the formation of rigid 
structures to withstand mechanical force. In the matrix, the distribution and the orientation of 
collagen reflects the function of the tissue in which it is found. For example, collagen 
transmits tension in the tendon by running parallel to the axis, lends structural support in skin 
by forming interlaced and branched structures, while in bone it mineralises to provide tensile 
strength and in the arteries it limits the expansion of the walls. Alterations in the stability of 
the triple helical structure of collagens resulting from missense mutations can lead to a range 
of heritable connective tissue disorders. For example, osteogenesis imperfecta results from 
mutations in type I collagen, Ehlers-Danlos syndrome type IV from mutations in type III 
collagen, Alport syndrome from mutations in type IV collagen, and Dystrophic epidermolysis 
bullosa from mutations in type VII collagen (Masse et al., 2005). However, instability of the 
collagen structures is not the only way that collagens contribute to the pathogenesis of 
connective tissue disorders. There is evidence that mRNA levels of collagen I and collagen II 
are increased during progression of osteoarthritis, suggesting the involvement of both 
collagens in the development of osteoarthritis (Miosge et al., 2004). In addition, structural 
remodelling of the left atrial tissue due to increased concentration of collagen I and III has 
been shown to be responsible in part for the pathogenesis of human arterial fibrillation (Boldt 
et al., 2004). 
 
1.1.2 Elastin and Elastic fibres 
In tissues such as large arteries and lung parenchyma where both strength and 
extensibility are necessary for proper functioning, collagen fibres are accompanied by elastic 
fibres in the ECM. This allows the tissue to stretch and recoil without damage (Mecham, 
1994). The elastic fibres are composed of two distinct parts, one being an abundant 
amorphous core component, elastin, which is surrounded by a sheet of fibrillin-rich 
microfibrils (Cleary, 1996; Kielty et al., 2002; Robb et al., 1999). Elastin in turn is 
synthesised as a soluble precursor tropoelastin. The tropoelastin molecule is composed of two 
main domain types; hydrophilic and hydrophobic domains (Miao et al., 2005; Mithieux and 
Weiss, 2005). The hydrophobic domains are rich in the non-polar residues glycine, valine and 
proline, which typically occur in repeating motifs. There have been suggestions that these 
domains are responsible for the self-assembly properties of elastin and for its elastomeric 
properties (Miao et al., 2003; Miao et al., 2005). Alternating with these domains are  
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hydrophilic regions which are rich in alanine and contain lysine residues which are destined 
to be involved in formation of covalent cross-links. Cross-linking is initiated by the 
extracellular enzymes lysyl oxidase which catalyses the oxidative deamination of lysyl ε-
amino groups. This allows the modified groups in the tropoelastin molecule to participate in 
covalent linkages that form the functional polymer. The cross-linking of tropoelastin is 
essential for stability and insolubility of the protein.  
Tropoelastin is initially secreted primarily from vascular smooth muscle cells and 
fibroblasts and it has been proposed that tropoelastin is chaperoned to the cell surface by 
elastin binding protein (Hinek et al., 2004). Secreted tropoelastin monomers then self-
aggregate via coacervation, a process that aligns and concentrates the protein into quantised 
spheres prior to cross-linking (Clarke et al., 2006; Vrhovski et al., 1997). Coacervation is an 
important prerequisite for cross-linking (Narayanan et al., 1978). The coacervate package 
remains attached to the cell surface possibly by binding to integrins, glycosaminoglycans 
(GAG) on cell surfaces, and non-integrin proteins (Broekelmann et al., 2005), which are then 
released on to the preformed fibrillin-microfibrils. Finally, lysyl oxidase promotes covalent 
cross-links of tropoelastin molecules to form mature elastic fibres. 
Elastogenesis in tissues involves a far more complex biochemical mechanism. This 
process involves the association of multiple extracellular proteins including fibulin-5, for 
directing elastin onto the microfibrils (Hirai et al., 2007; Nakamura et al., 2002; Yanagisawa 
et al., 2002; Zheng et al., 2007) and fibulin-4 which is important for the cross-linking of 
elastin by lysyl oxidase (McLaughlin et al., 2006). Recent studies have demonstrated that 
fibulin-4 interaction with lysyl oxidase enhances formation of a ternary complex with 
tropoelastin (Choudhury et al., 2009). The ability of microfibrillar-associated glycoprotein 
(MAGP)-1 to interact with tropoelastin (Brown-Augsburger et al., 1994; Jensen et al., 2001) 
and fibrillin-1 (Brown-Augsburger et al., 1994; Trask et al., 2000a), suggests that MAGP-1 
may serve as a bridging molecule between the two elastic fibre components during the 
assembly of elastic fibres. However, the involvement of MAGP-1 is not crucial for elastic 
fibre assembly as elastic fibre assembly is normal in mice lacking MAGP-1 (Wagenseil and 
Mecham, 2007).  
Several models have been proposed for the assembly of elastic fibres. One such 
model involves the self-aggregated tropoelastin on the cell surface interacting with fibulin-4 
to aid in the cross-linking of these aggregates by lysyl oxidase (McLaughlin et al., 2006). The 
aggregates stay attached to the surface of cells long enough for newly secreted tropoelastin to 
be added to the aggregates. The larger aggregates collected by cells are then transferred onto 
pre-existing fibrillin-microfibrils. The deposition of elastin aggregates on microfibrils is 
facilitated by fibulin-5, which is present on the microfibrils. The elastin aggregates on the  
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microfibrils come together to form larger structures and are further cross-linked by lysyl 
oxidase to form mature elastic fibre (Choudhury et al., 2009; Hirai et al., 2007; Wagenseil 
and Mecham, 2007).  
It has long been assumed that microfibrils provide a scaffold for elastin assembly 
before it is displaced to the periphery of the growing fibre (Cleary and Gibson, 1983; 
Mecham, 1994; Midwood and Schwarzbauer, 2002). Microfibrils are complex structures 
composed primarily of fibrillins, described in more detail in section 1.2.2.1. 
Mutations within the elastin gene cause several elastinopathies in humans. An 
example is the autosomal dominant cutis laxa (OMIM# 123700), characterised by lax skin 
due to markedly reduced elastin content of the dermis (Milewicz et al., 2000). The majority 
of elastin mutations associated with this disease are single nucleotide deletions near the 3’end 
of the gene (Urban et al., 2005; Zhang et al., 1999). These mutations result in a missense 
sequence that leads to alterations at the C-terminus of the tropoelastin molecule and thus 
interferes with deposition of normal elastin in dominant negative fashion (Milewicz et al., 
2000). In contrast to the dominant negative mutation typical of cutis laxa, supravalvular 
aortic stenosis  (OMIM# 185500) results from a loss of function mutation that produces 
haploinsufficiency of the ELN gene. Supravalvular aortic stenosis is characterised by 
narrowing of the ascending aorta and other blood vessels (Dridi et al., 2005). Supravalvular 
aortic stenosis occurs sporadically or as a familial condition with autosomal dominant traits 
(Curran et al., 1993; Eisenberg et al., 1964; Ewart et al., 1993; Olson et al., 1993). There 
have been more than 50 different mutations identified which lead to supravalvular aortic 
stenosis (Ewart et al., 1994; Ewart et al., 1993; Li et al., 1997; Metcalfe et al., 2000; Urban et 
al., 2000; Urban et al., 2001). It has been reported that abnormal deposition of elastin in 
arterial walls of patients with supravalvular aortic stenosis leads to increased proliferation of 
arterial smooth muscle cells which results in the formation of hyperplastic intimal lesions. 
This is in accordance with studies of mice hemizygous for the elastin gene, which showed 
50% thinner elastic lamellae, with additional lamellar units in the aortae of hemizygous mice 
compared to wildtype mice (Li et al., 1998b). These findings indicate that reduced levels of 
elastin mRNA result in the formation of abnormal elastic fibres which in turn lead to an 
increase in the number of individual lamellae deposited in the aortae during development (Li 
et al., 1998b). These hemizygous mice also display altered aging processes in the aorta, 
signalling that the early elastin arrangement determines the way the vessel evolves (Pezet et 
al., 2008). 
Elastin null mice generated by Li et al., (1998a) have highlighted the importance of 
elastin in development and provided a possible mechanism by which absent or damaged 
elastin may contribute to the pathogenesis of not only the inheritable disorders, but the more  
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common disorders such as atherosclerosis. Elastin deficient mice have been shown to be 
viable, but die within the first week after birth, due to subendothelial accumulation of 
proliferating smooth muscle cells that eventually obliterate the vascular lumen (Li et al., 
1998a). Similar reduction in luminal diameter in the systemic and pulmonary arteries of 
elastin null mice has also been detected. The results of the null mice studies therefore 
suggested that cell proliferation is promoted by the absence of elastin, raising the possibility 
that disruption of elastin by endothelial injury, thrombosis, or inflammation may contribute to 
obstructive arterial pathology by altering the proliferation rate of vascular cells at the site of 
injury (Dietz and Mecham, 2000). 
In addition to hereditary defects of elastin, uncontrolled protease activity causing 
destruction of elastin has been implicated in the manifestation of several disease states 
including emphysema, rheumatoid 
arthritis, cystic fibrosis, and aortic 
rupture (Hu et al., 2006).  
 
1.1.3 Proteoglycans 
Proteoglycans (PGs) are 
synthesised by most cells and are 
abundant components of the ECM, 
basement membrane (BM) and cell 
surfaces (Gallagher, 1989; Perrimon 
and Bernfield, 2001; Staprans et al., 
1986). They are primarily composed 
of a protein core to which GAGs 
chains are covalently attached 
(figure 1.1). GAG chains are 
negatively charged, long, 
unbranched polysaccharides 
containing repeating disaccharide 
units of either of two modified 
sugars, N-acetylgalactosamine 
(GalNAc) or N-acetylglucosamine 
(GlcNAc), and an uronic acid, 
glucuronate or iduronate (figure 
1.1). The specific GAGs of physiological significance are hyaluronic acid, dermatan sulphate, 
chondroitin sulphate (CS), heparin, heparan sulphate (HS) and keratan sulphate. HS, CS and 
Figure 1.1. Structure of glycosaminoglycans 
(GAGs) and proteoglycans (PGs). Heparan 
sulphate (HS), chondroitin sulphate (CS) and 
dermatan sulphate GAG side chains are linked to 
a protein core via a serine residue. Hyaluronic 
acid is not covalently linked to a PG, but 
synthesised directly into the extracellular space. 
HS, CS and DS are assembled via a serine residue 
to a PG backbone. Diagram taken from Taylor and 
Gallo (2006).        
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dermatan sulphate are assembled via a serine residue to the protein cores, defining them as 
PGs. Due to the differences in the basic carbohydrate backbone of the GAG chain, the length 
of the chains and the subsequent modifications in sulphation pattern, deacetylation and 
epimerisation of the chains, great diversity in GAG chains can be achieved. These 
modifications are also the factors that provide for the specific activities of the PG molecules 
(Taylor and Gallo, 2006). In particular in HS, CS and dermatan sulphate sulphation plays an 
important role in the GAG chain activity. The exception is hyaluronic acid, which is not 
sulphated and is not attached to a core protein. GAGs play important roles in biological 
processes such as in cell signalling and development (Hacker et al., 2005; Lin, 2004), 
angiogenesis (Iozzo and San Antonio, 2001), axonal growth (Chung et al., 2000), tumour 
progression (Breborowicz et al., 1996; Breborowicz et al., 1998), metastasis (Breborowicz et 
al., 1998; Teder et al., 2002) and anti-coagulation (Haslinger et al., 2001; McKee et al., 
1996). Heparin and heparan sulphate proteoglycans (HSPGs) have recently been shown to be 
critical for fibrillin-microfibril assembly (Ritty et al., 2003a; Tiedemann et al., 2001). 
However, their precise roles are as yet not clear. HS is composed of a repeated disaccharide 
structure (-4-glucuronic acid-β1-4-N-acetylglucosamine-α1-)n, which is modified in varying 
degrees by N-deacetylation and N-sulphation of the glucosamine, epimerisation of the D-
glucuronic acid to L-iduronic acid, and also by additional O-sulphation on both sugars 
(Sasisekharan et al., 2006). Structurally, what makes heparin distinct from HS is that heparin 
is more heavily modified (table 1.1), although HS can contain heparin-like regions (Taylor 
and Gallo, 2006). Heparin is less abundant in vivo, and is synthesised by, and stored 
primarily in, mast cells (Forsberg et al., 1999; Humphries et al., 1999; Rose and Page, 2004). 
HS, on the other hand, is more ubiquitously found on cell surfaces and in the ECM as part of 
a PG.  
There are essentially three broad classes of HSPGs: (1) those that are secreted by cells 
and located in the ECM, e.g. perlecan, agrin, collagen type XVIII, (2) those associated with 
the cell membrane, such as glypicans, a family of six HSPGs, which are linked to the cell 
surface via glycosylphosphatidyl inositol anchors and (3) the transmembrane HSPGs, e.g. the 
syndecan family, consisting of four members (Beauvais and Rapraeger, 2004). A component 
of this project is to further define the role of HS-side chains of HSPGs in the assembly of 
elastic fibres, as well as to verify potential roles independent of elastic fibres for the 
candidate HSPGs in elastic tissues. Two of the HSPGs, and possible candidates, are 
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Table 1.1. Key differences between heparan sulphate and heparin. Table taken and modified 
from Gandhi and Ricardo, (2008). 
 
1.1.3.1 Perlecan 
Perlecan is one of the major components of BM together with collagen IV, laminin 
and nidogen (Timpl and Brown, 1996). BMs are thin amorphous sheets of specialised ECM 
that form a close association with adjacent cells and can affect their survival, migration, 
proliferation and differentiation. They compartmentalise tissues, providing a barrier that 
allows the filtration of macromolecules while preserving tissue architecture (Miner et al., 
2004; Yurchenco et al., 2004). BMs are the first ECM made during embryogenesis, first 
occurring at embryonic day (E)-3. 
The complete sequence of perlecan was determined from a human colon cDNA 
library (Cohen et al., 1993; Dodge et al., 1991) and is encoded by the HSPG2 gene 
(Arikawa-Hirasawa et al., 2002; Cohen et al., 1993). Perlecan is a large HSPG (figure 1.2) 
with a mature core protein of approximately 467 kDa. When including the numerous post 
translational modifications, such as six potential GAG side chains of approximately 30 kDa 
each, and large number of potential glycosylations (Iozzo et al., 1994), the complete PG 
could reach the size of 850 kDa (Murdoch et al., 1994). The perlecan core protein contains 
five distinct domains (figure 1.2): domain I, a globular amino terminal domain containing 
three HS attachment sites; domain II, with four copies of sequences similar to the low-density 
lipoprotein (LDL) receptor ligand binding repeats; a central domain III, resembling the short 
arm of laminin chains with three globules and four regions of cysteine rich repeats; domain 
IV containing immunoglobulin (Ig) repeats; and domain V, a large globular carboxyl-
terminal domain resembling a part of the G domain of the laminin A chain where an 
additional GAG attachment site is present (Kallunki and Tryggvason, 1992).  
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Figure 1.2. Schematic molecular structure of human perlecan. Illustrating the various 
domains (Roman numerals) and the abbreviations for each module (top). LA, LDL receptor 
type A. L4, Laminin type IV domain. LE, Laminin EGF-like. Ig, Immunoglobulin 
superfamily. LG, Laminin type-G domain. The figure was taken from Whitelock et al., (2008) 
and modified.  
 
Perlecan protein binds to a number of ECM proteins including fibronectin (Hopf et al., 
1999; Hopf et al., 2001), laminin (Friedrich et al., 1999), collagen type IV (Battaglia et al., 
1992; Hopf et al., 1999), and fibulin-2 (Heremans et al., 1990; Hopf et al., 1999). Perlecan 
also binds to cell surface receptors such as α-dystroglycan (Peng et al., 1999) and integrins 
α2β1, β1 and β3 (Bix et al., 2004; Hayashi et al., 1992). Furthermore, perlecan binds to 
various growth factors such as platelet derived growth factors (Gohring et al., 1998), 
fibroblast growth factor -7, and -2 (Govindraj et al., 2006; Mongiat et al., 2000; Smith et al., 
2007). Some of these interactions are heparin/HS dependent, some are heparin influenced, 
and still others are with the core protein that occur independently of heparin/HS. Perlecan’s 
ability to interact with such a wide spectrum of matrix proteins suggests that perlecan is 
involved in matrix organisation and stabilisation, cell-matrix interaction, and in modulating 
growth factor signalling for cell growth and differentiation (Farach-Carson and Carson, 2007; 
Iozzo, 2005; Iozzo et al., 1994; Melrose et al., 2008; Timpl and Brown, 1996). Furthermore, 
perlecan has been shown to promote mitogenesis and angiogenesis through its interaction 
with fibroblast growth factor-2 (Aviezer et al., 1994; Iozzo and San Antonio, 2001), and to 
play key roles in the development of blood vessels and cartilage (Arikawa-Hirasawa et al., 
1999; Costell et al., 1999). 
Tiedemann  et al., (2005) demonstrated the interaction of perlecan with fibrillin-1 
microfibrils in vitro, as well as the colocalisation of the two proteins close to BM zones in 
human skin, blood vessels and eyes. The functional relevance of this interaction was also 
studied through analysis of microfibrils in perlecan knockout mice (Tiedemann et al., 2005). 
The significant reduction of fibrillin-1-microfibrils at the dermal-epidermal junction  
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suggested the involvement of perlecan in microfibril assembly (Tiedemann et al., 2005). The 
combined results of Tiedemann et al., (2005), was used as one of the reasons for selecting 
perlecan as a potential candidate HSPG for investigation in this project. 
Beside tissue development, perlecan plays an important role in embryogenesis. Early 
studies have shown perlecan expression in pre-implanted embryos prior to the formation of a 
BM (Dziadek et al., 1985). Perlecan has not only been detected in the blastocyst interior, but 
perlecan epitopes have been detected on the outer surface of the trophectoderm cells at the 
time of implantation. The obtained expression pattern of perlecan in developing embryos 
suggested the potential participation of this HSPGs in blastocyst attachment (Carson et al., 
1998; Carson et al., 1993; Smith et al., 1997). These findings supported previous reports of 
initial embryo attachment to the uterine epithelial surface being via a HS-dependent 
interaction with its various binding ligands such as laminin and fibronectin (Farach et al., 
1987). Aside from the embryo, expression of perlecan has also been detected in uterine 
tissues of mice during pregnancy (San Martin et al., 2004), thus preparing the uterine 
microenvironment for embryo attachment (San Martin et al., 2004).  
 Costell  et al., (1999) have demonstrated that almost half of mice lacking the perlecan 
gene die as embryos around E-11.5 due to either cardiac system failure caused by 
intrapericardial haemorrhage, or failure of the neural system to develop. Studies of perlecan 




Syndecans are cell surface HSPGs composed of an extracellular ectodomain specific 
for each syndecan, a conserved transmembrane domain and a short cytoplasmic domain 
(Beauvais and Rapraeger, 2004; Couchman, 2003) (figure 1.3). The divergent ectodomains 
share conserved attachment sites for GAGs, predominantly HS (Couchman, 2003). 
Syndecans interact with matrix proteins (David, 1993), growth factors including vascular 
endothelial growth factor and basic fibroblast growth factors (Chen et al., 2004; Chernousov 
and Carey, 1993; Rapraeger, 2000), and possibly growth factor receptors (Mundhenke et al., 
2002) via the HS-side chains. The ectodomains can be shed from cells by proteolytic 
cleavage (Fears et al., 2006; Fitzgerald et al., 2000). Once released from the cell surface, 
ectodomains can sequester soluble factors and compete for cell surface binding (Bellin et al., 
2002; Kato et al., 1998). The cytoplasmic domain contains a region unique to each syndecan 
(Couchman, 2003). In syndecan-1 the region regulates cell spreading, and actin and fascin 
bundling (Chakravarti et al., 2005). In syndecan-2, this region has been implicated in matrix 
assembly in fibroblasts (Klass et al., 2000), and left-right asymmetry in Xenopus (Kramer et  
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al., 2002; Kramer and Yost, 2002). The function of this region in syndecan-3 has not been 
described, while in syndecan-4 this unique region has been implicated in signal transduction 
and activation of protein kinase Cα (Horowitz et al., 2002; Lim et al., 2003). 
Syndecan-1 is primarily expressed in epithelial (Hinkes et al., 1993) and plasma cells 
(Seftalioglu and Karakus, 2003), and can also contain CS-GAGs in addition to HS-GAGs 
(Rapraeger et al., 1985). Syndecan-2 is highly expressed in fibroblasts and endothelial cells 
(Couchman, 2003; Fears et al., 2006) and is involved in cell adhesion, proliferation, 
angiogenesis and matrix assembly (Fears et al., 2006; Han et al., 2004; Klass et al., 2000). In 
addition a role for syndecan-2 has been shown in cell motility (Fears et al., 2006). Syndecan-
2 is also expressed in rat hippocampal neurons and interacts with the receptor tyrosine kinase, 
EphB2, to mediate dendritic spine formation in mice (Ethell et al., 2001). Syndecan-3 is the 
least investigated syndecan, and similar to syndecan-1 it can contain CS-GAG chains in 
addition to HS-GAGs (Tkachenko et al., 2005). It has been suggested that syndecan-3 is 
involved in mediating the formation of neuronal connections during development 
(Goutebroze et al., 2003), and acts as a receptor for the axonal growth factor, pleiotrophin 
(Raulo  et al., 1994). Syndecan-4 is involved in focal adhesions; in vitro binding studies 
demonstrated that syndecan-4 interacts with cytoskeletal protein, α-actinin (Alexopoulou et 
al., 2007; Greene et al., 2003). Over-expression of syndecan-4 in the presence of 
phosphatidylinositol 4, 5 bisphosphate can activate protein kinase Cα and downstream 
signalling that promotes the formation of focal adhesions and cytoskeletal stress fibres (Oh et 




Figure 1.3. Cell surface HSPGs syndecans. Potential and identified GAG attachment sites 
are indicated by red lines. The homologous transmembrane domain (dark blue) and 
intracellular domain (stipple) with conserved tyrosines (dots), as well as the Threonine, 
Serine, and Proline rich domain of syndecan-3 (crosshatch) are indicated. The image is a 
modified version of Lopes et al., (2006). 
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1.1.4 Glycoproteins  
Glycoproteins in the ECM generally have structural and adhesive properties. 
Numerous extracellular glycoproteins have been isolated and characterised as cellular 
effectors in the matrix which have specific adhesive affinities on one hand for the cell surface 
and on the other hand for other molecules of the matrix (Mark, 2002). A number of 
glycoproteins in the matrix are large molecules which are able to mediate cellular activities, 
both directly through interaction with cell surface receptors such as integrins, and indirectly 
by structuring a defined 3-dimentional ECM which is required by most cells to express their 
tissue specific features. Some of these glycoproteins with adhesive properties are fibronectins, 
laminins, tenascins, vitronectin, thrombospondin, and fibrillins (Mark, 2002).  
Fibronectin occurs as a soluble dimer with molecular weight of 540 kDa in plasma or 
as a fibrillar form in tissue extracellular matrices. Fibronectin has a wide range of biological 
activities which have been identified through in vitro and in vivo studies (George et al., 1993; 
Giancotti and Ruoslahti, 1999; Pearlstein et al., 1980). The importance of fibronectin has 
been demonstrated by the embryonic lethal effect of the fibronectin knockout in mice. Mice 
lacking fibronectin die near E-8.5 due to severe defects in embryonic development (George et 
al., 1993). Morphologically, the foetuses of fibronectin null mice display abnormalities in the 
heart and vasculature, and have a deformed neural tube. They also lack somites and 
notochords (Mark, 2002). In humans, mutations in the fibronectin gene have been linked to 
glomerulopathy with fibronectin deposits (Castelletti et al., 2008). Glomerulopathy with 
fibronectin deposits is a hereditary kidney disease (OMIM# 601894) which is characterised 
by proteinuria, microscopic hematuria, and hypertension, that results in end-stage renal 
failure between second to sixth decade of life (Castelletti et al., 2008).  
Structurally, fibronectin is a dimer of two similar polypeptide chains, with each chain 
being 60-70nm long, 2-3nm thick and having a molecular weight of 220-250 kDa. The two 
chains are held together by two disulphide bonds near the C-terminal region (Schwarzbauer, 
1991; Sottile and Mosher, 1993). There are at least 20 different fibronectin chains that arise 
from alternative RNA splicing of the primary transcript from the single fibronectin gene 
(Gutman and Kornblihtt, 1987; Kornblihtt et al., 1984; Schwarzbauer et al., 1987; 
Schwarzbauer et al., 1983).  
Fibrillins are another family of glycoproteins found in the matrix which form 
polymers that are the backbone structure of microfibrils. Fibrillin-microfibrils support the 
mature functional integrity of a particular organ by providing organs with a tissue specific 
architectural framework. Fibrillin-microfibrils also play a role in targeting growth factors to 
the right location in the ECM of organs (Charbonneau et al., 2004; Sengle et al., 2008). The 
importance of fibrillins in vivo has been highlighted by the development of inheritable  
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connective tissue disorders as a result of mutations in the fibrillin genes (Kielty et al., 2002; 
Ramirez and Dietz, 2007). Fibrillins will be discussed in more detail in section 1.2.2. 
 
1.2 Microfibrillar structures of the matrix  
Fibrillins and collagen VI are two matrix proteins present in a wide range of tissues 
that form distinct microfibrils (Cleary and Gibson, 1983; Finnis and Gibson, 1997). These 
microfibril-forming proteins have been well documented and have been shown to be 
structurally unrelated. In early studies the structure of these microfibrils and their 
composition was extensively studied using immuno-electron microscopy techniques and 
molecular approaches such as tissue extraction and cell culture (Engvall et al., 1986; 
Furthmayr et al., 1983; Kielty and Shuttleworth, 1995; Prosser et al., 1984). The structure 
and composition of these microfibrils are described in further detail in section 1.2.1 and 1.2.2. 
 
1.2.1 Collagen VI microfibrils 
Type VI collagen microfibrils are 3-5nm in diameter and are present as an extensive 
network in virtually all types of connective tissues where they are found in loose association 
with collagen fibres, BMs and cells (Timpl, 1994). Various molecules that specifically 
associate with type VI collagen include integrins (Pfaff et al., 1993), transforming growth 
factor-β-inducible gene-h3 (βig-h3) (Gibson et al., 1997; Hanssen et al., 2003) and matrix 
PGs including biglycan (Wiberg et al., 2002) and decorin (Nareyeck et al., 2004). Biglycan 
and decorin interact with matrilins in both native and reconstituted microfillar assemblies. 
Complexes between matrilin-1 and biglycan/decorin are found bound to native collagen VI 
microfibrils, mediating binding of type VI collagen to major constituents of ECM (Wiberg et 
al., 2003). Collagen VI microfibrils are involved in ECM signalling and cell-matrix stability, 
which makes them important components of the matrix (Alexopoulos et al., 2005; Guilak et 




Collagen VI monomers have relatively short triple-helical regions that are 60nm long 
separated by globular domains of 40nm long (Furthmayr et al., 1983; Kuo et al., 1989; 
Spissinger and Engel, 1995). The collagen VI monomers are comprised of three different 
polypeptide chains α1 (VI), α2 (VI), and α3 (VI), which have a triple helix flanked with the 
N-and C-terminal globular domains at each end (figure 1.4). Furthermore, the collagen VI 
polypeptide chains α1 (VI) and α2 (VI) have a molecular mass of 140,000 kDa, and α3 (VI)  
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has a molecular mass of 260,000-280,000 kDa (Colombatti et al., 1987; Kielty and 
Shuttleworth, 1997). The stabilisation of these monomers is made possible by both intrachain 
and interchain disulphide bonds present within the monomers (Odermatt et al., 1983). 
Type VI collagen dimers are formed by lateral aggregation of two antiparallel 
monomers with their helical rods overlapped by about 75nm (figure 1.4b). Tetramers, the 
basic unit of type VI collagen filaments, are formed by the aggregation of two dimers in a 
parallel fashion, with their ends in register (figure 1.4b) (Kuo et al., 1989). Their assembly 
into tetramers occurs intracellularly, before being secreted into the ECM. The evidence for 
this was first provided by biosynthetic studies on type VI collagen in fibroblast cultures 
(Engvall et al., 1986). It is possible that the initial associations for the formation of tetramers 
are guided by the specific interaction of the inner carboxyl globular domain with a binding 
site within the triple helix, or perhaps specific interactions between the helical domains. 
Intramolecular disulphide bonds are responsible for further stabilising the dimers and 

















Figure 1.4. Domain organisation and assembly of the alpha chains from collagen VI. a, A 
diagram showing the organisation of domains in α1, α2, and α3 chains of collagen VI. The 
blue and red rectangle represents the N- and C-terminal domains structurally. The 
collagenous region is shown in black as a molecular structure. b, Diagram showing the 
assembly of collagen VI microfibrils from three α chains. The formation of monomers, 
dimers and tetramers occurs intracellularly while the microfibril assembly occurs in the 
extracellular space. This diagram is taken from Baldock et al., (2003). 
 
Microfibril assembly occurs by end to end overlapping of the outer amino-terminal 
domains of the tetramers at, or close to, the cell surface (figure 1.4), through non-covalent 
interactions (Bruns et al., 1986; Furthmayr et al., 1983). Several studies have supported these 
non-covalent interactions of tetramers by showing the ready dissociation of collagen VI 
microfibrils into tetrameric subunits by treatment with a chaotropic agent (Kuo et al., 1989) 
or low pH (Spissinger and Engel, 1995). Adjacent microfibrils have been shown in some  
   - 14 - 
tissues, such as the human placenta at term and the rat lung (Reale et al., 2001), to associate 
laterally to form extensive networks that interact with collagen fibrils, other matrix molecules, 
and cells (Bruns et al., 1986; Hanssen et al., 2003; Kielty et al., 1998; Reale et al., 2001). 
 
1.2.1.1.2 Function and distribution of Collagen VI 
The microfibrillar type VI collagen is one of the major collagenous components of 
neonatal and foetal skin, where it was first identified beneath the dermal-epidermal junction, 
the subcutis, and to lesser extent in the dermis, at 6-weeks estimated gestational age (Smith, 
1994). As the gestation stages progress, collagen VI was observed to have overlapping 
distribution with other dermal collagens such as collagen type I, III and V in the dermal and 
subcutaneous connective tissue of developing skin (Smith, 1994). In the same study by Smith 
(1994), cell culture experiments showed the deposition of collagen type VI in the matrix 
precedes the matrix deposition of type I and II collagen. Thus one of the functions proposed 
for collagen VI from the study was that collagen VI networks provide the framework for 
assembly of collagen I and III in the matrix.  
Collagen VI microfibrils are also found in various other tissues (table 1.2). They are a 
significant component of the hyaline articular cartilage matrix (Ayad et al., 1984; Eyre et al., 
1987; Hagiwara et al., 1993; Keene et al., 1988; Poole et al., 1988; Wu et al., 1987) and are 
localised within the pericellular microenvironment around chondrocytes in adult canine 
articular cartilage. The results thus suggested that collagen VI coordinates cell-matrix and 
matrix-matrix interactions and maintains the pericellular microenvironment surrounding 
articular cartilage chondrocytes (Chang et al., 1997). Type VI collagen is also present in the 
sub-endothelium, the media and adventitia of the arteries, and in different areas of venous 
walls where it has been shown to associate with laminins. 
In the cornea, collagen VI is the second major collagen present, making up 
approximately 17% of the total collagen, after collagen I which makes up more than 80% of 
the collagen in this tissue (Michelacci, 2003; Zimmermann et al., 1986). Indirect 
immunofluorescence analysis has demonstrated that distribution of collagen VI occurs 
throughout the corneal stroma and in the Bowman’s layer, but not in the epithelium and 
endothelium cell layers or in the BM (Zimmermann et al., 1986). Therefore, collagen VI 
appears to be playing an important role in the architecture of the corneal tissue (Michelacci, 
2003). 
Disruption of the Col6α1 gene in mice results in significant musculoskeletal changes 
such as muscle weakness and wasting and contractures of multiple joints (Bertini et al., 2002). 
Mice lacking collagen VI show signs of accelerated development of hip osteoarthritis, 
delayed secondary ossification process and reduced bone mineral density (Alexopoulos et al.,  
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2009). Furthermore, the stiffness of the articular cartilage pericellular microenvironment is 
significantly reduced in collagen VI knockout mice (Alexopoulos et al., 2009). Therefore 
collagen VI plays a vital role in the mechanical environment of chondrocytes and in 
modulating chondrocytes and mesenchymal cell differentiation and proliferation activities 
(Alexopoulos  et al., 2009). The skeletal muscles of both homozygous and heterozygous 
mutant mice showed histological signs of myopathy (Bonaldo et al., 1998). In particular, the 
myopathy of collagen VI knockout mice had features in common with the human autosomal 
dominant inherited muscular dystrophy, Bethlem myopathy. Therefore, the Col6α1 mutant 
mice was considered as an animal model of Bethlem myopathy (Bonaldo et al., 1998). 
 
Table 1.2. Tissue distribution of type VI collagen using immunofluorescence. Table taken 
from Keene et al., (1988). 
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Figure 1.5. Model for supramolecular assembly 
in the ECM of connective tissue. Collagen VI 
filaments interact with collagen II or aggrecan 
networks via a complex formed by the small 
proteoglycans biglycan and decorin with 
matrillin-1. MATN-1, matrilin-1; BGN, biglycan; 
DCN, decorin. Diagram modified from Wiberg et 
al., (2003).  
In humans, Hambach et al., (1998) observed an increased amount of type VI collagen 
in the middle and deep layers of cartilage with moderate osteoarthritis. Horikawa et al., 
(2004), also reported an increase in the volume of the pericellular microenvironment in which 
collagen VI is very specifically localised, as well as an increase in the pericellular 
microenvironment to chondrocyte ratio as cartilage degeneration progressed. From this 
evidence it was concluded that type VI collagen may be playing an essential role in 
protecting the chondrocytes from mechanical stress, which occurs in association with the 
progress of osteoarthritis, by enlarging the volume of the pericellular microenvironment.  
 
1.2.1.1.3 Interaction of collagen VI with other matrix components 
Collagen VI has been shown to interact via its triple helical domain with the BM 
perlecan (Kielty et al., 1991; McDevitt et al., 1991), and with collagen XIV isolated from 
human placenta (McDevitt et al., 1991). In addition, collagen VI has recently been shown to 
covalently interact with βig-h3 (Hanssen et al., 2003). 
Collagen VI has also been 
shown to have a high-affinity, 
specific interaction with decorin 
(Bidanset et al., 1992). Furthermore, 
this interaction has been 
demonstrated to be inhibited by PGs 
with related leucine-rich repeat 
modules such as biglycan and 
fibromodulin, suggesting that a 
common structural motif is 
recognised by collagen VI (Bidanset 
et al., 1992). Wiberg et al., (2001) 
have further characterised the 
interaction of both decorin and 
biglycan as being within a domain 
localised close to the N-terminal part 
of the triple helical region of collagen 
VI. Moreover, a role for these small 
leucine-rich repeat PGs in the modification of collagen VI supramolecular structure and 
function has been suggested (Wiberg et al., 2001). An important role of biglycan and decorin 
is to serve as an adaptor protein connecting collagen VI to the major constituents of the ECM 
cartilage, collagen II and aggrecan, as well as to a number of procollagen molecules (Wiberg  
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et al., 2003) (figure 1.5). These may represent immobilised nucleation centres for collagen II 
fibril assembly. Thus collagen VI microfibrils act as a scaffold for the formation of the 
fibrillar collagen network, as well as presenting fibrillogenesis modulators, including decorin 
and biglycan, in proximity to the growing fibrils (Wiberg et al., 2003).  
Ultrastructurally, collagen VI microfibrils are often in close proximity to thicker 
fibrillin-microfibrils in a wide range of tissues (Wu et al., 1996), suggestive of molecular 
interaction between the two structures (Finnis and Gibson, 1997). In vitro binding studies of 
MAGP-1 and -2 with native and pepsin-treated collagen VI revealed that MAGP-1, but not 
MAGP-2, interacts with a site close to the triple helix region of the α3 (VI) chain specifically. 
This result provided biochemical evidence that fibrillin-microfibrils may indirectly link 
elastic fibres to collagen fibres via interaction of MAGP-1 with type VI collagen (Finnis and 
Gibson, 1997). 
Collagen VI binds cell surface receptors such as integrin, α1β1 (Loeser, 1997), and 
α2β1 (Pfaff et al., 1993). Integrins are αβ heterodimeric transmembrane receptors that 
mediate cell adhesion to the ECM, usually through a Arg-Gly-Asp (RGD) motif, and have 
widespread essential functions in development, tissue organisation, and the immune system 
(Roberts and Critchley, 2009). In addition, NG2, a PG widely expressed on numerous cell 
surfaces, has been shown through solid phase binding assays to interact with type VI collagen 
(Burg et al., 1996). Kuo et al., (1997) also demonstrated the interaction of intact native 
collagen type VI with type IV collagen, a major component of BMs, which is of significance 
as it provides a plausible explanation (section 1.2.1.1.4) for the Bethlem myopathy phenotype, 
a genetic disease caused by mutation in type VI collagen (Kuo et al., 1997). In addition, an 
interaction of intact type VI collagen with hyaluronan has been identified though Enzyme-
linked Immuno-Sorbent Assay (McDevitt et al., 1991), and a recombinant N-terminal region 
of human collagen VI has been shown to interact with both heparin and hyaluronic acid 
(Specks et al., 1992).  
 
1.2.1.1.4 Heritable disorders of collagen VI 
Three COL6A genes encode 3 subunits of collagen VI, α-1, α-2 and α-3, respectively. 
The COL6A1 and COL6A2 genes form a cluster on chromosome 21q22.3, whereas the 
COL6A3 gene is situated on chromosome 2q37. Deficiency of collagen VI in humans caused 
by mutations of COL6A genes leads to two main congenital muscular dystrophies; Bethlem 
myopathy (OMIM# 158810) and Ullrich Congenital Muscular Dystrophy (UCMD) (OMIM # 
254090) (Lampe and Bushby, 2005).  
Bethlem myopathy is an autosomal dominant form of slowly-progressive muscular 
dystrophy, and mutations can affect any of the subunits (Mercuri et al., 2005). Mutations in  
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any of the subunits may interrupt the assembly of collagen VI, and subsequently its 
anchorage to other ECM, resulting in Bethlem myopathy. The majority of these mutations 
result in amino-acid substitution, notably glycine, in the triple helix region (Jobsis et al., 1996; 
Sasaki et al., 2000; Scacheri et al., 2002). This disorder shows mild clinical features with 
proximal muscle weakness and early contractures predominantly in the fingers. The onset is 
usually in early childhood or sometimes at birth and occasionally patients become 
wheelchair-bound after 25 to 40 years of age (Jobsis et al., 1999). 
A complete loss or reduction of collagen VI due to mutations in any one of the three 
collagen VI genes has been associated with UCMD (Brockington et al., 2004; Camacho and 
Vajda, 2001; Ishikawa et al., 2004). UCMD is a more severe congenital muscular dystrophy, 
characterised by early onset with patients usually presenting with UCMD at birth or within 
the first six months of life. UCMD is characterised by generalised and rapid progression of 
muscle wasting and weakness, proximal joint contractures and distal joint hyperflexibility. 
UCMD patients usually have an early death due to respiratory failure caused by the rapid 
progression of the clinical symptoms (Camacho Vanegas et al., 2001; Demir et al., 2002). 
Other features such as foot deformities, rigidity of the spine, high arched palate, and tendency 
to have early respiratory failure have also been reported. Immunohistochemical studies have 
demonstrated a decrease or absence of collage VI in skeletal muscle (Higuchi et al., 2001; 
Ishikawa et al., 2004), foetal muscles and chorionic villus samples (Brockington et al., 2004) 
and skin biopsies of patients with Ullrich disease (Higuchi et al., 2001). In addition, through 
electron microscopy Ishikawa et al., (2004) showed that the absence of collagen VI results in 
the loss of anchoring between the basal lamina and the interstitium of skeletal muscles in 
these patients. 
 
1.2.1.2 Transforming growth factor-β-inducible gene-h3 (βig-h3)  
Transforming growth factor-β-inducible gene-h3 (βig-h3) is expressed as a 68 kDa 
protein in humans and is associated with collagen VI. Initially, βig-h3 was identified as two 
polypeptides in reductive saline extracts of bovine nuchal ligament and named microfibrillar 
protein (MP78/70) (Gibson et al., 1989). At the time, βig-h3 was assumed to be associated 
with fibrillin-microfibrils. However, subsequent immuno-electron microscopy studies in a 
range of tissues showed βig-h3 to be associated with collagen VI microfibrils rather than 
fibrillin-microfibrils (Gibson et al., 1997). 
In humans, Skonier et al., (1992) identified βig-h3 by differential screening of a 
cDNA library made from A549 human lung adenocarcinoma cells after stimulation with 
transforming growth factor-β (TGF-β)-1, so as to identify biological markers of TGF-β 
activity. Amino acid sequencing of this gene showed that βig-h3 is 93% identical to RGD- 
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CAP, which was isolated from a fibre-rich fraction of pig cartilage (Hashimoto et al., 1997), 
thus suggesting that RGD-CAP/βig-h3 are orthologs. Furthermore, βigh3 has also been found 
to have similarities with the rat osteoblast-specific factor-2 (Takeshita et al., 1993), and 
Drosophila  fasciclin-1 (Zinn et al., 1988). The high degree of homology between these 
species therefore suggests the importance of conserved sequences for the function of βig-h3. 
 
1.2.1.2.1 Structure of βig-h3 
The predicted 683-amino acid sequence of secreted βig-h3 contains the following 
important features: 1) a signal peptide sequence at the amino-terminus (residues 1-23), 
therefore indicating the protein is secreted; 2) an RGD sequence in the carboxyl-terminal 
domain that can bind integrins (Hynes, 1992) and 3) four repeat domains of 140 residues 
each that are homologous to the Drosophila fasciclin-I, an intercellular adhesion molecule 
(figure 1.6) (Zinn et al., 1988). All the repeats of βig-h3 contain two short regions, H1 and 
H2 which are highly conserved across species. The H1 and H2 regions are composed of 
hydrophobic amino acids forming a β-sheet-like structure (Hashimoto et al., 1997), and they 
may interact with other macromolecules. Evidence suggests that the βig-h3 molecule appears 
to undergo posttranslational modifications at the carboxyl terminus, to yield a 68-70 kDa 




  peptide (S), the cysteine-rich region (C), the four repeated fasciclin like-domains (I-IV), 
and the RGD sequence. The photograph is modified from Hanssen et al., (2003). 
 
 
1.2.1.2.2 Possible function of βig-h3 and its interaction with other matrix proteins  
A possible physiological function for βig-h3 is to serve as a bifunctional linker 
protein, interconnecting different matrix components with each other and resident cells 
(Billings et al., 2000; Billings et al., 2002; Gibson et al., 1997). It has been shown through 
quantitative binding assays using purified recombinant (r) full length βig-h3 (rβig-h3) and 
human bladder fibroblast cells that βig-h3 functions as an adhesion molecule (Billings et al., 
2002). The presence of actin stress fibres within the seeded cells further suggests that βig-h3 
supports attachment and spreading of cells (Billings et al., 2002). Stress fibre formation as a 
result of actin polymerisation is one response of cells following adhesion to the ECM. βig-h3 
 
Figure 1.6. Schematic diagram of the domain structure of βig-h3 molecule. The signal  
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mediates the adhesion of several other cell types (Kim et al., 2002) including dermal 
fibroblast cells (LeBaron et al., 1995), corneal epithelial cells (Kim et al., 2000), bronchial 
smooth muscle cells (Billings et al., 2000) and human astrocyte cells (Kim et al., 2002). The 
mechanisms through which βig-h3 mediates cell adhesion and spreading have also been 
investigated. Blocking experiments using various antibodies to integrin subunits have 
suggested the involvement of α6β4 integrin in βig-h3 mediated adhesion of astrocyte cells 
(Kim et al., 2002). Also a report by Ohno et al (1997), suggested that βig-h3 enhanced the 
spreading of fibroblasts via integrin α1β1 and that its RGD motif was not necessary for 
mediating cell spreading. Similar conclusions on the role of βig-h3 in mediating cell 
adhesions were reached from other studies. For example, Kim et al., (2000) demonstrated 
that two conserved amino acids, aspartic acid and isolucine, near H2 in the second and fourth 
repeated domains of βig-h3, were necessary for mediating human corneal epithelial cell 
adhesion by binding to α3β1. Kim et al., (2002) demonstrated βig-h3 motifs containing 
tyrosine and histidine and many leucine/isoleucine amino acid residues flanking the tyrosine 
and histidine are part of the αvβ5 integrin binding motif in βig-h3, promoting human lung 
fibroblast cell adhesion. Other studies have shown that βig-h3 can interconnect with other 
matrix proteins. For example, solid phase binding studies showed the stable binding of βig-h3 
to collagen I and fibronectin, which are abundant glycoproteins of the ECM (Billings et al., 
2000; Billings et al., 2002). Overall, these results verify the proposition that βig-h3 is capable 
of interacting with a range of matrix proteins and integrins.  
βig-h3 is a collagen VI-associated protein, as βig-h3 has been demonstrated to co-
purify with collagen VI microfibrils extracted from foetal nuchal ligament, even under 
denaturing conditions. The analysis of the molecular composition of the microfibrils by SDS-
PAGE and immunoblotting showed that βig-h3 was covalently bound to collagen VI by 
intermolecular reducible cross-links (Hanssen et al., 2003). Furthermore, ultrastructural 
analysis of the purified collagen VI microfibrils revealed that βig-h3 was predominantly 
associated with at least some of the microfibrils from nuchal ligament, and immunogold 
labelling localised the covalent binding site of βig-h3 to the N-terminal region of the collagen 
VI molecule. The demonstrated interaction of collagen VI and βig-h3 in vivo suggests that 
they are likely to be important for the normal development and morphology of a range of 
tissues including the cornea. 
In vitro binding assays using rβig-h3 protein found that it bound native and pepsin-
treated collagen VI, and the binding site was identified to be at the N-terminal end of the 
triple helix (Hanssen et al., 2003). Further analysis showed that the binding characteristics 
between rβig-h3 and collagen VI were those of a strong but reversible non-covalent 
interaction. These findings indicated that βig-h3 possesses both covalent and non-covalent  
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binding activities with collagen VI suggesting that βig-h3 may play an important role in 
collagen VI
 biology in developing tissues. These roles of βig-h3 therefore may be in cell-
microfibril interactions, and in the
 organisation and modulation of different collagen VI 
architectures
 to suit particular tissue environments (Hanssen et al., 2003). The important 
physiological functions of βig-h3 are being increasingly realised. In order to further define 
the role of this protein in living organisms, the interactions of βig-h3 with a wider spectrum 
of matrix proteins will be investigated as part of my project. 
 
1.2.1.2.3 Expression and tissue distribution of βig-h3 
Investigations through northern blot analysis have demonstrated that βig-h3 is widely 
distributed in various tissues such as the lung, heart, spleen, kidney, liver, adrenal glands and 
in the growth plate of new born pigs (Hashimoto et al., 1997). Furthermore, βig-h3 
expression has been identified in a variety of human and mouse tissues. During mouse 
development, βig-h3 expression is first detected during E-15.5 and is sustained until E-18.5 
with localisation in the corneal epithelium and stroma (Ferguson et al., 2003). The highest 
expression levels were found in the human corneal epithelium (Escribano et al., 1994), adult 
human skin (LeBaron et al., 1995) and in uterine tissue of both species. In addition, moderate 
mRNA levels of βig-h3 were found in the heart, breast, prostate, skeletal muscle, testes, 
thyroid, kidney, liver and stomach tissues of humans (Skonier et al., 1994). However, the 
expression of βig-h3 was absent from the brain (Escribano et al., 1994), spleen, and 
parathyloid tissues of humans (Skonier et al., 1994). 
At the protein level, the distribution of βig-h3 was examined in foetal bovine tissues 
(Gibson et al., 1997). Analysis showed βig-h3 had extensive co-distribution with type VI 
collagen in developing nuchal ligament, aorta, lung and mature cornea (Gibson et al., 1997). 
Immunoreactive material was also present in capsule and tubule BMs of developing kidneys, 
and reticular fibres in foetal spleen. The study thus revealed βig-h3 to be a widely-expressed 
component of the ECM in a number of organ systems where it associates with other matrix 
macromolecules. In normal adult skin, βig-h3 is abundant in the epidermis and the dermis, 
and it has been suggested that this protein may play a role in wound healing (LeBaron et al., 
1995). In fact, Cha et al., (2008), demonstrated fibroblasts from chronic wounds show 
decreased differential expression of βig-h3 using differential display analysis.  
 
1.2.1.2.4 Diseases associated with βig-h3 
Mutations in the coding region of the βig-h3 gene is linked to human autosomal 
dominant corneal dystrophies (Fujiki et al., 1998; Munier et al., 1997). More than 20 
mutations in the βig-h3 gene have been identified, and these have been shown to cause  
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distinct phenotypic characteristics (Klintworth, 2003). The most common mutation identified 
in βig-h3 (R124C) is on the N-terminal side of its first fasciclin domain (Munier et al., 2002; 
Nakamura et al., 2002), but others are in the third (P501T) (Ha et al., 2000) and fourth 
(L518P) fasciclin domains (Hirano et al., 2000; Yamamoto et al., 1998). These mutations are 
believed to cause the βig-h3 protein to denature, and result in the formation of amyloidogenic 
intermediates that eventually precipitate in the cornea (Munier et al., 1997). This condition 
results in a progressive loss of vision, which can ultimately lead to blindness. Similar corneal 
opacity has been identified in transgenic mice in which human βig-h3 was over expressed 
(Kim et al., 2007). From these findings it was concluded that βig-h3 needs to be properly 
expressed for normal development of the anterior segment of the eye (Kim et al., 2007). The 
anterior segment of the eye in vertebrates is structurally defined by the cornea, iris, ciliary 
body and the lens (Pei and Rhodin, 1970). Therefore, βig-h3 plays a vital role in the 
corneolenticular adhesion and the normal development of the cornea during ocular 
morphogenesis, and specific changes in its primary protein sequence could alter its functional 
role in the corneal ECM (Billings et al., 2000; Kim et al., 2007). 
Furthermore, a complex relationship between βig-h3 and cancer has been established 
(Sasaki et al., 2002). βig-h3 has been shown to be up-regulated in colorectal carcinoma when 
compared with the normal colonic mucosa (Kitahara et al., 2001). Also, βig-h3 gene 
expression has been found to be increased in most of the highly invasive breast cancer cell 
lines, but not in the weakly invasive cell lines (Zajchowski et al., 2001), and in lung cancer as 
well (Sasaki et al., 2002). 
 
1.2.2 Fibrillin-microfibrils 
Fibrillin-microfibrils are individually 10-12nm in diameter (Rosenbloom et al., 1993) 
and are found in association with elastin in elastic fibres present in some tissues (Kielty et al., 
2005). These tissues include the lungs, skin and large blood vessels as mentioned previously. 
They also occur as elastin-free bundles in tissues such as kidney, ocular zonule, and spleen 
(Ashworth et al., 2000; Cleary and Gibson, 1983; Gibson and Cleary, 1987; Henderson et al., 
1996; Keene et al., 1991; Kielty et al., 2002). In contrast to type VI collagen microfibrils, 
fibrillin-microfibrils appear to be complex structures that may contain or be closely 
associated with a number of glycoproteins in a tissue-specific manner (Kielty, 2006) 
including MAGPs (Gibson et al., 1996; Gibson et al., 1991; Trask et al., 2000b), latent 
transforming growth factor-β binding proteins (LTBPs) (Dallas et al., 2000; Dallas et al., 
1995; Isogai et al., 2003; Sakai et al., 1986), Emilins (Bressan et al., 1993; Colombatti et al., 
2000), fibulins (Reinhardt et al., 1996b; Roark et al., 1995), and PGs (Kielty et al., 1996; 
Tiedemann et al., 2005; Unsold et al., 2001). However, fibrillin molecules are the primary  
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components that assemble to form the scaffold of fibrillin microfibrils, and to date three 
fibrillins, namely fibrillins-1, -2 and -3, have been identified (Charbonneau et al., 2003; 
Corson et al., 1993; Nagase et al., 2001; Sakai et al., 1986; Zhang et al., 2005). 
  Microfibril assembly is a multi-step cell-associated process with one of its initial steps 
involving N- to C-terminal self interactions of fibrillins (Hubmacher et al., 2008; Marson et 
al., 2005; Reinhardt et al., 1996a). In addition to linear N-to-C terminal interactions, lateral 
homotypic interactions in various regions of fibrillin-1 may be crucial for the stabilisation of 
the initial multimers or the lateral associations of individual microfibrils (Marson et al., 2005; 
Trask et al., 1999).  
 
1.2.2.1 Fibrillins 
1.2.2.1.1 Structure of fibrillins 
  Structurally, fibrillins are large 350 kDa rod-like glycoproteins that are calcium 
binding. All three fibrillins have very similar complex multidomain molecular structures that 
are dominated by calcium binding epidermal growth factor (cbEGF)-like domains. As 
expected these cbEGF-like domains bind calcium and it has been shown through 
ultrastructural and X-ray diffraction studies that binding of calcium profoundly influences the 
packing and periodicity of isolated microfibrils and hydrated microfibril arrays (Cardy and 
Handford, 1998). Calcium binding is also necessary for fibrillin interaction with other 
proteins and for protection from proteolysis (Downing et al., 1996; Reinhardt et al., 1997a; 
Reinhardt  et al., 1997b). Mutations in the cbEGF-like domains in fibrillin-1 have been 
claimed to introduce protease-sensitive sites into the molecule, causing significant structural 
changes (Cardy and Handford, 1998; McGettrick et al., 2000). The EGF-like domains of 
fibrillins are interspersed by an 8-cysteine (8-cys) domain (Hubmacher et al., 2006) (figure 
1.7). Furthermore, fibrillins contain two hybrid domains which are composed of 8-cysteine 
modules and cbEGF-like domains (Ramirez and Sakai). The N- and C-terminal regions are 
homologous with the respective segments of LTBPs and fibulins (Giltay et al., 1999; 
Ramirez and Sakai). All three fibrillins also have cleavage sites of furin-type proprotein 
convertases at their N- and C-termini, and processing at these sites may be important steps in 
regulating fibrillin assembly (Raghunath et al., 1999; Ritty et al., 1999). It has been widely 
considered that microfibrils assemble pericellularly, following furin processing, through high 
affinity N- and C-terminal interactions (Hubmacher et al., 2006; Kielty, 2006). 
The major differences between the fibrillins are in the unique hydrophobic region 
towards the N-terminal that may act as a hinge region, the number of intergrin-binding RGD 
sequences they contain and in the number of glycosylation sites (Hubmacher et al., 2006; 
Kielty et al., 2005; Ramirez et al., 2007). The predicted hinge region, which is a 58 amino  
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acid region, is rich in proline in fibrillin-1, while the corresponding region in fibrillin-2 is 
rich in glycine. In fibrillin-3 however both glycine and proline are equally present in this 
region. It has been speculated that the hinge region is the flexible region of the protein which 
allows bending of the fibrillin molecule (Baldock et al., 2001; Baldock et al., 2006). While 
fibrillin-1 has only one RGD putative cell recognition site, there are two RGD cell 
recognition sites in fibrillin-2 and -3. Furthermore, there are 15, 12 and 10 potential N-
glycosylation sites in fibrillin-1, -2 and -3 respectively (Corson et al., 1993; Corson et al., 
2004). 
 
Figure 1.7. Schematic representation of the three fibrillins, showing high homology between 
them with some distinct differences. Fibrillin-3 lacks one of the EGF-like domains near the 
N-terminal region. The diagram for fibrillin-1 and -2 is generously given by Dr. Mark Gibson. 
 
1.2.2.1 2 Tissue distribution of Fibrillins  
  All three fibrillins are expressed during human development, but fibrillin-1 is by far 
the most abundant isoform in adult tissue (Charbonneau et al., 2003; Corson et al., 2004; 
Quondamatteo et al., 2002). Moreover, investigators have documented the overlapping but 
distinct distribution pattern of fibrillins in various tissues. Quondamatteo et al., (2002) 
showed, using immuno-labelling techniques, that the localisation patterns of fibrillins-1 and -
2 were overlapping in embryonic and early foetal human tissues such as in the skin, central 
nervous system anlagen, ganglia, aorta, lung, and heart. However there were differences in 
other human tissues such as kidneys, and notochords. Fibrillin-3 has a similar pattern of 
expression to the other two fibrillins in most human foetal tissues except in the kidney and 
lung, where it appeared to be absent from glomerular and tubular regions of the kidney and 
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from the blood vessels of the lungs (Corson et al., 2004). The distribution of fibrillins has 
also been studied in canine flexor digitorum profundus tendons. Fibrillin-1 is present in the 
outer-most cell layer of tenocytes, while fibrillin-2 is detected in the pericellular matrix of 
linearly-arrayed internal tendon cells (Ritty et al., 2002; Ritty et al., 2003b). 
The gene expression patterns of fibrillins have also been studied through northern 
blotting in embryonic and early human foetal tissues. Generally fibrillin-2 is expressed 
during organ development and it decreases rapidly thereafter (Zhang et al., 1995). In adults 
fibrillin-2 is found in limited elastic tissues such as cartilage (Zhang et al., 1995). In contrast 
fibrillin-1 expression increases at a gradual rate during development and fibrillin-1 continues 
to be expressed throughout postnatal growth and in adults (Kelleher et al., 2004). Studies by 
Quondamatteo et al., (2002) have demonstrated fibrillin-1 gene expression in human 
embryos as early as the time of gastrulation and all the way through to postnatal life. Similar 
to fibrillin-2, fibrillin-3 is mainly expressed in foetal tissues associated with microfibrils 
close to amorphous elastin (Corson et al., 2004).  
 
1.2.2.1.3 Functions of fibrillins 
Mouse models are providing powerful tools for unravelling the biological roles of 
fibrillins (Dietz and Mecham, 2000). Pereira et al., (1997) created fibrillin-1 gene-targeted 
mouse models, giving rise to a mutant allele (mg∆) that resulted in a ten-fold reduction in 
fibrillin-1 expression. The heterozygous fibrillin-1 mutant mice expressed very low levels of 
mutant protein and were morphologically and histologically indistinguishable from wild type 
mice. Homozygous mutant mice which produced only small amounts of mutant fibrillin-1, 
appeared normal at birth but died of vascular complications prior to weaning (Arteaga-Solis 
et al., 2001). Some mice showed thinning of the proximal aortic wall, which suggested that 
they experienced aneurismal dilatation of the aorta as in human marfan syndrome (section 
1.2.2.1.5). Substantially reduced extracellular fibrillin-1 staining but normal elastin staining 
suggested that organised elastic fibres can accumulate in the absence of normal fibrillin-1-
rich microfibrils.  
Mutant mouse models have been used to demonstrate the role of fibrillins in 
controlling TGF-β signalling in the ECM. A deficiency of fibrillin-1 gene expression in mice 
leads to TGF-β-mediated failure of distal alveolar septation (Neptune et al., 2003). The 
mechanism by which fibrillin-1 targets TGF-β and regulates its activation is through 
interacting with LTBPs (Dallas et al., 1995; Isogai et al., 2003; Rifkin, 2005). The interaction 
of TGF-β with LTBPs is discussed in more detail in section 1.2.2.2. 
  Fibrillin-microfibrils are involved in sequestration of another of the TGF-β-related 
growth factors, bone morphogenetic proteins (BMPs) (Gregory et al., 2005; Sampath et al.,  
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1990). However, the mechanisms that modulate extracellular control of BMP bioavailability 
differ from those of TGF-β. Unlike TGF-β, BMPs are directly targeted to microfibrils by 
non-covalent association between the pro-domain of BMP-7 and the N-terminal of fibrillins 
(figure 1.8) (Sengle et al., 2008). It appears that through the interaction with the pro-domain 
of BMP-7, fibrillins target and modulate the activity of this growth factor in the matrix 
(Gregory et al., 2005; Sengle et al., 2008). Mice with fibrillin-2 mutations demonstrate this 
biological role of fibrillin-microfibrils. Fibrillin-2 knockout mice display auditory defects and 
limb-patterning defects, which include fusion of third and fourth phalanges that are not 
observed in fibrillin-1 null mice (Arteaga-Solis et al., 2001; Chaudhry et al., 2001; Penner et 
al., 2002). Digit formation is the combined result of chondrogenic outgrowth and interdigital 
cell death. This process is under the control of several signalling molecules, some of which 
are BMPs (Dahn and Fallon, 2000). Therefore, it has been hypothesised that the defects 
observed in the outer extremities are due to either aberrant fibrillin-2-rich microfibrils in the 
cartilaginous limb skeleton, or impaired commitment of mesenchymal cells in the prospective 
interdigital tissue to undergo apoptosis due to failed activation of BMP-induced cell death 
(Arteaga-Solis et al., 2001). 
  Mice lacking both fibrillins (fib-1
-/-; fib-2
-/-) die in the middle of gestation (E1-4.5), 
which is significantly earlier than in both fibrillin-1 (fib-1
-/-) and fibrillin-2 (fib-2
-/-) mutant 
mice (Carta et al., 2006). Histologically, the aortic media of these double mutant mice is 
poorly developed, due to impaired or delayed elastogenesis (Carta et al., 2006). The 
heterozygous fib-1
-/-; fib-2
+/- mutant mice survive through neonatal and early postnatal life, 
while 50% of heterozygous fib-1
+/-; fib-2
-/- mutant mice die as embryos (Carta et al., 2006). 
The findings from the analysis of the double mutant mouse models indicated that fibrillin-1 
compensates for the absence of fibrillin-2 during embryonic development (Carta et al., 2006). 
Collectively these mouse models demonstrate the importance of fibrillins in organ formation 
and tissue homeostasis.  
 
1.2.2.1.4 Interaction of fibrillins with other matrix components 
  One of the first functions suggested for microfibrils in the extracellular space was to 
provide a molecular scaffold for the deposition and alignment of tropoelastin molecules 
(Kielty et al., 2005; Kielty et al., 2002; Mecham, 1994). This alignment presumably allows 
for proper cross-linking and maturation of the elastic fibre as previously mentioned (section 
1.1.2). The prevalence of fibrillins within microfibrils made them candidates for the binding 
and alignment of tropoelastin molecules. Trask et al., (2000b) has showed that recombinant 
and purified tropoelastin binds to recombinantly expressed N-terminal fragments of fibrillin-
1 (figure 1.8) and fibrillin-2. Using solid phase binding assays and co-immunoprecipitation  
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experiments the site of interaction on fibrillin-2 was localised to a region encompassing the 
glycine-rich region down-stream EGF-like domains and most of the second 8-cys domain. 
From the results the authors concluded that both fibrillins could be playing a role in the 
organisation of the elastic matrix. Following from this, Rock et al., (2004), demonstrated 
with the use of in vitro binding assays additional tropoelastin binding sites on fibrillin-1 
(figure 1.8). It is possible that the ability of tropoelastin to bind to both fibrillins may be an 
advantage that ensures that elastin can assemble on any microfibrillar bed. 
Other matrix components that have been identified as binding ligands for fibrillin-1 
include three of the five members of the fibulin family, fibulin-2, -4 and -5 (figure 1.8) 
(Choudhury et al., 2009; El-Hallous et al., 2007; Freeman et al., 2005). All three fibulins 
have been shown to not just interact with fibrillin-1, but to associate with microfibrils (El-
Hallous  et al., 2007). Indirect immunofluorescence was used to demonstrate the 
colocalisation of endogenously-produced fibulin-2 and exogenously-produced fibulin-4 and -
5 with immature and mature microfibrils. Thus fibulin-2, -4 and -5 can associate with 
microfibrils at different stages of maturity (El-Hallous et al., 2007). The interaction of 
fibrillin-1 with fibulin-2, -4 and -5 has been suggested to be important in the assembly of 
elastic fibres (El-Hallous et al., 2007; Freeman et al., 2005). Choudhury et al., (2009) further 
defined the roles of fibulin-4 and -5 in biogenesis of elastic fibres, and respectively suggested 
an important role in regulating elastin cross-linking and elastin deposition on microfibrils for 





Figure 1.8. The schematic illustration of the binding sites of various ECM components 
on fibrillin-1.  
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Fibrillin-microfibril assembly itself is a poorly understood process. Recent cell 
culture and RNA interference studies have demonstrated the deposition of microfibrillar 
arrays is dependent on the assembly of fibronectin (Kinsey et al., 2008; Sabatier et al., 2009). 
The knockdown of fibronectin in human dermal fibroblasts using RNA interference resulted 
in severe reduction in both fibronectin and fibrillin-microfibril deposition. Furthermore, 
specific antibodies to integrins α5 and β1 were shown to inhibit fibronectin assembly and, as 
a consequence, fibrillin-microfibril assembly. Therefore, α5β1 integrin is also critical for the 
deposition of fibrillin-1 microfibrils (Kinsey et al., 2008). 
It is becoming increasingly clear that fibrillin-1 is a major heparin/HS binding 
molecule (Cain et al., 2005; Ritty et al., 2003a; Tiedemann et al., 2001) (figure 1.8). Based 
on inhibition of fibrillin-1 assembly by heparin/HS, it has been hypothesised that interaction 
of fibrillin-1 with HSPGs is necessary for mediating fibrillin-1 assembly (Ritty et al., 2003a; 
Tiedemann et al., 2001). A study by Cain et al., (2005), demonstrated that heparin has no 
effect on the homotypic fibrillin-1 (N- and C- terminal) interaction using solid phase 
inhibition assays. However, the same group show that heparin does compete with both 
MAGP-1 and tropoelastin for binding to fibrillin-1. These findings showed the potential 
regulatory role of heparin 1) on deposition of elastin on fibrillin-1 microfibrils and 2) on the 
association of MAGP-1 with the fibrilln-1 microfibrils. Since HS occurs in two main sites in 
vivo, on cell surfaces and in BMs in the matrix, interaction of fibrillin-1 with HS at both sites 
was considered important (Cain et al., 2005). For instance, HS on cell surfaces may be 
involved in alignment and multimerisation of fibrillin-1 molecules (Cain et al., 2005). 
Therefore, HSPGs are major players in elastic fibre organisation. 
Recently double immunofluorescence studies demonstrated the colocalisation of 
fibrillin-1 and perlecan in fibroblast cultures as well as in dermal and ocular tissues 
(Tiedemann  et al., 2005). Furthermore, double immunogold labelling confirmed the 
colocalisation of perlecan to microfibrils in various tissues at ultrastructural level. A detailed 
study of the interactive regions by solid phase binding assays revealed that perlecan binds to 
the central region of fibrillin-1 (figure 1.8). This result suggested that the interaction between 
perlecan and fibrillin-1 is important to anchor the microfibrils to the BM (Tiedemann et al., 
2005). Another PG, decorin, has been shown to interact with the N-terminal region of 
fibrillin-1 near the proline rich region through immunoprecipitation studies (Kielty et al., 
1996; Trask et al., 2000a). This interaction is important for fibrillin formation as treating 
purified microfibrils with chondroitinase ABC disrupts the beaded microfibrillar architecture. 
The significance of fibrillins interacting with decorin in elastic fibre assembly or function is 
not yet known. However, decorin has been shown to influence collagen fibril assembly both 
in vitro and in vivo (Danielson et al., 1997) by regulating fibre diameter and interfibrillar  
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spacing. Thus decorin may play a similar role in regulating the assembly of microfibrils. 
Isogai  et al., (2002), also revealed that versican has the ability to bind centrally to the 
fibrillin-1 molecule. However, its non-periodic association with microfibrils indicates that 
versican is probably not an integral structural component. Instead because of the ability of 
versican to bind hyaluronan, it has been suggested that it connects microfibrils to a 
hyaluronan-rich matrix (Isogai et al., 2002). 
Fibrillins can communicate with neighbouring cells through their RGD sequence by 
interacting with cell surface integrin receptors (Lee et al., 2004). Several studies using 
rfibrillin-1 fragments demonstrated integrins αvβ3 and α5β1 to be major receptors mediating 
adhesion to fibrillin-1 peptides (Bax et al., 2003; Pfaff et al., 1996), which in turn influence 
cell shape, migration and ECM deposition. Fibrillin-1 has further been shown to mediate cell 
adhesion through αvβ6 (Jovanovic et al., 2007). Integrin αvβ6 is expressed at low levels in 
adult tissues and is up-regulated in response to injury, inflammation and wound healing, as 
well as during development (Jovanovic et al., 2007). Therefore, fibrillin-1 acts as a linker 
molecule between cells and their micro-environment and may play a role in regulating cell 
behaviour in connective tissue. 
 
1.2.2.1.5 Congenital disorders related to fibrillins 
  Human disorders caused by mutations in fibrillins include marfan syndrome and 
congenital contractural arachnodactyly (CCA) (Pyeritz, 2000; Ramos Arroyo et al., 1985). 
Marfan syndrome (OMIM # 154700) is an autosomal dominant disorder that occurs as a 
result of mutations in the fibrillin-1 gene located on the long arm of chromosome 15 
(Milewicz et al., 2000). The majority of these mutations are missense or nonsense point 
mutations (Dietz and Pyeritz, 1995; Eldadah et al., 1995; Milewicz et al., 2000; Zhao et al., 
2009). However, exon deletions in fibrillin-1 have also been reported in children with severe 
marfan syndrome (Blyth et al., 2008). Marfan syndrome is characterised by cardiovascular, 
ocular and skeletal defects (Whiteman and Handford, 2003). The skeletal abnormalities of 
marfan syndrome are the most striking features. The skeletal complications typical of 
marfran syndrome patients include arachnodactyly, dolichostenomelia, pectus deformities 
and kyphoscoliosis. The most life threatening aspect of this disease is the cardiovascular 
complications (Whiteman and Handford, 2003). The most common cardiovascular 
abnormalities caused in marfan syndrome patients are mitral valve prolapse and more 
importantly dilation of the ascending aorta owing to cystic medionecrosis. The major ocular 
complications seen in marfan syndrome patients are ectopia lentis and myopia. Additional 
manifestations seen in a number of individuals with marfan syndrome include congenital 
pulmonary emphysema (Hennekam, 2005).   
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The underlying pathogenesis of these conditions was originally considered to be due 
to the loss of fibrillin-1 as a structural component that prevented proper assembly of elastic 
fibres (Ng et al., 2004). Therefore, marfan syndrome patients were thought to lack functional 
elastic fibres starting from late foetal development. However, the structural and functional 
integrity of normal vessel walls is maintained by elastic lamina anchored to the intima and 
smooth muscle cells through connecting filaments of fibrillin-1. Consequently, the loss of 
these filaments subsequently initiates vascular smooth muscle cells to over-produce matrix 
elements and elastin proteases including matrix metalloproteinases -2 and -9, resulting in 
medial degeneration. Therefore, the marfan vascular phenotype develops gradually 
throughout life rather than developing from prenatal defect. 
As mentioned in section 1.2.2.1.3, fibrillin-microfibrils are involved in sequestration 
and proper activation of TGF-β. There has been an important discovery that the dysregulated 
TGF-β signalling is linked to the clinical severity of marfan syndrome (Neptune et al., 2003). 
Subsequently, the association of fibrillin-1 mutations and dysregulation of TGF-β signalling 
have been linked to the progression of mitral valve prolapse, muscle hypoplasia and aortic 
aneurysm (Habashi et al., 2006; Ng et al., 2004). 
The fibrillin-2 gene has been mapped to chromosome 5q23-31 through in situ 
hybridisation (Lee et al., 1991; Putnam et al., 1995). Mutations in this gene have been shown 
to cause CCA (OMIM # 612907) which is an autosomal dominant condition that is clinically 
related to marfan syndrome (Chaudhry et al., 2001). CCA patients present with similar 
skeletal features to marfan patients e.g. they have tall, slender bodies with long limbs. CCA is 
also characterised by a crumpled appearance to the pinna of the external ear. The major 
difference between the two disorders is that CCA patients do not typically present with the 
ocular and life threatening cardiovascular complications associated with marfan syndrome 
(Whiteman and Handford, 2003).  
 
1.2.2.2 Latent transforming growth factor-β binding proteins 
LTBPs and fibrillins constitute a family of large extracellular glycoproteins. LTBPs 
have molecular masses between 120-220 kDa, so they are considerably smaller than fibrillins. 
LTBPs are mainly composed of repeated structures of EGF-like domains and conserved 8-
cys domains. There are four human LTBP genes (Oklu and Hesketh, 2000; Saharinen et al., 
1999; Shipley et al., 2000) (figure 1.9) that have been isolated and characterised. All LTBPs 
except LTBP-2 covalently bind latent-TGF-ß intracellularly, and play a central role in 
modulating tissue levels of this potent cytokine through regulation of its secretion, 
localisation and activation (Annes et al., 2003; Koli et al., 2001; Mangasser-Stephan and 
Gressner, 1999).   
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As mentioned previously, TGF-ßs are multifunctional cytokines that modulate growth, 
differentiation and apoptosis of mammalian cells (Hyytiainen et al., 2004). TGF-β is secreted 
primarily as a latent complex consisting of the TGF-β homodimer, the TGF-β pro-peptides 
latency-associated peptide and the LTBP. The mature TGF-β remains associated with 
latency-associated peptide by non-covalent interactions that block TGF-β from binding to its 
receptor. Complex formation between latency-associated peptide and LTBP is mediated by 
an intramolecular disulfide exchange between the third 8-cys domain of LTBP with a pair of 
cysteine residues in latency-associated peptide, this complex is called the large latent 
complex. The release of TGF-β from inhibition by latency-associated peptide can be 
mediated by several different molecules including proteases, thrombospondin-1, and the 




Figure 1.9. Schematic representation of human LTBPs 1-4. The small (s) isoforms of LTBP-
1 and -4 are illustrated. Photograph taken and modified from (Saharinen and Keski-Oja, 
2000). 
 
1.2.2.2.1 Structure and function of LTBPs 
  The overall structure of all known LTBPs is similar and it can be divided into four 
regions; the N-terminal region, the adjacent hinge domain, a central cluster of EGF-like 
domains and the C-terminal TGF-β binding region (Olofsson et al., 1995; Saharinen et al.,  
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1996). The N-terminal region of LTBPs does not contain the repetitive structures of EGF-like 
or 8-cys domains. However there are cysteine residues present in this region that may be 
involved in disulfide binding of LTBPs with the ECM structures on which they are deposited 
(Nunes  et al., 1997; Saharinen et al., 1999). LTBPs (except LTBP-3) contain a RGD 
sequence for putative cell adhesion (figure 1.9). Moreover, all LTBPs contain numerous 
glycosylation sites. The hinge domain has the highest degree of sequence diversity. The 
hinge sequence of LTBP-1 and -2 are sensitive to proteolytic cleavage which, at least for 
LTBP-1, may be for the release of TGF-B from the matrix (Hyytiainen et al., 1998; Taipale 
et al., 1995) (figure 1.9), while the hinge sequences of LTBP-3 and -4 are not (Penttinen et 
al., 2002).  
In LTBP-1 the N-terminus contains transglutaminase substrate motifs which are 
required for the proteins’ incorporation into the matrix (Nunes et al., 1997). The importance 
of the N-termini of LTBPs in binding ECM is highlighted by the observation that soluble 
LTBP-1 from platelets is lacking the N-terminal region, possibly due to proteolytic events in 
the regulated secretary pathway in the megakaryocytes (Miyazono et al., 1991). In addition, 
Unsold et al., (2001) demonstrated the association of LTBP-1 with fibroblast ECM through 
its N-terminal region and suggested the first interactions with the ECM may involve this very 
region.  
The central part of all LTBPs is composed of EGF-like domains (figure 1.9), which 
are suggested to form a rod-like structure found in similar regions of fibrillins (Downing et 
al., 1996). The EGF-like domains are found in many extracellular proteins, functioning as 
structural components and also mediating protein-protein interactions. However, how they 
mediate this interaction is not well understood. This region is resistant to proteolysis 
(Saharinen et al., 1998; Taipale et al., 1995) and the majority of the EGF-like domains in 
LTBPs, as in the fibrillins, are of the calcium binding type (Rosenbloom et al., 1993; Sakai et 
al., 1986; Zhang et al., 1994).  
  The 8-cys domains are found only in LTBPs and fibrillins, thus characterizing the two 
glycoprotein groups as one superfamily (Oklu and Hesketh, 2000; Saharinen et al., 1999). All 
of the cysteine residues in the 8-cys domains are involved in intradomain disulphide bonding. 
Although the third 8-cys domain in LTBPs binds latent TGF-β as mentioned previously, the 
binding affinity for the growth factor varies amongst the LTBP family members. LTBP-1 and 
-3 readily form disulphide bonds with TGF-β propeptide latency-associated peptide (Gleizes 
et al., 1996; Saharinen et al., 1999; Saharinen et al., 1996), while the 8-cys3 domain in 
LTBP-4 is less efficient in binding with latency-associated peptide (Saharinen and Keski-Oja, 
2000). Nuclear magnetic resonance studies have shown that the initial interaction of LTBPs 
with latency-associated peptide is facilitated by a region of negative electrostatic surface  
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potential, created by acidic amino acid residues surrounding the 2-6 cysteine pair disulphide 
bond, which has been identified in the exchange of disulphide bonds with latency-associated 
peptide (Lack et al., 2003). The eight cysteine residues in 8-cys3 bind in a 1-3, 2-6, 4-7, 5-8 
pattern for stabilisation of the domain’s conformation (Lack et al., 2003). In the same study, 
comparison of 8-cys3 structure in LTBP-1 and-4 revealed a ring of five negatively charged 
amino acid residues surrounding the 2-6 disulphide bind in LTBP-1, whereas the same site in 
LTBP-4 is surrounded by only three negatively charged amino acid residues, explaining 
poorer LTBP- latency-associated peptide complex formation (Lack et al., 2003). 
  Various isoforms of all LTBPs can be produced by alternative promoters (Moren et 
al., 1994). It has been shown that in human LTBP-1 and -4, there is more than one alternative 
N-terminal region (Olofsson et al., 1995; Saharinen et al., 1998). Through northern blots, two 
mRNA sequences coding for two different N-terminal variants of LTBP-1 were detected 
(Moren et al., 1994). In LTBP-1, the mRNA sequences coding for a shorter LTBP-1S lack a 
346 amino acid extension which was found to be present in the long LTBP-1L isoform 
(Kanzaki et al., 1990; Noguera et al., 2003; Tsuji et al., 1990). The longer form has been 
found to interact more efficiently with the ECM (Olofsson et al., 1995), further supporting 
the importance of the N-termini of the LTBP in the ECM association. Moreover, different 
distribution patterns have been observed for LTBP-1S and LTBP-1L. High LTBP-1L 
expression has been detected in  the heart, kidney, lung, testes and placenta, while a broader 
distribution has been observed for LTBP-1S (Noguera et al., 2003). In LTBP-4 at least three 
different N-terminal regions have been identified at the cDNA level (Saharinen et al., 1998). 
Since the N-terminal region of LTBPs is thought to be important for interacting with the 
ECM structures (Dallas et al., 1995), the variation in the N-terminal region of these 
glycoproteins could result in them having different affinities with various ECM components. 
There are also reports of alternative splicing of the hinge region of LTBP-1, and -3 (Oklu et 
al., 1998; Yin et al., 1998), and also in the long stretches of EGF-like repeats in LTBP-1, -3 
and -4 (Oklu and Hesketh, 2000). 
  The full spectrum of the biological roles of LTBPs is still uncertain. Mouse models 
have aided in understanding the in vivo functions of LTBPs. Null (loss of function) or 
hypomorphic (partially functional) mutations in Ltbp-1L, Ltbp-3 and Ltbp-4 genes causes 
abnormalities in the development of the heart, bones and lungs respectively (Dabovic et al., 
2002a; Dabovic et al., 2002b; Sterner-Kock et al., 2002; Todorovic et al., 2007). For 
example, severely reduced expression of LTBP-4 in mice leads to the development of severe 
pulmonary emphysema, cardiomyopathy and colorectal cancer (Sterner-Kock et al., 2002), 
associated with fragmented and disintegrated elastic fibres, and with an improper deposition 
of TGF-β in the matrix (Sterner-Kock et al., 2002). In contrast, mice deficient in LTBP-3  
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suffer from premature obliteration of synchondroses, osteosclerosis and osteoarthritis 
(Dabovic et al., 2002a) that is associated with impaired TGF-β signalling on bone physiology. 
Studies by Todorovic et al., (2007) demonstrated the congenital heart defects present in mice 
lacking Ltbp-1L genes are caused by a decrease in TGF-β activity. Overall, the mouse models 
described here highlight LTBPs as crucial components of the matrix that regulates TGF-β 
bioavailability during development. In addition to regulating TGF-β signalling, a second role 
as a structural component of elastic fibres has been suggested for LTBP-4 (Sterner-Kock et 
al., 2002). 
  A study by Dallas et al., (2005) has shown that fibronectin is critical for the 
incorporation of LTBP-1 and TGF-ß into the ECM of osteoblasts and fibroblasts. Through 
immunolocalisation studies it was suggested that fibronectin provides an initial scaffold that 
precedes the deposition of LTBP-1. This initial template has been suggested to be later lost as 
both fibronectin and LTBP-1 localise in separate fibrillar networks. To further support the 
hypothesis, Dallas et al., (2005) showed that the absence of fibronectin impaired the 
incorporation of LTBP-1 and TGF- ß into the ECM. Furthermore, LTBP-1 failed to assemble 
in embryonic fibroblasts that lacked the gene for fibronectin, and the addition of full length 
fibronectin rescued the assembly of LTBP-1. Fibronectin is also essential for fibrillin-1 
microfibril assembly (Sabatier et al., 2009). 
From the members of LTBP family, LTBP-2 is the only member that is not involved 
in the targeting of TGF-β as well as in regulating its activity. Structurally, LTBP-2 is similar 
to LTBP-1 except that LTBP-2 has 13 copies of consecutive EGF-like domains in the middle 
of the molecule compared to LTBP-1 which has 11 copies (Saharinen and Keski-Oja, 2000).  
Alternative splicing of the N-terminal region of LTBP-2 mRNA results in different 
isoforms of LTBP-2 protein. In humans, LTBP-2 occurs as a protein of 240 kDa under 
reducing conditions which is larger than LTBP-1 (190-200 kDa) (Miyazono et al., 1991; 
Moren et al., 1994), whereas the size of LTBP-2 protein found in bovine cell cultures and in 
tissue extracts appeared even larger (260-310 kDa) (Gibson et al., 1995). In addition, similar 
to LTBP-1, LTBP-2 was found to be released from the matrix by direct processing of the N-
terminal region of LTBP-2 with elastase and plasmin (Hyytiainen et al., 1998). 
 
1.2.2.2.2 Tissue distribution of LTBP-2 
The mRNA expression levels of LTBP-2 in various tissues have been investigated 
and compared with the expression of other LTBP family members. It has been established 
that LTBPs have only partial overlap of expression patterns. In situ hybridisation and 
immunohistochemical studies have shown LTBP-2 expression mainly in the lung, heart, 
placenta, skeletal muscle, liver and the aorta (Hirani et al., 2007; Moren et al., 1994). LTBP- 
   - 35 - 
1 expression is also detected in the same tissues as LTBP-2, except for the liver, and in 
additional tissues including the kidney, prostate, testis, aorta and the ovary (Hirani et al., 
2007; Olofsson et al., 1995). Meanwhile, LTBP-3 and -4 are predominantly expressed in the 
aorta, heart, small intestine and ovaries (Giltay et al., 1997; Saharinen et al., 1999). The 
expression levels of LTBP-3 and -4 are significantly lower in foetal tissues than in adult.  
The temporal and spatial pattern of LTBP-2 expression has also been determined in 
developing mouse and rat in order to gain insight into the likely function of LTBP-2 in 
development. The expression of LTBP-2 by in situ hybridisation was revealed to be largely 
parallel to tropoelastin expression (Giltay et al., 1997). Both proteins were expressed at 
embryonic day E-13.5 in the perichondrium surrounding developing vertebrae, at E-15.5 in 
the snout, lung, and dermis, and at E-17.5 both proteins were primarily detected in the aorta 
and other large vessels. In the rat tissue, LTBP-2 and tropoelastin were co-expressed in the 
lung, pericardium, epicardium and heart valves (Shipley et al., 2000). In the young adult 
mouse, both proteins were expressed in the capsule of the spleen and ubiquitously throughout 
the mesenchyme of the lung (Shipley et al., 2000). Additionally, there were tissues where 
LTBP-2 was differentially expressed to tropoelastin. For example, in the testes tropoelastin 
expression was weak and only observable in cells lining the outside of spermatic ducts 
(Shipley et al., 2000). In contrast there was intense LTBP-2 expression observed in cells 
within the lumen of the epididymis (Shipley et al., 2000). More recently, it has been shown 
using in situ hybridisation analysis that LTBP-2 expression is highly restricted in the brain 
(Dobolyi and Palkovits, 2008). 
 
1.2.2.2.3 Possible function of LTBP-2 
  Knockout studies in mice revealed LTBP-1, -3 and -4 have specific functions in 
targeting of TGF-β as well as in the regulation of its activity (Dabovic et al., 2002a; Sterner-
Kock et al., 2002; Todorovic et al., 2007). However, the function of LTB-2 is less clear. 
Knockout mouse studies carried out by Shipley et al., (2000) demonstrated the vital 
importance of LTBP-2 during development. Distinct from heterozygous mice with a 
disrupted LTBP-2 gene which were phenotypically normal in all aspects, the complete 
knockout of the LTBP-2  gene resulted in an embryonic lethal phenotype. More detailed 
experiments determined that the homozygous mutant affected implantation of the blastocysts, 
implying that LTBP-2 may play an essential developmental role during implantation (Shipley 
et al., 2000). Using genome-wide linkage scan, LTBP-2 was identified as a candidate gene 
for contributing to bone mineral variation in the hip and fracture etiology (Cheung et al., 
2008). In a cell culture study by Goessler et al., (2005), the expression of LTBP-2 during 
chondrogenic differentiation of mesenchymal stem cell and chondrocytes was found to be up- 
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regulated during dedifferentiation and down-regulation during chondrocyte differentiation. In 
addition, LTBP-2 expression level in the joint varied between patients and controls with 
osteoarthritis (Appleton et al., 2007) and in the synovium of patients with systemic lupus 
erythematosus arthritis (Nzeusseu Toukap et al., 2007). Based on these findings, it has been 
proposed that LTBP-2 may be involved in osteoblast differentiation and matrix homeostasis 
(Appleton et al., 2007; Nzeusseu Toukap et al., 2007).  
  Cell interaction with ECM components is important for events during development as 
well as later stages of life (Gumbiner, 1996). Cells adhere to the ECM through the interaction 
of cell surface receptors with integrin receptors, non-integrin receptors and RGD recognition 
sequences of ECM proteins (Ruoslahti, 1996). Since LTBP-2 contains a RGD sequence in 
vitro binding assays implicated a role for it in the modulation of cell adhesion (Hyytiainen 
and Keski-Oja, 2003; Vehvilainen et al., 2003). Further experiments demonstrated that 
melanoma cell adhesion to LTBP-2 could be mediated at least by the α3β1 integrin receptor. 
Recently in vitro binding assays have demonstrated that LTBP-2 competes with LTBP-1 for 
binding to fibrillin-1 in the developing aorta (Hirani et al., 2007) (figure 1.8). This suggests 
that LTBP-2 may be playing a role in modulating the storage of TGF-β on microfibrils in-
directly. Moreover, examination of LTBP-2 and fibrillin expression in cultured cell lines and 
their distribution in the matrix resulted in the conclusion that fibrillin-1 is necessary for 
efficient assembly of LTBP-2 (Vehvilainen et al., 2009). Suppression of fibrillin-1 resulted in 
the inability of LTBP-2 to deposit in the matrix (Vehvilainen et al., 2009). Furthermore, 
using a cell culture system of human skin fibroblasts, LTBP-2 was demonstrated to regulate 
assembly of elastic fibres by binding to fibulin-5 promoting its deposition on fibrillin-1 
microfibrils, and thus promoting elastogenesis preferably onto fibrillin-1 microfibrils (Hirai 
et al., 2007). From these findings a potential involvement in elastic fibre assembly can be 
elucidated for LTBP-2. 
 
1.2.2.2.4 Diseases associated with the LTBP-2 
  Recently null mutations in LTBP-2 have been reported to be the cause of primary 
congenital glaucoma in a number of consanguineous families (Ali et al., 2009). Primary 
congenital glaucoma is a rare cause of glaucoma that is inherited as an autosomal recessive 
condition in most families. Primary congenital glaucoma usually manifests within the first 
year of life and it is characterised by high intraocular pressure causing irreversible damage to 
the optic nerve (Anderson, 1981; Kupfer and Kaiser-Kupfer, 1979). This in turn leads to 
permanent loss of vision if it is left untreated. Affected patients usually present with tearing, 
photophobia, corneal clouding and enlargement of the cornea (Ho and Walton, 2004). 
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Aims of the present study 
  The components of the matrix have an influencing role in normal development of 
mammalian organs and homeostasis of mammalian tissues. The matrix components interact 
with various other structural proteins in the matrix to link the matrix together, as well as with 
resident cells via cell surface receptors or integrins to control and regulate cascade of events 
during embryo and organogenesis and later stages of life (Gumbiner, 1996). In addition, 
components of the matrix have the potential to interact with growth factors to store these 
cytokines in tissues and subsequently regulate their activation. For proper functioning of the 
connective tissue appropriate assembly of the matrix is required. Genetic studies have 
demonstrated the correlation between proper construction of the matrix and its function. For 
instance, generated LTBP-2 null mutant mice do not survive past E-6.5, prior to implantation. 
  LTBP-2, a matrix protein well documented to be associated with elastic fibres in 
humans, mouse and bovine tissues, has been demonstrated to bind to fibrillin-1 and to 
colocalise with fibrillin-1-microfibrils in human foetal aorta and bovine nuchal ligaments. 
LTBP-2 interacts with other microfibrillar/elastic fibre-associated proteins such as fibulin-5. 
Through these interactions it has been proposed that LTBP-2 plays a regulatory role in the 
deposition of elastin on fibrillin-1 microfibrils. Previously, Hirani et al., (2007) demonstrated 
the lack of interaction between recombinantly expressed LTBP-2 and fibrillin-2, MAGP-1 
and -2, tropoelastin and the small CS/dermatan sulphate-PGs, decorin and biglycan, using 
solid phase binding assays. With the emerging data on the involvement of HSPGs in elastic 
fibre biology, as yet studies have not been conducted to analyse the consequence of the 
interaction between LTBP-2 and HSPGs on assembly of elastic fibres. 
  This research project focused on the role of LTBP-2 in assembly of elastic fibres. In 
particular it aimed to establish if LTBP-2 interacts with HSPGs in the matrix or on cell 
surfaces and to further characterise the interaction if such an interaction was identified. It also 
aimed to determine if LTBP-2 and its HSPGs binding ligands have similar distributions in 
elastic tissues, the developing human foetal aorta, which is a major elastic tissue. In 
conjunction with studying the role of LTBP-2 within elastic fibre biology, through these aims 
we intend to find out if LTBP-2 has functions independent of elastic fibrillogenesis.  
  It is also an aim to elucidate clues for novel potential functions for LTBP-2 through 
isolating binding ligands for this matrix protein using a more systematic approach. Also using 
the same system, it is aimed to isolate binding partners for βig-h3, a matrix protein which is 
associated with collagen VI microfibrils, which can be used for comparing and verifying the 
specificity of the isolated binding partners by the two distinct matrix proteins. 
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Specific aims 
1.  To define and characterise molecular interactions of LTBP-2 with heparin/HSPGs, in 
particular perlecan and syndecans using solid phase binding assays. 
 
2.  To determine if LTBP-2 colocalises with these HSPGs within tissues. 
 
3.  To identify novel molecular binding partners for LTBP-2 and βig-h3 using affinity 
binding and proteomics.  
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CHAPTER 2  
MATERIALS AND METHODS 
 
2.1 General molecular biology protocols 
The following molecular biology protocols were adopted to facilitate cloning of 
human LTBP-2 fragments LTBP-2NT(H) and LTBP-2C(H) complementary (c) DNA 
sequences into mammalian expression vectors. 
 
2.1.1 Polymerase Chain Reaction (PCR) 
Polymerase chain reactions (PCR) were carried out using an Eppendorf mastercycler 
gradient PCR machine (Eppendorf, Hamburg, Germany) as previously described in Kitahama 
et al., (2000). Each PCR reaction mix contained 100ng of template DNA (BM40:LTBP-
2:his6 in pGEM-T-easy) (Hirani et al., 2007), 10µM of each primer pair (specific for the 
central or amino-terminal fragments) (appendix A), 0.2mM of each dNTP, PCR reaction 
buffer provided by Stratagene as a 10×stock (appendix B), and 2.5U of Pfu turbo DNA 
polymerase (Stratagene, La Jolla, CA). The final reaction volume of 50µl was made up using 
ddH2O. PCR cycles were conducted with a heated lid at 100˚C, and denaturation of template 
and activation of DNA polymerase was set at 94˚C for 3 min. This was followed by 25 cycles 
with denaturation temperature at 94˚C for 1 min, annealing temperature (at 57˚C for LTBP-
2NT(H) and 59˚C for LTBP-2C(H) fragments) for 1 min, extension temperature at 72˚C for 3 
min and a final extension step at 72˚C for 10 min. All completed reactions were chilled to 
4˚C prior to long term storage at -20˚C. 
 
2.1.2 DNA Purification by Agarose Gel Electrophoresis  
The PCR product (approximately 50-200ng of cDNA) was mixed with 6×DNA 
loading buffer (appendix B) to a final concentration of 1× and was loaded into wells of a 
0.8% (w/v) agarose gel (Invitrogen, Carlsbad, CA) dissolved in 1×TAE buffer (appendix B). 
Electrophoresis was carried out at 120V for 1 hr in 1×TAE buffer. Resolved DNA bands 
were stained with Ethidium bromide (2µg/ml) (Boehringer Mannheim GmbH, Mannheim, 
Germany) and they were visualised by an ultraviolet illuminator, wavelength= 254nm 
(Chromato-VUE Transilluminator, Model 0-62, Ultraviolet Products INC) and photographed 
using a Nikon COOLPIX-990 digital camera. Specific DNA bands were excised from the 
agarose gel using a clean scalpel blade and purified using the ultraclean gelspin filter kit 
(MoBio, Solana Beach, CA) exactly following the manufacturer’s instructions. cDNA yields  
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were approximately 20-40µg/ml. Concentration of purified cDNA was calculated from A260 
readings of 1:25 dilution of cDNA in ddH2O in a UV-1601 spectrophotometer (Shimadzu, 
Kyoto, Japan). The cDNA fragment was then “A”-tailed in preparation for ligation into 
pGEM-T-easy vector (Promega, Madison, WI). 
 
2.1.3 “A”-tailing and Ligation 
“A”-tailing of the LTBP-2NT(H) and LTBP-2C(H) cDNA fragments was carried out 
by incubating the PCR (section 2.1.3) insets with 5U of platinum taq DNA polymerase 
(Stratagene, La Jolla, CA), 1×platinum taq DNA polymerase buffer supplied by Stratagene as 
a 10×stock, 2.5mM MgCl2 and 0.2mM dATP in a total volume of 10µl. The volume was 
made up using ddH2O. Incubation was carried out in the Eppendorf mastercycler gradient 
PCR machine (Eppendorf, Hamburg, Germany) for 1 hr at 70˚C with the heated lid of 94˚C. 
Ligation of the cDNA PCR fragments was conducted using a 5:1 ratio of insert to 
vector. “A”-tailed PCR fragments of LTBP-2NT(H), 191ng, or LTBP-2C(H), 200ng, were 
incubated overnight at 4˚C with 50ng of pGEM-T-easy vector (Promega, Madison, WI), 3U 
of T4 DNA ligase and 1×ligation buffer (supplied by Promega as a 10×solution) in a total 
volume of 10µl.  
Ligated cDNA fragments were purified by ethanol precipitation. Briefly, 0.1 vol of 
3M sodium acetate (pH 5.2) and 2.5 vol of ice-cold 100% ethanol were incubated with the 
ligation reaction respectively for 30 min at -20˚C. Following incubation, the mixture was 
immediately centrifuged at 4˚C for 25 min at 17,500×g. The DNA pellet was washed with 
ice-cold 70% (v/v) ethanol and centrifuged at 17,500×g for 10 min before decanting the 
ethanol and air-drying the pellet. The DNA was resuspended in 10µl of ddH2O prior to use in 
transformation of JM109 competent cells (Promega, Madison, WI). 
 
2.1.4 Transformation of Competent Cells 
JM109 competent cells (107 colony forming units/µg), totalling of 100µl were 
incubated on ice for 20 min with 50ng of ligated and purified DNA in a volume of 10µl. 
Competent cells were heat shocked at exactly 42˚C in a water bath for 45 sec and were 
immediately returned to ice for a further 2 min. Cells were incubated in 900µl of SOC media 
(appendix B) for 1.5 hrs at 37˚C with agitation and pelleted by centrifugation at 2,000×g for 
5 min at RT. The pellet of transformed cells was resuspended in 100µl of SOC media before 
being spread onto solid agar plates containing luria broth (appendix B), 100µg/ml ampicillin, 
0.5mM IPTG and 40µg/ml X-Gal. The coated plates were incubated overnight at 37˚C. The 
X-Gal and IPTG allows for blue/white colony selection. White colonies indicate the 
transformation of JM109 competent cells with pGEM-T-easy vector containing the required  
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cDNA insert, while blue colonies indicate cells transformed with re-ligated, empty pGEM-T-
easy vector. The presence of a cDNA insert in the vector interrupts the transcription of the 
Lac-Z gene whose protein product metabolises X-Gal and IPTG into a blue compound. White 
colonies were selected and were sub-cloned onto solid agar plates containing Luria broth and 
100µg/ml ampicillin. The coated plates were incubated in a 37˚C incubator for 16 hrs, prior 
to propagation of the colonies in Luria broth (appendix B) containing 100µg/ml of ampicillin 
for plasmid DNA purification. The liquid cultures were incubated for 16 hours at 37˚C with 
agitation. Plasmid DNA was purified from 2ml of Luria broth culture using the high pure 
plasmid isolation kit (Roche Diagnostics GmbH, Mannheim, Germany), following 
manufacturer’s instructions. The DNA was eluted from the spin column using ddH2O and 
DNA yields were calculated at A260 using 1:25 dilutions of stock DNA in ddH2O. DNA 
yields in the range of 4.3-20µg/ml were generally obtained. The presence of a correct size 
insert was confirmed by PCR as described in section 2.1.2, using 100ng of the purified DNA 
as template. 
 
2.1.5 Restriction digests 
Restriction digests with HindIII restriction enzyme were carried out by incubating 
0.136-1µg of DNA with 5U of restriction enzyme HindIII (Promega, Madison, WI) in the 
presence of 1×buffer E (Promega, Madison, WI), and 2µg acetylated BSA in a volume of 
20µl made up using ddH2O. The mixture was incubated for 2 hrs at 37˚C.  
Digestion of the pCEP-4:BM40:LTBP-2C(H):his6 was carried out as follows; 1µg of 
purified plasmid was incubated at 37˚C for 3 hrs with 5U of restriction enzyme KpnI 
(Promega, Madison, WI), 2µg acetylated BSA and 1×buffer J (Promega, Madison, WI) in a 
volume 20µl. Digested DNA samples were analysed on a 0.8% agarose gel. 
 
2.1.6 DNA Sequence Analysis  
To ensure the integrity of the DNA and to confirm the orientation of cDNA inserts, 
DNA sequencing was conducted by incubating Big-Dye version 3.0 ready reaction mix (1µl) 
with 200ng of purified plasmid DNA, 1×Big Dye sequencing buffer (supplied Molecular 
Pathology sequencing, Institute of Medical and Veterinary Science, Adelaide as 5×stock) and 
5pmol sequencing primers (M13F or M13R (appendix A), in a reaction volume of 20µl 
made up with ddH2O. Sequencing was carried out using the PCR conditions of heating of the 
samples to 96˚C for 1 min, then 25 cycles of 96˚C for 10 sec, 50˚C for 10 sec, 60˚C for 4 min, 
followed by a final step of incubating samples at 25˚C for 10 sec before holding the reaction 
at 4˚C prior to DNA precipitation with isopropanol.   
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Sequencing reactions were precipitated by adding 80µl of 75% (v/v) isopropanol to 
the sequencing reaction and vigorously agitating it for a few seconds before incubating at RT 
for 20 min to precipitate PCR products. Samples were centrifuged for 20 min at 17,500×g 
and the isopropanol was carefully aspirated. To wash the pellet 250µl of 75% isopropanol 
was added, agitated briefly and centrifuged for 10 min at 17,500×g. The isopropanol was 
removed without disturbing the pellet and the pellet was air dried. The samples were then 
sent to the Molecular Pathology Sequencing Centre, Institute for Medical and Veterinary 
Science, Adelaide, Australia for automated sequence analysis using the 3700 DNA analyser 
(Applied Biosystems, Foster City, CA). Further sequencing was undertaken of the full length 
of LTBP-2C(H) cDNA insert using LTBP-R2 or HLTBP-F3 primers (appendix A) to select 
error-free clones. Cells containing error free clones were grown in luria broth sterile glycerol 
in a 7:3 ratio and the stocks were stored at -70˚C.  
 
2.1.7 Dephosphorylation 
After linearization, the modified pCEP-4 vector (pCEP-4:BM40:his6) (section 2.1.5), 
was dephosphorylated using Shrimp alkaline phosphatase (Boehringer Mannheim GmbH, 
Mannheim, Germany). For the 500ng of vector DNA, 20U of shrimp alkaline phosphatase 
with 1×dephosphorylation buffer supplied by Boehringer Mannheim GmbH as 10×stock was 
incubated in a volume of 100µl at 37˚C for 2 hrs. The enzyme was deactivated by incubation 
at 65˚C for 15 min and the dephosphorylated vector was recovered using ethanol 
precipitation (section 2.1.3). The recovered vector was resuspended in ddH2O to give 10ng/µl. 
DNA T4 ligase was used in conjunction with 4:1 ratio of insert to vector for ligation of 
LTBP-2C(H) into the dephosphorylated modified pCEP-4 vector.  
 
2.2 Production of human LTBP-2 fragments 
2.2.1 LTBP-2C(H) 
The central fragment (LTBP-2C(H)) cDNA was obtained by PCR amplification of 
bases (2758-5142) from full length human LTBP-2 clone (LTBP-2:BM40:his6:pCEP-4) 
constructed by Dr. E. Hanssen (see Hirani et al., 2007). Primers LTBP-2 Central Forward 
and LTBP-2 Central Reverse (appendix A) containing HindIII restriction site were used 
under the conditions described in section 2.1.1 to produce a PCR product of 2373 base pairs. 
The LTBP-2C(H) PCR product was purified from 0.8% (w/v) agarose gel and was “A”-tailed 
and ligated to pGEM-T-easy vector (section 2.1.2 & 2.1.3). The pGEM-T:LTBP-2C(H) 
construct was transformed into JM109 competent cells (section 2.1.4) and purified plasmid 
DNA from selected clones was sequenced to identify error-free clones (section 2.1.6).  
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The LTBP-2C(H) insert was excised from the pGEM-T-easy vector with HindIII 
restriction enzyme (section 2.1.5) for ligation into the dephosphorylated modified pCEP-4 
vector (section 2.1.7). The modified vector contained a BM40 signal peptide at the 5’end and 
a his6-tag at the 3’ end. 
For preparation of the pCEP-4:BM40:his6 modified vector, the full length LTBP-2 
insert was removed from the pCEP-4:LTBP-2 plasmid by HindIII  restriction enzyme 
digestion (section 2.1.5). The pCEP-4:BM40:his6 vector and full length LTBP-2 cDNA insert 
were separated using agarose gel electrophoresis (section 2.1.2). The pCEP-4:BM40:his6 
vector band (approximately 10356bp) was purified from 0.8% agarose gel, a portion of it 
being ligated back to itself using T4 DNA ligase (section 2.1.7) and propagated in JM109 
cells (section 2.1.4). Glycerol stock of a clone was made for future use of the vector. The 
remaining portion was dephosphorylated (section 2.1.7) prior to ligation with the HindIII-
digested LTBP-2C(H) cDNA insert. JM109 cells were transformed with the ligated construct 
and plasmid DNA from individual colonies was purified (section 2.1.4). The desired pCEP-
4:LTBP-2C(H) clones in the correct orientation were identified using KpnI (Promega, 
Madison, WI) enzymatic digestion (section 2.1.5). Digestion of the modified pCEP-4 content 
in the correct orientation produces two fragments of approximately 728 base pairs and 12013 
base pairs. 
The recombinant pCEP-4:LTBP-2C(H) expression construct needed to be highly 
purified, and larger quantities of the plasmid were required for transfection into mammalian 
cells. Luria broth cultures of the selected clone were prepared (section 2.1.4) and plasmid 
DNA was purified using the QIAfilter® midi kit (Qiagen GmbH, Hilden, Germany), 
following the manufacturer’s instructions for low-copy number plasmids. Purification of 
plasmid DNA was carried out from 50ml of Luria broth cultures. A slight modification in the 
final elution step was made where eluted DNA (8ml) was aliquoted equally between 8 tubes 
with the manufacturer’s recommended amount of isopropanol (2.5ml) equally divided 
between them. The DNA was precipitated by centrifugation and the pellet in each individual 
tube was resuspended in ddH2O and then pooled together. The concentration of the purified 
plasmid DNA was found to be 0.5-1mg/ml from the absorbance reading (A260) using 1:25 
dilution of stock DNA in ddH2O.  
 
2.2.2 LTBP-2NT(H) 
A cDNA encoding the amino-terminal region of human LTBP-2, LTBP-2NT(H), 
corresponding to bases 2758-5142, was obtained by PCR amplification from a full length 
human LTBP-2 clone as described above using primers LTBP-2NT(H) Forward and Reverse 
(appendix A) (section 2.1.1). The PCR product of 2272 base pairs was analysed by  
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electrophoresis on a 0.8% agarose gel, and the LTBP-2NT(H) cDNA was excised from the 
gel (section 2.1.2) and purified. The purified cDNA fragment was “A”-tailed and ligated into 
the pGEM-T-easy vector (section 2.1.3) and the pGEM-T-easy:LTBP-2NT(H) construct was 
transformed into JM109 competent cells (section 2.1.4). Purified plasmid DNA from selected 
clones was digested with a HindIII restriction enzyme to confirm the presence of the HindIII 
restriction sites (section 2.1.5) on the insert, prior to sequencing using pGEM-T-easy primers 
(pUC/M13 forward & reverse) (appendix A). However, only a low number of colonies in 
transformed JM109 cells were obtained and I was unable to identify any error-free clones. 
Time constraints prevented the repeat of the procedure. 
 
2.3 Expression of recombinant LTBP-2C(H) 
For expression of rLTBP-2C(H), 293 EBNA human embryo kidney (HEK) cells 
(Invitrogen, Carlsbad, CA) were grown in Dulbecco’s Modification of Eagles Medium 
(DMEM) to confluency at 37˚C and in the presence of 0.5% CO2. The medium was 
reconstituted from powder following the manufacturer’s instructions (Gibco, Carlsbad, CA) 
(appendix B) and it was supplemented with 1×non-essential amino acids (NEAA) (Thermo 
electron, Australia), 10% (v/v) heat deactivated (∆) foetal calf serum (FCS) and 250mg/L 
geneticin (for selection of EBNA-1 containing cells) (Gibco, Carlsbad, CA). Cells were 
counted with trypan blue stain, using a 1:1 ratio of trypan blue to cell solution and were 
plated at 2×10
5 cells/ml. Transfection of the plated cells was carried out with 2µg/ml of 
plasmid DNA and 4µg/ml of lipofectamine 2000 reagent (Invitrogen, Carlsbad, CA). The 
DNA was substituted with ddH2O in one set of control wells, while the second set of control 
wells lacked both Lipofectamin 2000 and DNA.  
24 hrs after transfection the medium was removed from the cells and the cells were 
gently washed with Dulbecco’s PBS (appendix B) to remove the entire transfection reagent. 
Dulbecco’s PBS was used to remove cells from the surface of the wells by agitation and these 
were washed in 5ml of DMEM (no supplement). The cells were pelleted by centrifugation for 
5 min at 260×g, gently resuspended in 25ml DMEM/10% (v/v) ∆FCS/ 1×NEAA/ geneticin 
(250mg/L) and then divided equally into 10 fresh wells. Only two fresh wells were plated for 
each control. 
48 hours after transfection, the medium was changed to a fresh medium (DMEM, 
10% (v/v) ∆FCS, 1×NEAA, geneticin (250mg/L), hygromycin (250mg/L)). This medium had 
the addition of hygromycin (Roche Diagnostics GmbH, Mannheim, Germany) which is the 
selective antibiotic for the pCEP-4:LTBP-2C(H) plasmid. Selection continued until the 
control cells in the selection medium had died, which was suggestive that the remaining 
viable cells in the transfection wells contained the selected recombinant plasmid.  
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Prior to full scale protein production, individual clones were tested for expression of 
the recombinant protein using small scale Nickel Chelate chromatography (section 2.4). The 
colony expressing the highest level of the specific recombinant protein was chosen for 
propagation. When the hygromycin-selected cells had reached confluency, the cells were 
washed with Dulbecco’s PBS, removed with agitation and pelleted (centrifuged 260×g for 5 
min). Cells from each well of 9.6cm
2 were divided in two 80cm
2 propagation flasks with 
10ml of culture medium (DMEM, 10% (v/v) ∆FCS, 1×NEAA, geneticin (250mg/L), and 
hygromycin (250mg/L)) and grown until the cells were confluent. One of the confluent flasks 
was used for recombinant protein expression described below, while the other was used for 
continued propagation of transfected cells. 
Full Length human LTBP-2 cDNA and βig-h3 cDNA expression constructs were 
prepared as previously described (Hanssen et al., 2003; Hirani et al., 2007), and the 
recombinant proteins were expressed and purified as described below.  
 
2.4 Purification of recombinant full length LTBL-2, βig-h3 and LTBP-2C(H)  
fragment 
Standard practice was to use 12×175cm
2 flasks of propagating cells; 11 were placed 
into a serum-free medium for production of recombinant protein and a flask was passaged 
into 4 flasks and then 12 flasks for continuation of cell propagation. Confluent cells were 
washed with 3×Dulbecco’s PBS (appendix B) prior to incubation with serum-free DMEM 
supplemented with 1×NEAA, geneticin (250mg/L) and hygromycin (250mg/L) for 3 days 
prior to harvest. 
To maximise the quantity of recombinant protein harvested from the 11 flasks, the 
cells were re-incubated with DMEM supplemented with heat deactivated new born calf 
serum (∆NBCS) (Invitrogen, Carlsbad, CA) (∆FCS was substituted with ∆NBCS during 
protein production) overnight followed by a second round of serum free-medium for an 
additional three days. 
The serum-free conditioned medium was centrifuged at 260×g for 5 min to remove 
the cells and then centrifuged at 50,000×g for 30 min at 4˚C in a Heraeus Biofuge stratos 
centrifuge (Kendro laboratory products GmbH, Hanau, Germany) to remove any residual cell 
debris that may have not been previously removed. The medium was then filtered through a 
0.45µm bell filter (Pall Corporation, Pensacola, FL) to remove further cell debris. To prepare 
the medium for Ni-Chelate chromatography, the medium was adjusted to contain a final 
concentration of 20mM NaH2PO4 and 10mM imidazole using 8×phosphate buffer and 2M 
imidazole (BDH Chemicals, Carle Place, NY) (appendix B). The addition of a low 
concentration of imidazole to the medium prior to incubation with Ni-sepharose resin had  
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been found to reduce the amount of non-specific binding of proteins without competing with 
the his6-tagged protein. 
Recombinant proteins were purified using a His-trap sepharose column, following the 
manufacturer’s instructions (Pharmacia Biotech, Uppsala, Sweden). Briefly, for every 100ml 
of serum-free media, 1ml of Ni-sepharose for rLTBP-2 and rLTBP-2CH and 400µl of Ni-
sepharose for rβig-h3 was used. Preparation of the sepharose was carried out as follows: the 
ethanol storage solution was washed from the beads with 5 column (col) vol of ddH2O, then 
1.5 col vol of NiSO4 (0.1M) (appendix B) was added and incubated with the sepharose beads 
for 5 min. The nickel solution was then drained and the sepharose was washed with 5 col vol 
of ddH2O prior to equilibration with 10 col vol of 10mM imidazole buffer (appendix B). 
Successfully charged sepharose beads appeared blue in colour.  
The Ni-sepharose beads were incubated with the serum-free medium on a rotator 
wheel for 3 hrs at RT, or overnight at 4˚C. Beads were collected by centrifuging at 260×g for 
2 min and were then transferred to a 2ml Econo column. The media was drained and further 
unbound proteins were eluted with 5 col vol of 10mM imidazole buffer the first three col vol 
of washes were combined with the drained medium and were stored at 4˚C for re-application 
to a fresh Ni-sepharose column to recover further recombinant protein. Three rounds of 
purification were performed per batch of serum-free medium to recover all of the 
recombinant protein. Bound recombinant protein was eluted with 10 col vol of 500mM 
imidazole buffer (appendix B) and 10 fractions were collected, each corresponding to one 
col vol. It is the high concentration of imidazole that displaces the his6-tag protein from the 
Ni-sepharose. After collection of recombinant protein from the Ni-sepharose, the column was 
washed with 10 col vol of 10mM imidazole buffer in preparation for a second round 
purification of recombinant protein.  
When the final round of purification was completed, Ni-ions were stripped from the 
chelating-sepharose beads using 10 col vol of 0.05M EDTA solution (appendix B). Removal 
of any precipitated proteins in the column was then carried out by incubation of the nickel 
stripped sepharose with 0.1M NaOH solution (from a 1M NaOH solution, appendix B) for at 
least 2 hrs at RT, followed by extensive washing of the beads with ddH2O. The Ni-sepharose 
beads were to be either charged with nickel to use for the next batch or stored in 20% (v/v) 
ethanol at RT. The purification and authenticity of recombinant proteins was checked by 
SDS-PAGE and western blot analysis (section 2.6). Concentrations of purified proteins were 
determined from a SDS-PAGE resolved sample using the public domain NIH Image program 
version 1.63 (developed at the U.S. National Institutes of Health and available on the Internet 
at http://rsb.info.nih.gov/nih-image/).  
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The first two fractions of 500mM imidazole elution for full length rLTBP-2 were 
generally found to contain the highest concentration of recombinant proteins. These fractions 
were pooled and dialysed into TBS containing 0.5M NaCl (TBS/0.5M NaCl) (appendix B). 
The addition of salt was to prevent the precipitation of purified recombinant protein from the 
solution. The removal of 500mM imidazole from purified protein was essential as it was 
found to interfere with assays where anti-(his6-tag) antibodies were used for protein detection. 
Dialysis was carried out in Spectrapor membrane with a pore size of 6-8000Da (Spectrum 
Laboratories, Inc., Rancho Dominguez, CA), overnight at 4˚C or for 3 hrs at RT with several 
changes of buffer at least 100 times the volume of the sample. Dialysed protein was aliquoted 
and stored at -20˚C. For longer storage the aliquots were stored at -80˚C. 
A similar eluting pattern was observed for rLTBP-2C(H) where the highest 
concentration of the recombinant protein was found in the first two collected fractions. 
However, in contrast to this result, only fraction two of the full length rβig-h3 was found to 
have a majority of the recombinant protein. Fractions containing recombinant proteins were 
pooled, dialysed and stored similarly as described for full length rLTBP-2. The exception is 
the storage of rβig-h3 at 4˚C since freezing of the protein causes precipitation.  
 
2.5 Freezing and Thawing of recombinant protein expressing cells.  
Cells at 5×10
6/ml were rinsed with Dulbecco’s PBS and were collected in a 10ml tube 
with 5ml of Dulbecco’s PBS with the 10ml made up with DMEM. The cells were pelleted 
(centrifuged 260×g for 5 min) and once the supernatant was removed the pellet was 
resuspended in 5ml of freezing solution A (appendix B). Freezing solution B (5ml) 
(appendix B) was then added drop wise with shaking prior to preparation of 1ml aliquots in 
cryovials. The cryovials were stored at -70˚C overnight prior to storage in liquid nitrogen. 
The frozen vials (5×10
6/vial) of transfected cells were thawed by placing the vial into 
a 37˚C water bath until almost thawed, then 10ml of DMEM (no supplements) was added to 
the cells at RT and it was incubated for 5 min, before centrifuging at 260×g for 5 min. The 
cells were then resuspended in 1ml of DMEM and transferred into a 80cm
2 flask with 10mls 
of culture medium (DMEM, 10% (v/v) ∆FCS, 1×NEAA, geneticin (250mg/L), and 
hygromycin (250mg/L). 
 
2.6 SDS-PAGE Coomassie Blue staining and western immunoblotting 
Purified proteins were analysed using microslab SDS-PAGE, and the discontinuous 
buffer system of Laemmli (Laemmli, 1970). The separating gel ranged from 6.5-15% (v/v) 
acrylamide and stacking gel concentration of 3% (v/v) acrylamide (Sigma-Aldrich, St. Louis, 
MO) (appendix B). Protein samples were precipitated with 10 vol of ice-cold 90% (v/v)  
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acetone at -20˚C for 20 min. This was followed by pelleting of the precipitated protein by 
centrifugation at 17,500×g for 10 min. The supernatant was removed carefully and discarded 
and the pellet was washed with 90% (v/v) acetone for 10 min, at 17,500×g. Acetone was 
carefully removed, the pellet was resuspended in protein sample loading buffer (appendix B) 
containing 2% (v/v) β-mercaptoethanol (Sigma-Aldrich, St Louis, MO) and boiled for 2 min. 
The samples were loaded into individual wells of a polyacrylamide gel and resolved at 150V 
in the chamber buffer (appendix B) until the dye front was a few millimetres from the 
bottom of the gel. Broad range molecular weight protein standards (Bio-Rad Laboratories, 
Hercules, CA) at 0.5µg/protein band were run simultaneously. 
For visualisation and quantitation of protein bands, SDS-PAGE gels were stained 
with fresh Coomassie Blue (appendix B) for 15 min with gentle agitation. The gels were 
destained by rinsing and then incubated in 40% (v/v) methanol/acetic acid solution 
(appendix B) for 5 min. This was followed by incubation of the gel with 7.5% (v/v) 
methanol/acetic acid solution (appendix B) for a minimum of 30 min or until sufficient 
destaining of the gel was achieved. The gel was washed in ddH2O prior to drying overnight 
between cellophane sheets. Protein quantitation was performed on a Macintosh computer 
using the NIH Image program version 1.63 (developed at the U.S. National Institutes of 
Health and available on the Internet at http://rsb.info.nih.gov/nih-image/). 
For western immunoblotting, SDS-PAGE gels were used as above but the proteins 
were transferred onto polyvinylidene difluoride (PVDF) membrane as follows. The gel was 
washed twice in a Tris/Glycine buffer (appendix B) for 10-15 min, while the Bio-trace 
PVDF membrane (0.45µm) (Pall Corporation, Pensacola, FL) was activated by rinsing in 
100% (v/v) methanol for 1 min, followed by rinsing in ddH2O for 5 min and Tris/Glycine 
buffer for 10 min. The gel was sandwiched between the smooth side of the PVDF membrane 
and Whatman paper (3mm grade, Whatman International Ltd, Maidstone, England) prior to 
placing it into the wet transfer apparatus. Protein bands were transferred onto PVDF 
membrane using 60V in a negative to positive direction for 90 min with gentle stirring of the 
Tris/Glycine buffer using a magnetic stirrer. After transfer, the lane containing the Bio-Rad 
standard proteins was cut off and stained with Coomassie Blue. The remainder of the 
membrane was washed 2×5-10 min in TBS (appendix B) and incubated into a blocking 
solution (appendix B) for 1 hr at RT with gentle shaking. 
The primary antibody at the designated concentration (appendix C) was incubated 
with the blot for 2.5 hrs at RT or at 4˚C overnight in antibody solution (appendix B). The 
PVDF membrane was washed 2×5 min in Tris/Tween-20/Triton X-100 solution (appendix B) 
followed by 5 min in TBS with gentle agitation. Diluted secondary antibody conjugated with 
alkaline phosphatase (Bio-Rad Laboratories, Hercules, CA) in the antibody solution was  
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incubated with the membrane for 1.5 hrs at RT with gentle agitation. The membrane was then 
washed in Tris/Tween-20/Triton X-100 solution (appendix B) for 3×5 min with gentle 
shaking, rinsed with substrate buffer (appendix B) and developed with developing solution 
(appendix B). When sufficient development of the protein bands was achieved, colour 
development was stopped by rinsing the membrane in ddH2O prior to air drying of the 
membrane. 
 
2.7 Silver staining 
The silver staining method used at first to detect protein bands separated by SDS-
PAGE was adopted from Cheng et al., (1994). Upon separation of protein samples under 
reduced conditions (section 2.6), the proteins were fixed by incubating the gel with 25% (v/v) 
isopropanol, 10% (v/v) acidic acid for 30 min, followed by 2× 10min washes with 10% (v/v) 
isopropanol 5% (v/v) acetic acid. Sensitisation of the gels was carried out by incubating in 
5µg/ml (w/v) of dithiothreitol for 15 min, prior to staining with 0.1% (w/v) silver nitrate for 
15 min. The gels were then rapidly rinsed in ddH2O once and then twice with the developing 
solution (0.5% (v/v) paraformaldehyde, 3% (w/v) sodium carbonate). The gels were exposed 
to the developing solution until protein bands were developed satisfactorily, when further 
development was terminated by rinsing the gels in 1% (v/v) acetic acid. The gels were 
washed in ddH2O and then dried overnight between cellophane sheets. 
The second silver staining protocol used for protein detection was a method obtained 
from Dr. Wilson, R. of Murdoch Children’s Research Institute and Department of Paediatrics, 
University of Melbourne, Australia, a modified version being described in (Gromova, 2006). 
Briefly, protein samples were separated under reduced conditions using SDS-PAGE. Each 
gel was fixed in 50% (v/v) methanol, 12% (v/v) acetic acid, and 0.05% (v/v) formalin with 
gentle shaking for 30 min. The gel was then washed in 35% (v/v) ethanol for 3×10 min, 
sensitised with 0.02% (w/v) sodium thiosulphate for 2 min and rinsed quickly in ddH2O. The 
gel was stained in ddH2O containing 0.2% (w/v) AgNO3, 0.076% (v/v) formalin for 20 min 
and rinsed with ddH2O. The gel was rinsed quickly and then stained with developer (5% (w/v) 
NaCO3, 0.05% (v/v) formalin, and 0.008% (w/v) Na2S2O3) until the desired level of protein 
staining was reached. Development was stopped with 50% (v/v) methanol, 12% (v/v) acetic 
acid solution and the gel was washed in ddH2O for 5 min before drying overnight between 
cellophane sheets.  
 
2.8 Determining the molecular weight of unknown proteins 
Protein samples of unknown size were electrophoresed under denaturing or non-
denaturing conditions along side standard proteins of known size (section 2.6) prior to  
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Coomassie Blue staining. The unknown molecular weights were determined by preparing a 
standard curve of relative mobility (Rf) of the standard proteins versus the log of the 
molecular weight of each standard protein. Briefly, the distance from the top of the resolving 
gel to the top of each standard protein band in SDS-PAGE was measured in millimetres. The 
distance from the top of the resolving gel to the top of the dye front was also obtained. The Rf 
of each protein standard was calculated using the equation Rf= distance of protein migration/ 
distance of the dye front. The log of the molecular weight was plotted against the Rf value of 
the standard proteins and the line of best fit was drawn through the data points. The 
molecular weights of other proteins run on the same gel was determined by measuring the 
migration distance of the band, calculating the Rf value and then using the standard curve to 
read the log of the molecular weight from the graph. 
 
2.9 Mass spectrometric analysis 
For verification of the rLTBP-2C(H) mass fingerprinting was performed at the 
Adelaide Proteomics Centre under the supervision and guidance of Dr. C. Bagley. Under 
reducing conditions the sample was separated by SDS-PAGE (section 2.6) and Coomassie 
Blue stained. The gel was rinsed with H2O prior to excision of the band. The band was cut 
again in two and each half was placed into a 1.5ml eppendorf and each half was cut again 
into 2 or 3 smaller pieces followed by 2× 500µl washes with 100mM NH4HCO3 at RT with 
shaking. After the removal of the solution, the gel pieces were destained by incubating with 
500µl of 100mM NH4HCO3 in 50% (v/v) acetonitile for 15 min at RT with agitation. The gel 
particles were spun down by pulse centrifugation and excess liquid was then removed. The 
step was repeated until gel pieces were 90% clear. Two rounds of this step were required for 
sufficient destaining. The gel pieces were then incubated with acetonitrile (200µl) for 15 min 
at RT until they had shrunk, at which point they became white and stuck together. The gel 
pieces were collected at the bottom of the tube by centrifugation and the liquid was removed 
prior to using a vacuum centrifuge for 4 min to dry the gel pieces. To reduce the protein, 
dried gel pieces were re-swelled with 50µl of 10mM dithiothreitol in 100mM NH4HCO3 at 
56˚C for 15 min, rinsed with 100mM NH4HCO3 and shrunk with 200µl of acetonitrile for 15 
min at RT with agitation. After collecting the gel pieces by centrifugation and removal of the 
supernatant, the gel pieces were incubated with 50µl of 55mM iodoacetamide in 100mM 
NH4HCO3 in the dark for 30 min. The iodoacetamide solution was removed and the gel 
pieces were rinsed and incubated with 100µl with 5mM NH4HCO3 at RT for 10 min. The 
solution was then removed and the gel pieces were shrunk and dried by vacuum centrifuge as 
previously described. At this stage one sample was stored and the other sample was digested 
with trypsin as follows. The gel pieces were rehydrated with 10µl of diluted trypsin (100ng/µl  
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in 5mM NH4HCO3) for 10 min before the addition of 20µl of 5mM NH4HCO3 solution (no 
trypsin) and incubation at 37˚C overnight with shaking. Digested peptides were present in the 
solution, so the 20µl solution was transferred into a new eppendorf tube. To ensure all of the 
digested peptides were removed from the gel, the gel was sonicated with 20µl of 1% (v/v) 
Trifluoroacetic acid for 5 min, 20µl of 0.1% Trifluoroacetic acid (v/v) in 50-60% (v/v) 
acetonitrile for 15 min and 50µl 100% acetonitrile for 15 min respectively in a water bath. 
After each incubation the solution was transferred to a new tube before the next solution was 
added to the gel. Finally the solutions containing the extracted peptide were pooled and dried 
down to 2-10µl using vacuum centrifugation. Matrix-assisted laser-desorption/ionisation 
time-of-flight mass spectrometry (MALDI-TOF-MS) analysis was used to authenticate 
LTBP-2C(H) by comparing the originated molecular weights of the peptide to the published 
LTBP-2 amino acid sequence and also to the protein sequence databases. 
 
2.10 Synthesis and Fractionation of Covalently bound conjugates of heparin and 
albumin 
For synthesis of heparin-albumin conjugates (HAC) a method modified from Hennink 
et al., (1983) was used. Briefly, a 1.6:1 ratio of molar concentration of heparin sodium salt 
from porcine intestinal mucosa (Sigma-Aldrich, St Louis, MO) to albumin (bovine serum 
albumin (BSA) (Sigma-Aldrich, St Louis, MO)) was resuspended in ddH2O (for 77mg of 
heparin 5ml of ddH2O was used) and the solution was adjusted to pH 5. A white precipitate 
was formed which contained both heparin and albumin, and the precipitate dissolved within 1 
hr. To the solution 8×100µl portions of N-(3-Dimethylaminopropyl)-N’-ethylcarbodiimide 
hydrochloride (EDC) (Sigma-Aldrich, St Louis, MO) (32.5mg/ml) were added at 30 min 
intervals with stirring. The solution was maintained at pH 5. Half an hour after the last 
addition of EDC, the solution was adjusted to pH 7.6 and stirring was continued for 20 hrs at 
4˚C. The solution was dialysed for 2×1 hr against 0.025M Tris, pH 7 (in volume of 50ml 
each time) for subsequent ion chromatography. 
Fractionation of unreacted albumin and HAC was achieved by ion exchange 
chromatography on a column of DEAE-sepharose Cl4B (2.3ml of resin to 5ml of solution), 
which had been pre-washed with 10 col vol of ddH2O to remove ethanol and equilibrated 
with 10 col vol of equilibration buffer (0.3M NaCl/0.025M Tris pH 7). Unreacted albumin 
was eluted with an equilibration buffer (0.3M NaCl/0.025M Tris pH 7) (15×2ml fractions), 
then unfractionated purified conjugate (HAC) was eluted with 0.9M NaCl/0.025M Tris-HCl, 
pH 7 (10×2ml fractions) and stored at -70˚C. 
The albumin concentrations of eluted fractions (free or conjugated) were determined 
from A280 readings of 1:4 dilution of eluted fractions (50µl) to 0.3M NaCl/0.025M Tris pH7  
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(for determining free albumin) or 0.9M NaCl/0.025M tris pH 7 (for detection of conjugated 
albumin) (150µl) in UV-1601 spectrophotometer (Shimadzu, Kyoto, Japan), using a BSA 
standard curve (0-200µg) diluted in the same buffer. The amount of albumin present in each 
fraction was determined by correlating the (A280) with an established BSA standard curve. 
The majority of albumin (free or conjugated) was present in the first four fractions, and after 
that no albumin was detected in the fractions. The heparin concentration was determined 
using an uronic acid assay described in section 2.11. 
 
2.11 Uronic acid assay 
Hexosamine and uronic acid are components of the repeating unit of all GAGs with 
the exception of keratosulphate. To determine the quantity of GAGs in biological substances, 
uronic acid assay is widely used (Blumenkrantz and Asboe-Hansen 1973). A standard curve 
was established using a serial dilution of D-glucuronic acid (0-200µg) diluted in 0.9M 
NaCl/0.025M Tris pH 7. The volume was made up to 200µl using ddH2O. Individual 
fractions containing HAC (1/50 and 1/100) in 0.9M NaCl/0.025M Tris pH 7 were also 
diluted and transferred into pyrex disposable culture tubes (Borosilicate Glass). Sulphuric 
acid (H2SO4)/sodium tetraborate solution (1.2ml) (appendix B) was added to the sample 
tubes, and the samples were vortexed and heated for 5 min at 100˚C, before cooling in an ice 
water bath. After cooling, 20µl m-hydroxydiphenyl solution was added and the samples were 
vortexed well before reading at A520 within 10 min of preparing the samples.  
 
2.12 Determination of protein concentration using Bradford assay 
The Bradford assay (Bradford, 1976) was used to determine the concentration of 
proteins in tissue extracts and proteins eluted from affinity chromatography columns. This 
assay uses coomassie brilliant blue G250 which binds protein causing a shift in the 
absorption maximum from 465nm to 595nm. To prepare the assay solution, Coomassie 
Brilliant Blue G250 (25mg) was dissolved in a mixture of 12.5ml of 95% ethanol and 25ml 
of 85% phosphoric acid. The volume was made up to 250ml using ddH2O and the solution 
was mixed for at least 40 min on a stirrer. The solution was filtered through Whatman’s 
paper before use to remove any Coomassie Brilliant Blue that had not dissolved. A serial 
dilution of ovalbumin (0-10µg) was prepared in a total volume of 100µl of appropriate buffer 
for establishment of a standard curve. To each diluted protein sample or standard 1ml of the 
Coomassie Blue reagent was added. The samples were then vortexed and left for 2 min to 
allow the binding of Coomassie Blue to the protein before analysis in a spectrophotometer 
(UV-1601, Shimadzu, Kyoto, Japan) at 595nm. The A595 readings of the samples were used 
to determine their concentration from the established standard curve.  
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2.13 Solid phase binding assay 
2.13.1 Detecting interaction between two proteins 
The wells of Immuno-Maxisorb modules (Nalge-Nunc International, Roskilde, 
Denmark) were coated with 400ng of test protein diluted in TBS/2mM CaCl2 (unless 
otherwise stated) and incubated overnight at 4˚C in a humidity chamber. Candidate proteins 
used for coating of the wells were HAC (see section 2.10), human recombinant syndecan-2 
and syndecan-4 (R&D Systems, Minneapolis, MN) or purified perlecan (Whitelock, 2001). 
Control wells were coated with the molar equivalent of BSA. All experiments were carried 
out using triplicate wells and each experiments was performed a minimum of three times for 
consistency. Unbound material was washed with 3×TBS/ 2mM CaCl2, and wells were 
blocked for 1.5 hrs at RT with 5% (w/v) low fat dried milk (Diploma instant, Rowville, Vic, 
Australia) in TBS/2mM CaCl2 with gentle agitation. The wells were then rinsed with 
3×TBS/2mM CaCl2 prior to incubation with 200ng of second test protein (LTBP-2 and its 
fragments unless otherwise stated in the figure legends) diluted in TBS/2mM CaCl2. Controls 
of HAC-coated wells were incubated with the molar equivalent of BSA in solution to assess 
the level of cross reactivity of the antibodies being used. After the wells were washed with 
3×TBS/2mM CaCl2 the wells were incubated with primary antibodies specific to the second 
test protein (concentrations as stated in appendix C) in TBS/2Mm CaCl2/0.05% low fat milk 
for 2.5 hrs in humidity chamber at 37˚C. Following antibody incubation the wells were then 
washed with 3×TBS/0.05% (v/v) Tween-20/2mM CaCl2 before they were incubated with the 
secondary antibody, horseradish peroxidase-conjugated (Bio-Rad Laboratories, Hercules, CA) 
at required dilution (appendix C) in TBS/2mM CaCl2 for 1.5 hrs at 37˚C in the humidity 
chamber. After final washes with 4×TBS/ 0.05% (v/v) tween-20/2mM CaCl2, interaction was 
detected using 100µl of 3,3’,5,5’-tetramethylbenzidine substrate (Sigma-Aldrich, St. Louis, 
MO) at RT. Colour was allowed to develop for up to 1 hr at RT with no agitation and colour 
development was stopped by using 0.5M H2SO4 (50µl per well). Absorbance was detected at 
450nm, using Titertek Multiskan MC (Flow Laboratories, North Ryde, NSW, Australia). 
 
2.13.2 Saturation binding curve 
For saturation curves, maxisorb modules were coated with uniform amounts of the 
solid phase test protein and blocked as stated previously in section 2.13.1. Control wells were 
coated with a molar equivalent of BSA. A serial dilution of the liquid phase protein (in 
TBS/2mM CaCl2) was added to the wells and incubated for 2.5 hrs in a humidity chamber at 
37˚C. Reciprocal curves were also produced where serial dilution of a solid phase test protein 
was incubated with a constant amount of second test protein in a liquid phase (TBS/2mM 
CaCl2). The control wells contained a serial dilution of molar equivalent of BSA coated on  
   - 54 - 
the wells. After blocking, the appropriate primary antibody was used for the detection of 
protein-protein interaction using horseradish peroxidase-conjugated secondary antibody and 
3,3’,5,5’-tetramethylbenzidine substrate revelation as stated previously.  
 
2.13.3 Inhibition of binding 
For inhibition of binding experiments, maxisorb modules were coated overnight at 
4˚C in a humidity chamber with test proteins (HAC or perlecan) diluted in TBS/2mM CaCl2, 
and blocked as described previously in section 2.13.1. Control wells were coated with the 
molar equivalent of BSA. For complete inhibition, full length rLTBP-2 (in TBS/2mM 
CaCl2/0.05% (w/v) diploma brand low fat dried milk) was pre-treated with 10-fold molar 
excess of free heparin or chondroitin-6-sulphate (C-6-S) for 15 min at RT with gentle 
agitation. Positive controls where full length rLTBP-2 in the absence of free heparin or C-6-S 
was incubated for 15 min at RT were included. The pre-treated rLTBP-2 was added to 
triplicate wells and incubated for 2.5 hrs at 37˚C. Unbound proteins were washed with 
3×TBS/2mM CaCl2 and bound LTBP-2 was detected using anti-(LTBP-2) antibody (LTBP-
2C) followed by goat anti-rabbit IgG horseradish peroxidase-conjugate. The interaction was 
detected with 3,3’,5,5’-tetramethylbenzidine substrate as stated above. 
For inhibition binding curves, maxisorb plates were coated with HAC or BSA 
(2pmol/well) and were blocked with milk as described above. Full length rLTBP-2 
(1pmol/well) was pre-treated with increasing molar excess of free heparin (0-20pmol) as 
described previously. 
 
2.13.4 Determination of dissociation constants 
Dissociation constants (Kd) for specific interactions were calculated from the ELISA 
binding curves. Maxisorb modules were coated with a constant amount of HAC (33ng/well) 
overnight at 4˚C, followed by incubation with an increasing amount of recombinant test 
protein (full length LTBP-2 or LTBP-2C(H)) for 3 hrs at 37˚C, to establish a saturation curve. 
A standard curve of recombinant test protein was concurrently constructed where maxisorb 
wells were coated overnight with an increasing amount of recombinant test protein. Control 
wells were coated with a molar equivalent of BSA. Anti-LTBP-2 antibody (LTBP-2C) was 
used for detection of full length LTBP-2, and anti-(tetra-his) antibody was used for detection 
of LTBP-2C(H). The amount of recombinant test protein bound to heparin in the saturation 
experiment was calculated from the standard curve. After subtraction of the background 
binding to the BSA-coated control wells, the amount bound was plotted against the total 
amount added using data from three repeat experiments. Non-linear regression analysis using  
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Graphpad Prism version 4.02 software for windows (Graphpad Software, San Diego, CA, 
www.graphpad.com) was used to determine the dissociation constant.  
 
2.13.5 Statistical analysis  
The statistical analysis was calculated by two-tailed unpaired t test using Graphpad 
Prism version 4.02 software. P< 0.05 was considered sufficiently significant. The Error bars 
indicate standard error of the mean. 
 
2.13.6 Digestion of glycosaminoglycans (GAGs) 
  HS-side chains were removed from perlecan by treatment with heparitinase. Briefly, 
perlecan (12.5µg) was digested in 100µl of 0.2M Tris/6mM calcium acetate pH 7, containing 
1.7U/mg-HS heparitinase (Seikagaku Corp, Tokyo, Japan). Digestion with 0.021U enzyme 
was carried out for 1hr at 43˚C, then for another 5 hrs following addition of an equal amount 
of fresh enzyme. The extent of digestion was determined by SDS-PAGE and Coomassie Blue 
staining (section 2.6). 
 
2.14 Tissue sectioning and immunofluorescence  
Frozen sections (5µm thick) were cut using a cryostat 1720 (Leitz, Solms, Germany) 
from tissue blocks of 20-weeks-old human foetal thoracic aorta and human placenta 
embedded in optimal cutting temperature compound (Miles Inc., Elkhart, IN). The sections 
were air-dried for 30 min, fixed in cold 100% acetone for 2 min and rehydrated in PBS 
(appendix B) for 5 min. The rehydrated sections were then incubated with antibodies 
specific for LTBP-2, perlecan, fibrillin-1, and laminin at the required concentration 
(appendix C) diluted in PBS overnight at 4˚ in humidity chamber. Control sections were 
incubated with a matched concentration of rabbit IgG for polyclonal antibodies and with 
mouse IgG for monoclonal antibodies. Sections were gently washed in PBS for 10 min prior 
to incubation with the appropriate secondary antibody conjugated to flurophore Alexa 488 
(Invitrogen, Carlabad, CA) or Cy5 (Jackson Immunoresearch, West Grove, PA) at the 
required concentration (appendix C) for 90 min at RT in the dark. Sections were then 
washed with PBS for 10 minutes and mounted in anti-fade solution (90% (v/v) glycerol/10% 
(v/v) PBS and 0.1% p-phenylenediamine (Sigma-Aldrich, St. Louis, MO)) prior to laser 
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2.15 Coupling of rβig-h3 and rLTBP-2 to Cyanogen Bromide (CNBr)-activated 
Sepharose 4B 
Recombinant protein (rβig-h3 or rLTBP-2) (1.2µM) was dialysed into a coupling 
buffer (appendix B) in preparation for coupling to CNBr-activated sepharose 4B (Amersham 
Biosciences). 
The CNBr-activated sepharose was prepared following the manufacturer’s instruction. 
Briefly, 0.036g of freeze-dried powder was swollen in 500µl of 1mM HCl (to give a total 
sepharose volume of 126µl), and washed with 1mM HCl in aliquots (500µl/min) for 15 min. 
Immediately after draining recombinant protein was incubated with the activated-CNBr 
sepharose overnight at RT on a rotator. Unbound ligand was washed out with 5 col vol of 
coupling buffer (0.1M NaHCO3, 0.5M NaCl) and analysed by SDS-PAGE (see section 2.6) 
to determine the percentage of bound ligand. The sepharose was then incubated with a 
blocking buffer (appendix B) for 3 hrs at RT to block the remaining CNBr groups on 
sepharose and washed extensively with alternating pH buffers 3×(5 col vol of 0.1M acetate, 
0.5M NaCl, pH 4, and 5 col vol of 0.1M Tris-HCl, 0.5M NaCl, pH 8), followed by 
equilibration with 10 col vol of TBS/0.5M NaCl. 
A protein mixture extracted from 210-250-day-old foetal nuchal ligament with 1M 
NaCl was diluted with TBS to give a 1mg/ml of solubilised proteins in TBS/0.5M NaCl. The 
extracted protein was tested for non-specific binding to sepharose CL4B before it was 
incubated with the protein coupled-sepharose overnight at RT. 
After incubation, the sepharose was drained and washed with the 10×1ml of 
TBS/0.5M NaCl (if matrigel TBS was used) to remove unbound proteins followed by elution 
of the bound proteins with 6M urea. The eluted proteins were analysed by SDS-PAGE and 
either Coomassie Blue stained or silver stained. After eluting the bound protein, the columns 
were washed with the binding buffer and the columns were stored at 4˚C. Columns of 
sepharoseCL4B or BSA coupled to CNBr-activate sepharose were used as controls.  
 
2.16 Using nickel chelate chromatography for identification of binding partners of rβig- 
h3. 
Chelating sepharose CL4B (Amersham Pharmacia), 100µl, was primed with nickel 
prior to incubating the column with rβig-h3 (30µg/600µl) as described in section 2.4. Control 
columns were incubated with 600µl of 10mM imidazole buffer (appendix B) in place of 
rβig-h3. The flow-through was analysed by SDS-PAGE to confirm that all of the rβig-h3 was 
bound to the Ni-sepharose. The coupled sepharose and the control-sepharose were then 
washed with PBS, and incubated for 3 hrs at RT while rotating gently with a protein mixture. 
This protein mixture was extracted from bovine nuchal ligament with 1M NaCl then dialysed  
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into PBS, and had prior incubation with Ni-sepharose to remove non-specifically-binding 
proteins. After the incubation with the protein mixture, the Ni-sepharose was centrifuged at 
1000 rounds per minute for 5 min and was washed with 10 col vol of 10mM imidazole buffer. 
Bound rβig-h3, plus its potential binding partners, was eluted with 10 col vol of 500mM 
imidazole buffer (appendix B) and 500µl fractions were collected. Further bound proteins 
were then eluted with 10mM imidazole buffer containing 6M urea. Each fraction was 
analysed by silver staining. The Ni-sepharose was washed with 10 col vol of 10mM 
imidazole buffer and stored at 4˚C. 
 
2.17 Two-Dimension Gel Electrophoresis (2-DGE) 
Using the manufacturer’s recommendation (Bio-Rad Laboratories Inc, Hercules, CA), 
samples (175µg/125µl) in a rehydration buffer (appendix B) were applied to a 7cm linear pH 
3-10 IPG strip and incubated overnight at RT. The proteins were separated according to their 
isoelectric charge using a slow ramping preset method, where the voltage is increased 
quadratically. This mode is used for high resistance samples to minimise high power input 
initially while achieving high voltage as quickly as possible. Maximum voltage was set at 
4,000V, which is the recommended level for 7cm IPG strips. In this mode the voltage is 
increased quadratically. The conditions were a running temperature of 20˚C, a maximum of 
50µA/Gel, a conditioning step of 250V for 15 min and a total focusing time of 60,000 volt-
hrs on Protean IEF Cell (Bio-Rad Laboratories Inc, Hercules, CA). After the isoelectric 
focusing step, the IPG strip was equilibrated with a dithiothreitol equilibration buffer and an 
iodoacetamide equilibration buffer (appendix B) respectively, for 20 min before separation 
in the second dimension by 15% polyacrylamide gel. The final gel was silver stained (section 
2.7). Except for Cydye DIGE Fluor dye labelled samples the gel was scanned with Typhoon 
Trio+ variable mode imager and analysed using DeCyder 2-D Differential Analysis Software 
(GE Healthcare, Uppsala, Sweden). 
 
2.18 Difference Gel Electrophoresis (DIGE) using CyDye DIGE Fluor Dyes  
Using the manufacture’s recommendation (GE Healthcare Fairfield NY), proteins 
eluates (5µg) from rβig-h3-sepharose and rLTBP-2-sepharose columns were dialysed into the 
rehydration buffer containing thiourea (appendix B), and labelled with fluorescent dye Cye 3 
or Cy 5 (40pmol) on ice in the dark for 30 min. The reaction was then stopped by addition of 
10mM lysine, samples were pooled, the volume was made up to 125µl with the rehydration 
buffer containing thiourea and analysed as previously described in section 2.17.  
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CHAPTER 3 
BINDING INTERACTION OF HUMAN LTBP-2 WITH HEPARIN/ 
HEPARAN SULPHATE PROTEOGLYCANS 
 
LTBP-2 is a member of LTBP/Fibrillin superfamily and it has been found to 
colocalise with microfibrils and directly interact with fibrillin-1 in vitro (Gibson et al., 1995; 
Hirani et al., 2007). A number of other matrix components have been identified to interact 
with fibrillin-1-microfibrils, including MAGP-1, -2 (Gibson et al., 1998; Gibson et al., 1996; 
Henderson et al., 1996), fibulin-2, -4, and -5 (El-Hallous et al., 2007; Freeman et al., 2005; 
Reinhardt et al., 1996b), LTBP-1, -2 and -4 (Hirani et al., 2007; Isogai et al., 2003), various 
PGs such as decorin, biglycan (Reinboth et al., 2002; Trask et al., 2000a), perlecan 
(Tiedemann et al., 2005) and isolated HS-GAG chains (Tiedemann et al., 2005). Not all of 
these components are associated with microfibrils in all tissues. Associated components vary 
as they have tissue-specific functions (depending on the functional and mechanical 
requirements of a given tissue) (Kobayashi et al., 2007; Penttinen et al., 2002; Sterzel et al., 
2000). The biological roles of many of the associated proteins are far from clear and 
continuing study of these associated components is needed to understand how each 
contributes to the structure and function of fibrillin-microfibrils.  
Research into the biological roles of LTBP-2 in relation to microfibrils has shown that 
LTBP-2 is not an integral component of microfibrils (Kielty et al., 1998). Also, in contrast to 
other LTBPs, LTBP-2 does not appear to be directly involved in tissue storage of TGF-β on 
microfibrils as LTBP-2 does not bind covalently to latent TGF-β (Gibson et al., 1995; 
Saharinen and Keski-Oja, 2000). However, the findings of Hirani et al., (2007) have 
indicated that LTBP-2 may be a major modulator of the storage of the growth factor on 
fibrillin-1-microfibrils. This was elucidated from solid phase binding assays showing that 
LTBP-2 competes with LTBP-1 for binding to fibrillin-1 (Hirani et al., 2007). Therefore, the 
examination of the interaction of LTBP-2 with other potential binding ligands is required to 
determine if any additional binding partners of LTBP-2 can be identified to further elucidate 
its full tissue function. In this regard, associated components of microfibrils are the best 
candidates for investigation for relevant interactions. LTBP-2 does not interact directly with 
MAGP, biglycan, decorin, and tropoelastin (Hirani et al., 2007), but its ability to interact with 
heparin/HS-GAGs has not yet been investigated.  
In chapters 3 to 5, the interaction of rLTBP-2 with heparin conjugated to albumin 
(HAC) was studied using solid phase binding assay. Heparin was used because it is  
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structurally similar structure to HS and is a suitable substitute for HS-GAG, and is also 
commercially available in large quantities. To determine the physiological relevance of the 
interaction between LTBP-2 and heparin, the HSPGs perlecan and syndecans were also 
tested for interactions with rLTBP-2 and its fragments.  
The expression clone for human full length rLTBP-2 has been previously used in our 
laboratory to produce rLTBP-2 protein. In addition, three recombinant fragments of LTBP-2 
were made to cover the entire length of the LTBP-2 molecule, consisting of the amino-
terminal fragment (LTBP-2NT(H)), the central fragment (LTBP-2C(H)), and the carboxy-
terminal fragment (LTBP-2CT(H)) (figure 3.1). The construction of LTBP-2CT(H) has 
previously been described (Hirani et al., 2007). The construction and expression of rLTBP-
2NT(H) and rLTBP-2C(H) will be described in section 4.1. The purified rLTBP-2 fragments 
were used for mapping of the heparin binding site(s) on LTBP-2. 
 
 
Figure 3.1. Schematic representation of rLTBP-2 and rLTBP-2 fragments. Domain structure 
of rLTBP-2 constructs. Domain structures: green box, 4-cys domain; red and black striped 
box, EGF-like domain; green crosshatched box, cbEGF-like domain; black diamond, hybrid 
domain; blue ovoid, 8-cys domain; H, his6-tag. 
 
3.1 Expression and purification of human recombinant LTBP-2  
Full length human LTBP-2 cDNA had previously been cloned into the episomal 
expression vector pCEP-4 (Hirani et al., 2007). For production of human rLTBP-2, a number 
of amino acid changes were introduced compared with the published sequence. The 
endogenous LTBP-2 signal peptide was substituted by the signal sequence of human BM 
protein BM40 (Hirani et al., 2007) to allow for enhanced gene expression within the HEK 
cell line (Nischt et al., 1991). A his6-tag was also added to the C-terminus to allow for protein 
purification. The expression LTBP-2 construct was transfected into mammalian 293 EBNA 
cells and rLTBP-2 protein was purified from the conditioned medium using Ni-sepharose 
chromatography (section 2.4). Initially rLTBP-2 was purified from cells that had been 
incubated in three different media to determine which was the most suitable for maximum 
expression of rLTBP-2. The three tested media were serum-free DMEM, DMEM containing 
LTBP-2(H) 
H LTBP-2 NT(H)  
H LTBP-2 CT(H) 
H  LTBP-2 C(H)
H 
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serum and serum-free Ex-Cell 293 medium which is designed specifically for use with 
suspension cultures of 293 EBNA cell lines. 
Purified samples from different media were analysed by western blotting with anti-
(tetra-his) antibody used to detect purified recombinant protein (section 2.6). A single band 
was detected at 210 kDa in serum-free DMEM and DMEM plus serum, with the intensity of 
the band in serum-free DMEM appearing to be greater (figure 3.2A). In contrast, no antibody 
staining was detected in the sample purified from serum-free Ex-Cell 293 (figure 3.2A). The 
results indicated that rLTBP-2 was not highly expressed using Ex-Cell 293 medium, while 
the highest expression of rLTBP-2 was in serum-free DMEM medium. Hence serum-free 
DMEM was used for larger scale rLTBP-2 production.  
Recombinant LTBP-2 was purified from serum-free DMEM migrated on SDS-PAGE 
as two bands at 226 kDa and 210 kDa under reducing conditions and was free of major 
contaminants (figure 3.2B). The observed molecular weight values of the rLTBP-2 protein 
corresponded well to the previously-reported size of purified rLTBP-2 which was 210 and 
219 kDa under reducing conditions (Hirani et al., 2007), and to the predicted LTBP-2 
polypeptide molecular weight of 195 kDa (Gibson et al., 1995; Moren et al., 1994). The 
discrepancy between the measured molecular mass compared with the theoretical mass 
calculated from the protein sequence of the mature recombinant protein and/or the multiple 
bands present is possibly due to varying degrees of post-translational modifications of the 
protein. LTBP-2 has been shown to contain 10 potential N-glycosylation sites (Hyytiainen et 
al., 1998). Furthermore, the size of the rLTBP-2 doublet was reduced by 15 kDa in the 
presence of N-glycosidase with no dramatic changes in the presence of O-glycosidase (Hirani 
et al., 2007). Western blots showed the purified protein was immunoreactive to anti-(LTBP-2) 
antibody (LTBP-2C) confirming the identity of the purified protein as LTBP-2 (figure 3.2B). 
Approximately 1.7µg of rLTBP-2 was produced per ml of DMEM medium and a total of 
2.1mg of rLTBP-2 was purified.  
There were differences with regard to the medium selected for expression and 
purification of rLTBP-2 between reports of Hirani et al., (2007) and the observed results in 
the present study. Hirani et al., (2007) previously described the purification of larger 
quantities of rLTBP-2 free of contaminants from the Ex-Cell 293 medium compared to the 
observed lower qualities of less pure rLTBP-2 purified from cells grown in serum-free 
DMEM. The differences between the results of Hirani et al., (2007) and those described here 
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3.2 Synthesis and purification of heparin-albumin conjugate 
Covalent conjugates of BSA and heparin were prepared for use in the coating of 
individual wells of maxisorb microtitre plates which have a high affinity for proteins with 
both hydrophilic and hydrophobic domains. The conjugates were obtained by a condensation 
reaction between albumin and heparin using 1-ethyl-3-(dimethylaminopropyl)-carbodiimide 
(section 2.10). Unfractionated conjugate was purified by ion-exchange chromatography on 
diethyl-aminoethyl (DEAE) sepharose CL4B (section 2.10). Briefly, after the mixture was 
applied to the column, un-conjugated albumin was washed with 0.3M NaCl, and 0.9M NaCl 
was used to elute the more strongly bound heparin-albumin conjugates (HAC) bound to the 
sepharose (figure 3.3). 
The concentration of heparin in HAC was determined by an uronic acid assay using a 
produced D-glucuronic acid standard curve (section 2.11). The A520 readings for the HAC 
fractions were plotted against the standard curve to determine the amount of heparin present 
in the conjugates.  
The amount of free or conjugated albumin in the collected fractions was determined 
spectrophotometrically (A280) using a BSA standard curve (see section 2.10). Fraction 12 
(figure 3.3) contained the highest amount of both heparin and albumin and this was selected 
for solid phase binding studies. It should be noted that this fraction provided a sufficient 
amount of HAC for the binding studies, and that purification of HAC that remained in the 
initial column flow through was not performed. Hence not all of the conjugate was purified 
from the condensation reaction mixture. The yields of heparin and albumin in the conjugate 
were 4.8mg and 19mg, giving an average (wt/wt) ratio of 1:4 heparin to albumin in the 
conjugate. It was estimated that 6% and 7% of heparin and albumin respectively from the 
original material were conjugated. 
 
3.3 The analysis of LTBP-2 interaction with heparin 
3.3.1 Solid phase immuno-assays  
For examining the interaction between LTBP-2 and heparin, a solid phase binding 
method was employed (section 2.13.1). These assays involved coating HAC onto individual 
wells of maxisorb microtitre plates. The non-specific binding sites were blocked with 3-5% 
low fat dried milk or BSA solution. The rLTBP-2 was then added in solution (TBS/2mM 
CaCl2) and incubated with the coated wells. Interaction was detected using rLTBP-2 specific 
antibody followed by colour detection. Control wells replaced the HAC with the molar 
equivalent of BSA to determine the level of background binding of LTBP-2 and LTBP-2 
fragments to the well. In addition, an initial control where LTBP-2 was replaced with the  
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Figure 3.2. Optimisation of expression and purification of rLTBP-2.  A, Optimisation of 
rLTBP-2 expression by 293 EBNA cells grown in three different media compared using 
SDS-PAGE and immunoblotting with anti-(tetra-his) antibody. Serum-free DMEM (lane 1), 
DMEM plus serum (lane 2), and serum-free Ex-Cell 293 (lane 3). B, Serum-free DMEM 
was selected for the further production of rLTBP-2 and a typical analysis is shown of the 
purified protein, Coomassie Blue staining (lane 1), immunoblotting with anti-(LTBP-2) 
antibody (LTBP-2C) (lane 2). Two specific immunoreactive bands at 226kDa and 210 kDa 




Figure 3.3. Fractionation of un-conjugated albumin and heparin-albumin conjugate (HAC) 
on DEAE sepharose Cl4B. The arrows indicate I, elution of free albumin bound on the 
column with 0.3M NaCl/0.025M tris pH 7. II, elution of heparin-albumin conjugate with 
0.9M NaCl/0.025M tris pH 7. The concentration of free or conjugated albumin was 
determined spectrophotometrically (A280) from a BSA standard curve, while an uronic acid 
assay (A520) was used to determine the concentration of heparin in HAC using a glucuronic 
acid standard curv. 
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molar equivalent of BSA was used for detection of any cross-reaction of the HAC with 
antibodies specific to rLTBP-2. Equilibrium dissociation constants were calculated from 
specific binding curves to determine the strength of each association. 
Firstly, binding conditions needed to be optimised to prevent non-specific background 
binding of LTBP-2 to the wells and to maximize detection of authentic LTBP-2-heparin 
binding. For sensitive detection of authentic binding between LTBP-2 and heparin-coated 
wells, two antibodies were considered, anti-(tetra-his) antibody and anti-(LTBP-2) antibody 
(LTBP-2C) (appendix C). While comparing the detection capabilities of the two antibodies, 
a higher specific binding signal was observed for the interaction of LTBP-2 with heparin 
using anti-(LTBP-2) antibody (LTBP-2C) compared to anti-(tetra-his) antibody (figure 3.4). 
Neither antibody cross-reacted with the HAC-coated on the wells (figure 3.4). However, 
both antibodies detected a high level of non-specific interaction of LTBP-2 with BSA-coated 
wells, even though the wells were incubated with 3% BSA solution prior to incubation with 
LTBP-2 (figure 3.4). Overall the results of the initial binding assays indicated that the 
interaction of LTBP-2 and heparin was specific, although a large amount of LTBP-2 was 
interacting non-specifically with BSA-coated wells resulting in a high background. 
To reduce the background signal caused by non-specific interaction of LTBP-2 with 
BSA-coated wells, 5% low fat dried milk was tested as an alternative blocking solution. This 
resulted in a slight decrease in the background signal. However, the reduction was not 
achieved at satisfactorily low levels (data not shown). Therefore, the addition of carrier 
proteins such as BSA or low fat dried milk in solution was considered. The addition of up to 
0.04% BSA to the solution did not reduce the non-specific interaction of LTBP-2 with the 
wells. However, the addition of 0.05% low fat dried milk to the solution dramatically reduced 
the non-specific background binding of LTBP-2 (figure 3.5). These data suggested that the 
optimised protocol for conducting solid phase binding assays included blocking of the wells 
with 5% low fat dried milk solution, dilution of rLTBP-2 in TBS/2mM CaCl2 containing 
0.05% low fat dried milk and using anti-(LTBP-2) antibody (LTBP-2C) for detection of 
heparin/HSPG binding.  































Figure 3.4. Optimisation of the conditions for solid phase assays. Wells coated with molar 
equivalent of HAC or BSA control were blocked with 3% BSA solution prior to incubation 
with rLTBP-2 or a molar equivalent of BSA as a control. Two antibodies, anti-(tetra-his) 
antibody (0.1µg/ml), and anti-(LTBP-2) antibody (LTBP-2C) (0.1µg/ml), were tested for 
their effectiveness in detecting specific binding. At the concentration of 0.1µg/ml used, anti-
(LTBP-2) antibody (LTBP-2C) produced a higher binding signal. Neither of the antibodies 
cross-reacted with HAC on the wells. * indicates statistical significance of P≤ 0.05. *1, P= 


























Figure 3.5. Reducing non-specific interaction of LTBP-2 with the addition of carrier protein 
in solution. Heparin (HAC) (11.1pmol) and molar equivalent of BSA were coated on the 
wells prior to blocking the excess binding sites with 5% low fat dried milk solution. 
Recombinant LTBP-2 (10nM) in liquid phase containing 0.05% low fat dried milk was 
incubated with the wells and binding was detected with either anti-(tetra-his) antibody 
(0.1µg/ml) or with anti-(LTBP-2) antibody (LTBP-2C) (0.1µg/ml). Non-specific background 
was reduced significantly with the addition of a carrier protein in solution. * indicates 
statistical significance of P≤ 0.05. * P= 0.001.       
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3.3.2 LTBP-2 interacts with heparin-albumin conjugate (HAC)  
To investigate the interaction of LTBP-2 with heparin, solid phase binding assays 
were conducted under optimised conditions (section 3.3.1). A negative control of molar 
equivalent of BSA-coated on the wells was included and experiments were performed in 
triplicate. Incubation of LTBP-2 in the liquid phase with immobilised heparin (HAC) resulted 
in a strong binding signal, while in comparison a minimal signal was observed for the 
interaction of LTBP-2 with BSA-coated control wells, as seen previously in figure 3.5. The 
results indicated that LTBP-2 interacted specifically with heparin and non-specific 
interactions with BSA or the plastic wells were minimal. To authenticate the novel 
interaction between LTBP-2 and heparin, binding and inhibition curves were produced 
(section 2.13.2 & 2.13.3). Increasing molar concentrations of rLTBP-2 in solution were 
incubated with a constant molar amount of heparin (HAC)- or BSA-coated on the wells. The 
resulting binding curve showed a dose-dependent increase. The specific binding of LTBP-2 
with heparin increased as the concentration of added LTBP-2 increased until saturation was 
reached (figure 3.6A).The non-specific interaction of LTBP-2 protein with the BSA-coated 
wells was in direct proportion to the increase in LTBP-2 concentration, indicative of non-
specific binding. The established curve showed specific binding was proportional to the 
concentration of rLTBP-2. The reverse of the experiment was also performed to confirm the 
saturating interaction between LTBP-2 and heparin. Incubating increasing molar amounts of 
heparin (HAC) coated on the well with constant LTBP-2 concentration resulted in a saturable 
binding curve (figure 3.6B). Furthermore, there was a low background signal detected for the 
constant concentration of LTBP-2 added in solution (figure 3.6B). 
The specific interaction of LTBP-2 with heparin was further confirmed by blocking 
the binding of LTBP-2 with heparin-coated wells with the addition of un-conjugated heparin 
in solution. An inhibition curve was prepared by incubating an increasing excess molar 
concentration of free heparin (compared with heparin coated on wells) with LTBP-2 in 
solution prior to incubation with the heparin-coated wells. This resulted in a decrease in 
binding which was in a non-linear relationship to the increase in molar amounts of un-
conjugated heparin added (figure 3.7). The signal dropped to background levels when the un-
conjugated heparin in solution was five-fold in excess of the molar amount of heparin (HAC) 
coated on the wells. Furthermore, background binding to BSA-coated wells was consistently 
low. The results indicated that the un-conjugated heparin completely blocked the interaction 
of LTBP-2 with the heparin-coated wells through competition for binding to LTBP-2. Based 
on the above results, it was deduced that the interaction between LTBP-2 and heparin was 
specific. 
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Figure 3.6. Saturation binding curve of the interaction of LTBP-2 and heparin. A, Increasing 
concentration of rLTBP-2 (0-50nM) in solution was incubated with constant molar amount of 
immobilised heparin (HAC) (2.8pmol), black circles, or BSA, white circles, at molar 
equivalent to HAC. Anti-(LTBP-2) antibody (LTBP-2C) (0.1µg/ml) was used for detection 
of binding. B, Constant LTBP-2 (10nM) in solution was incubated with increasing molar 
amounts of heparin (HAC) (0-11.1pmol), black circles, or BSA, white circles, at the same 
molar equivalent, which had been coated on the wells.   

































Figure 3.7. Inhibition binding curve of LTBP-2 interaction with heparin. Increase in excess 
molar concentration of free heparin (0-208nM) was incubated with LTBP-2 (10nM) in 
solution for 15 minutes prior to incubation with constant heparin (HAC) (2.1pmol), black 
circles, or molar equivalent of BSA, white circles. Free heparin in solution blocked the 
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3.3.3 The interaction of LTBP-2 with heparin is not a non-specific interaction with 
polyanionic GAGs  
Sulphated GAGs which include CS, dermatan sulphate, heparin and HS are repeating 
disaccharide units composed of uronic acid (GlcA or IdoA) and an amino sugar 
(galactosamine or glucosamine) (Mulloy et al., 2006). All of these GAG chains are strongly 
negatively-charged due to their high content of uronic acids and sulphate groups. To confirm 
that the interaction of LTBP-2 with heparin is not solely a charge-related interaction with all 
GAGs, the blocking of the binding with an alternative negatively-charged GAG, CS, was 
conducted. Using the solid phase binding assay, LTBP-2 in solution was incubated with a 
ten-fold molar excess of C-6-S (compared to heparin coated on the wells), prior to incubation 
with the heparin-coated wells. A positive control where LTBP-2 was incubated with heparin 
in the absence of C-6-S was included, in addition to the BSA negative controls. As shown 
previously (figure 3.6), a strong signal was detected for the interaction of LTBP-2 with 
heparin (HAC) in the absence of C-6-S (figure 3.8) and a similarly strong signal was 
detected for the interaction of LTBP-2 with heparin (HAC) in the presence of C-6-S. 
Furthermore, there was minimal non-specific binding detected for the interaction between 
LTBP-2 and BSA-coated wells in the presence or absence of C-6-S. These findings indicate 
that the interaction of LTBP-2 with heparin is not a non-specific charge-related interaction 
with GAGs, but is a specific heparin/HSPG interaction. 
 
3.3.4 LTBP-2 interaction with heparin depends on calcium or other divalent cations  
LTBP-2 protein is composed mainly of a large number of cbEGF-domains and their 
conformation is dependent on calcium ions (Gibson et al., 1995). Recently, Hirani et al., 
(2007) showed the addition of 2mM calcium ions in solution enhanced the interaction of 
LTBP-2 with fibrillin-1. Thus, the interaction studies described in this chapter between 
LTBP-2 and heparin had been initially performed in the presence of 2mM calcium ions. To 
determine if calcium ions actually influence the interaction between LTBP-2 and heparin, 
immuno-assays were conducted under three different conditions, a) in the absence of added 
calcium ions or, in the presence of b) 5mM EDTA or c) 5mM EGTA. EDTA and EGTA are 
chelating agents that sequester divalent metal ions, but EGTA has a much higher specificity 
for calcium ions. The highest level of binding was detected when the interaction was 
conducted in the presence of calcium ions (figure 3.9). The absence of added 2mM calcium 
ions was found to give slightly lower interaction levels compared to those with added 
calcium. However this difference was considered to be insignificant. When the non-specific  

























Figure 3.8. Interaction of LTBP-2 with heparin is specific and is not a non-specific charge-
related interaction. Incubation of Chondroitin-6-sulfate (208nM) with LTBP-2 (10nM) in 
solution for 15 minutes prior to incubation with heparin (HAC) (2.1pmol) or molar 
equivalent of BSA coated on the wells. LTBP-2 does not interact with negatively-charged 







































Figure 3.9. The interaction of LTBP-2 with heparin is cation dependent. Recombinant 
LTBP-2 (10nM) in various solutions; TBS+2mM calcium, TBS only, TBS+5mM EDTA or 
TBS+5mM EGTA was incubated with immobilized heparin (HAC) (2.8pmol) or molar 
equivalent of BSA. Antibody specific to LTBP-2 was used to detect specific binding of 
LTBP-2 with heparin in the various solutions. Presence of EDTA or EGTA blocked the 
interaction of LTBP-2 with heparin, while the presence of calcium ions enhanced the 
interaction. * indicates statistical significance of P≤ 0.05. *1,2, P= 0.0001. *3, P= 0.002. *4, P= 
0.003. *5, P= 0.01.     
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binding of LTBP-2 to the wells was compared in the presence and absence of calcium ions a 
decrease was detected in the presence of calcium, but again the difference was insignificant. 
In the presence of EDTA or EGTA, there was much lower binding with signals close 
to background levels (figure 3.9), compared with binding detected in the presence of calcium. 
It was also noted that the presence of these chelating agents also slightly decreased the non-
specific background interaction of LTBP-2 with the wells. Overall, the data showed that the 
presence of a chelating agent such as EDTA or EGTA almost completely abolished the 
interaction between LTBP-2 and immobilised heparin (HAC). Thus from the results it was 
concluded that the interaction between LTBP-2 and heparin is dependent on the presence of 
divalent metal ions. This may be due to either direct or indirect alterations of the 
conformation of one or more cbEGF-domains of LTBP-2. EGTA inhibited the binding of 
LTBP-2 with heparin (HAC) more effectively than EDTA. This indicates that the interaction 
between LTBP-2 and heparin is most likely to be calcium dependent.  
 
3.3.5 Kinetic analysis of the interaction between LTBP-2 and heparin 
To analyse the dynamic interaction between LTBP-2 and heparin, the Kd was 
calculated from saturation binding experiments using non-linear regression analysis for one 
site binding (GraphPad Prism version 4 for windows, GraphPad Software, San Diego 
California USA, www.graphpad.com) (section 2.13.4). The Kd is expressed in molar units (M) 
and corresponds to the concentration of ligand at which the binding site on the target protein 
is half occupied. More importantly, it is a measure of the affinity (strength) of the interaction. 
Producing a saturation binding curve for binding of LTBP-2 with heparin involved the 
incubation of a constant molar amount of heparin (HAC)- or BSA-coated on the wells with 
increasing molar concentrations of LTBP-2 in solution. Figure 3.10A illustrates the binding 
curve after subtraction of the BSA background. Simultaneously, a standard curve was 
established by directly coating wells with known molar amounts of LTBP-2 or BSA, as the 
relative signal of the known quantities was determined with anti-LTBP-2 antibody (LTBP-2C) 
(figure 3.10B). A standard curve was necessary to determine the molar amount of LTBP-2 
that bound to the heparin-coated wells. After subtraction of the background, using data from 
three repeated experiments, the molar amount of LTBP-2 bound was calculated for each 
HAC amount and plotted against the total molar concentration of LTBP-2 added (figure 
3.10C). The Kd was calculated as 14.5±3.7nM. Therefore, binding of heparin to LTBP-2 was 





























































Figure 3.10. Kinetic analysis of the interaction between LTBP-2 and heparin using solid phase binding assay. A, Saturation binding curve for LTBP-2 and 
heparin after subtraction of the background BSA. Increasing molar concentration of LTBP-2 in solution was incubated with constant molar amount of 
heparin (HAC) (2.1pmol) or molar equivalent of BSA coated on the wells. B, Standard ELISA curve for LTBP-2 after subtraction of the background. 
Increasing molar amount of LTBP-2 (0-160fmol) was coated on the wells overnight and signal levels for each specific quantity was determined using anti-
LTBP-2 antibody (LTBP-2C) (0.1µg/ml). C, LTBP-2-heparin (HAC) binding curve used to calculate Kd. The total molar concentration of LTBP-2 added in 
solution in A was plotted against the molar amount bound determined in B. The Kd.was calculated to be 14.5±3.7nM, suggesting LTBP-2 has a strong 
affinity for heparin. 
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CHAPTER 4 
THE CENTRAL REGION OF LTBP-2 CONTAINS A BINDING SITE 
FOR HEPARIN 
 
Results from Chapter 3 indicate that LTBP-2 has a specific and moderately strong 
interaction with heparin. The interaction was shown to be probably calcium dependent 
(section 3.3.4), thus heparin may be interacting with LTBP-2 via one of its many cbEGF 
domains. Narrowing down the heparin binding site(s) on LTBP-2 will aid in further 
characterisation of this interaction. As more binding partners for LTBP-2 are identified and 
characterised, we can deduce how these novel ligands may influence each other’s interaction 
with LTBP-2 and modulate the function of LTBP-2.  
To define the binding regions for heparin on LTBP-2, production of expression 
constructs for rLTBP-2 fragments was necessary. Our laboratory had already cloned an 
expression cDNA encoding the carboxyl-terminus of LTBP-2 (LTBP-2CT(H) (Hirani et al., 
2007). This chapter describes the construction of the expression plasmids in order to express 
the amino-terminal region of LTBP-2 and the central fragment of LTBP-2, for use in the 
solid phase binding analyses with heparin. 
 
4.1 Expression, purification and characterisation of the central region of LTBP-2 
(LTBP-2C(H)) 
4.1.1 Expression and purification of LTBP-2C(H) 
A cDNA encoding the central region of LTBP-2 (bases 2758-5142, and residues 750-
1584 of the published LTBP-2 sequence, Genbank accession number NM_000428) was 
amplified from the full length LTBP-2 cDNA template, using designed primers containing 
HindIII restriction sites at their 5’ ends (section 2.2.1). The presence of the HindIII sites is 
important for subsequent subcloning into the modified mammalian expression vector pCEP-4. 
These primers flank the region of the cDNA encoding the third EGF-like domain to the 
region just prior to the last 8-cys domain. The amplified PCR product of 2384 bases (figure 
4.1A) was subcloned into modified pCEP-4 (Hanssen and Gibson unpublished). The LTBP-
2C(H) expression construct was transfected into 293 EBNA cells and rLTBP-2C(H) was 
purified using affinity chromatography from the serum-free conditioned medium (section 2.3 
& 2.4). Purification produced yields of approximately 0.7µg/ml of medium. Purified rLTBP-
2C(H) was stored in TBS/0.5M NaCl at -20˚C.  
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4.1.2 Analysis and authentication of rLTBP-2C(H) 
Purified rLTBP-2C(H) was resolved free of major contaminants as a single band at 97 kDa 
under non-reducing conditions and at 130 kDa under reducing conditions (figure 4.1B) 
(section 2.6). This size was larger than the predicted molecular weight of 85 kDa. A 
discrepancy between the predicted and the apparent molecular weight has been reported for 
other recombinant LTBP-2 fragments including LTBP-2CT(H), and some of the fibrillin 
constructs (Hirani et al., 2007). These differences are often the result of post-translational 
modifications including glycosylation, as LTBP-2 is N-glycosylated (Hirani et al., 2007). 
Aside from LTBP-2, the predicted size of the mature MAGP-2 polypeptide encoded by the 
cDNA for both the bovine and human forms of the protein was also smaller than its apparent 
molecular weight observed on SDS-PAGE (Gibson et al., 1996). This discrepancy was 
suggested to be due to glycosylation of the protein which has a consensus sequence for N-
linked carbohydrate attachment (Gibson et al., 1996). Furthermore, it is not uncommon for 
polypeptides to appear on gels as differently sized from their predicted size. These 
differences may occur as a result of a particular conformation of the proteins which may 
affect the mobility of the proteins through the polyacrylamide pores during electrophoresis 
and thus result in the protein migrating at a different size compared to the predicted size. For 
instance, the deviation in molecular mass of MAGP-1 on SDS-PAGE compared with its 
actual molecular mass was suggested to be a function of the primary structure of MAGP-1 
(Gibson et al., 1991). Other examples were fibulin-3 and -4, which showed an increase in 
electrophoretic mobility when the recombinant proteins were examined under reducing 
conditions, due to the many intracellular disulphide bonds present in both recombinant 
proteins (Giltay et al., 1999). When the purified recombinant protein was examined for 
reactivity to anti-(tetra-his) antibody under reducing conditions, a single band at 130 kDa was 
detected (figure 4.1C). No other bands were detected by the antibody suggesting purified 
LTBP-2C(H) was free of his-rich contaminants. Overall the results confirmed the purification 
of a recombinant protein from serum-free DMEM with relatively high purity, though the size 
of the purified protein was substantially different to the predicted size of the expected 
recombinant protein. Furthermore, the discrepancy observed for size of rLTBP-2C(H) was 
substantial compared to the differences reported for other recombinant proteins. Therefore it 
was necessary to authenticate the recombinant protein as LTBP-2C(H). 
The simplest method of authentication of the purified protein as LTBP-2C(H) was 
through western blot analysis using a LTBP-2 antibody. However, the available anti-LTBP-2 
antibody (LTBP-2C) produced in the Gibson laboratory (Hirani et al., 2007) was specific to 
the carboxy-terminal 8-cys domain and thus it was unable to recognise the central fragment  
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of LTBP-2. To confirm that the recombinant protein was a fragment of LTBP-2, peptide 
mass finger-printing was considered (section 2.9).  
 
                         
 
Figure 4.1. PCR amplification of a cDNA encoding rLTBP-2C(H) and analysis of purified 
recombinant protein. A, LTBP-2C(H) PCR product analysed on a 0.8% (w/v) agarose gel and 
stained with ethidium bromide. A single band of expected product size of 2384 bases was 
detected. B, Purified rLTBP-2C(H) resolved by 12% SDS-PAGE. Coomassie Blue indicated 
a contaminant-free protein band of 97 kDa when sample is non-reduced (lane 1) and 130 kDa 
when sample is reduced (lane 2). C, Anti-(tetra-his) antibody confirmed the purified protein 
as recombinant protein. 
 
4.1.3 Peptide mass finger-printing of rLTBP-2C(H)  
MALDI-TOF-MS was used to perform peptide mass finger-printing for identification 
of the purified recombinant protein as LTBP-2C(H) (section 2.9). To do this, the LTBP-2C(H) 
band was excised from SDS-PAGE and digested with trypsin. Trypsin was the favoured 
protease enzyme for peptide mass finger-printing as it is relatively cheap, highly effective 
and generates peptides with an average size of about 8-10 amino acid (Thiede et al., 2005). 
Trypsin also generates peptides with C-terminal basic residues which facilitates ionisation 
and, if necessary, de novo sequencing (Olsen et al., 2004). The experimentally-obtained 
molecular masses for the peptides were compared with the theoretical peptide masses present 
in databases using mass search programs (Aebersold and Mann, 2003). Results were 
statistically analysed to find the best match. 
Peptide mass finger-printing was carried out on the putative rLTBP-2C(H) fragment. 
After acquiring a mass spectrum using the Adelaide Proteomics Centre, the generated data 
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server, matching against SwissProt and also against the human LTBP-2C(H) protein 
sequence for protein identification. The MALDI-TOF spectrum of the digested LTBP-2C(H) 
sequence with matching peptide signals identified the protein as LTBP-2C(H). A search on 
Expasy proteomics (http://www.expasy.ch/) for glycosylation modifications identified five 
potential sites of N-linked glycosylation of the LTBP-2C(H) protein. This therefore can 
explain the discrepancy in the predicted and the apparent size of the recombinant protein. 
Following the authentication that the recombinant fragment is LTBP-2C(H), binding studies 
were performed to determine if this region contains heparin binding site(s). 
 
4.2 The central region of LTBP-2 contains a binding site for heparin  
In order to narrow down the binding region(s) for heparin on LTBP-2, solid phase 
binding assays were conducted to screen for interactions between the rLTBP-2 fragments, 
rLTBP-2C(H) and rLTBP-2CT(H) and heparin. Moreover, in light of the C-terminal region 
of rLTBP-2 containing the fibrillin-1 binding site (Hirani et al., 2007), it was of interest to 
see if this region also interacted with heparin. Molar equivalents of each rLTBP-2 fragment 
in the solution were incubated with HAC-coated wells. A positive control using full length 
rLTBP-2 was included for comparison. BSA-coated wells were included as negative controls 
for determining the non-specific protein interaction of each fragment. Using anti-(tetra-his) 
antibody a strong signal was detected for full length rLTBP-2 and a marginally lower but 
positive signal was detected for rLTBP-2C(H) (figure 4.2A). In comparison to full length 
rLTBP-2 and its central fragment, rLTBP-2C(H), only a background signal was detected for 
the C-terminal rLTBP-2CT(H). 
To demonstrate the specificity of the LTBP-2C(H) interaction with heparin, a 
saturation binding curve was established using a range of molar concentrations of rLTBP-
2C(H) in solution with the amount of immobilised heparin constant. The binding signal 
between the two molecules was found to intensify with the increase in molar concentration of 
rLTBP-2C(H) (figure 4.2B). However, saturation was not achieved even with the rLTBP-
2C(H) in solution being three times the molar concentration of heparin coated on the well. 
This was in contrast to the ability of full length rLTBP-2 to saturate the interaction at twice 
the molar concentration of heparin. The binding curve for rLTBP-2C(H) interaction with 
heparin supports the hypothesis that LTBP-2 contains more than one heparin binding site. 
This assumption is possible under the conditions that a) the rLTBP-2C(H) fragment contains 
only one heparin binding site and b) the second binding site contains equal binding affinity to 
the binding site identified in rLTBP-2C(H). Briefly, if full length rLTBP-2 contained only 
one heparin binding site in its central region (see figure 4.2A), then the binding curve 
established for rLTBP-2C(H) should be similar to that of the full length rLTBP-2. With this  
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not being the case, the alternative explanation was that LTBP-2 contains two heparin binding 
sites of equal affinity, hence four times the molar concentration of rLTBP-2C(H) would be 
required for saturation. As a result, the highest molar concentration of rLTBP-2C(H) used 
was insufficient for saturating heparin binding.  
Since the binding curve appeared sigmoidal in shape, an alternative explanation for 
the curve was that the heparin binding site in rLTBP-2C(H) was of low affinity. Weak 
interactions take longer to reach equilibrium and are easier to disrupt. Thus it was possible 
that at low concentrations equilibrium had not been reached and/or that rigorous washing had 
disrupted much of the bound ligand. To confirm the possibility of additional heparin binding 
sites on LTBP-2, as well as the strength of the interaction, the Kd of rLTBP-2C(H) for 
heparin needed to be determined and this is further discussed in the following section. 
 
4.2.1 Defining the affinity between central region of LTBP-2 and heparin 
The K d for rLTBP-2C(H) and heparin was calculated to determine the strength of 
binding relative to full length rLTBP-2 (section 2.13.4). A saturation curve for rLTBP-2C(H) 
interacting with heparin (HAC) was established by incubating increasing molar 
concentrations of rLTBP-2C(H) in solution with a constant molar amount of heparin coated 
on the wells (figure 4.3A). The saturation binding curve had an obvious sigmoidal 
appearance, once again implying binding is especially weak at low concentrations of rLTBP-
2C(H). Concurrently a standard curve to calculate the molar amount of rLTBP-2C(H) bound 
was established by coating increasing molar amounts of rLTBP-2C(H) directly on the wells 
and detecting the signal with anti-(tetra-his) antibody (figure 4.3B). The molar amount of 
bound rLTBP-2C(H) was plotted against the total molar concentration added (figure 4.3C) 
and the value of Kd was estimated using non-linear regression analysis for one site binding 
(GraphPad Prism). The Kd was calculated to be 52.2±6.9nM. This result confirmed that the 
binding site in rLTBP-2C(H) fragment has a strong affinity for heparin. 
Comparison of the binding affinity of rLTBP-2C(H) to heparin with full length 
rLTBP-2, revealed that the interaction of heparin with rLTBP-2C(H) is not as strong as with 
the full length rLTBP-2, therefore suggesting that there may be additional heparin binding 
site(s) in the N-terminal region of LTBP-2.  
Construction of the rLTBP-2NT(H) expression plasmid was commenced concurrently 
with that of rLTBP-2C(H) (section 2.2.2). However, I was unable to express rLTBP-2NT(H) 
during candidature in 293 EBNA cells due to time constraints. Continuation of this work in 
our laboratory by others showed an additional binding site in the amino-terminus of LTBP-2 
(Parsi et al., 2010). 
  


















































Figure 4.2. Heparin binds specifically to rLTBP-2C(H). A, Full length rLTBP-2 and rLTBP-
2 fragments; rLTBP-2C(H) and rLTBP-2CT(H) in solution were incubated with immobilised 
heparin (HAC) or similar molar equivalent of BSA. Anti-(tetra-his) antibody (0.1µg/ml) was 
then used for binding detection. B, Solid phase binding curve of the interaction of rLTBP-
2C(H) with heparin. Increased molar concentration of rLTBP-2C(H) (0-154nM) in solution 
was incubated with constant amount of heparin (HAC) (2.8pmol) or same molar equivalent 
of BSA coated on the wells. The resulting curve is after subtraction of BSA. * indicates 







































































Figure 4.3. Kinetic analysis of the interaction between central fragment of LTBP-2 and heparin using solid phase binding assay. A, Saturation binding 
curve for rLTBP-2C(H) and heparin (HAC) after subtraction of the background BSA. Increasing molar concentration of rLTBP-2C(H) (0-154nM) in 
solution was incubated with constant molar amount of heparin (HAC) or molar equivalent of BSA coated on the wells. B, Standard ELISA curve for LTBP-
2 after subtraction of the background. Increasing molar amount of rLTBP-2C(H) (0-0.12pmol) was coated on the wells overnight and signal levels for each 
specific quantity was determined using anti-(tetra-his) antibody (0.1µg/ml). C, LTBP-2C(H)-heparin (HAC) binding curve used to calculate Kd. The total 
molar concentration of rLTBP-2C(H) added in solution in A was plotted against the molar amount bound determined in B. The Kd was calculated to be 
52.2±6.9nM, suggesting the heparin binding site in the central region of LTBP-2 is of strong affinity. 
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CHAPTER 5 
LTBP-2 INTERACTIONS WITH PERLECAN AND SYNDECANS 
 
The interaction of rLTBP-2 with heparin as demonstrated in chapters 3 and 4, reflects 
the interaction of LTBP-2 with HS-associated PGs in the ECM or at the surface of cells in 
tissue. HSPGs found in the ECM include perlecan, agrin and collagen type XVIII (Ackley et 
al., 2003; Batmunkh et al., 2007; Dong et al., 2003; Iozzo, 1998; Tsen et al., 1995). Perlecan 
was a candidate HSPG for investigation for interaction with LTBP-2 since perlecan is a 
constituent of BM of all human tissues (Murdoch et al., 1994), while agrin is less widespread 
being a major HSPG of neuromuscular junctions and renal BMs (Denzer et al., 1995; Tsen et 
al., 1995).  
Cell surface HS are mostly members of two major groups of membrane-bound protein 
groups, syndecans and glypicans (Bernfield et al., 1999). Syndecans are expressed on the 
surface of all adherent cells, while glypicans are expressed predominantly in the central 
nervous system (David et al., 1992). Therefore, syndecans were also candidate HSPGs to be 
tested for interaction with LTBP-2. 
 
5.1 LTBP-2 interacts with Perlecan 
Solid phase binding assays were used to determine if LTBP-2 interacts with perlecan. 
When rLTBP-2 in solution was incubated with perlecan coated on wells, a strong signal was 
detected with anti-LTBP-2 antibody (LTBP-2C) (figure 5.1A). In addition, a minimal non-
specific binding signal was detected for the interaction of rLTBP-2 with BSA control wells. 
This result indicated that LTBP-2 specifically interacts with perlecan. To confirm the 
interaction, a binding curve was established where a constant concentration of rLTBP-2 in 
solution was incubated with increasing amounts of immobilised perlecan. The binding 
relationship was linear, showing that the interaction of rLTBP-2 with perlecan was 
proportional to the amount of perlecan coated on the wells (figure 5.1B). The binding 
between rLTBP-2 and perlecan did not reach saturation even when the highest amount of 
perlecan coated on the wells was incubated with rLTBP-2 in solution. This may have been 
due to the presence of excess rLTBP-2 compared with perlecan. With limited availability of 
purified perlecan (a gift from Professor John Whitlock, University of New South Wales), we 
were unable to repeat the experiment with a lower ratio of rLTBP-2 to perlecan to achieve 
saturation of the interaction. For the purposes of this work the established graph was  
































Figure 5.1. LTBP-2 interacts specifically with perlecan. A, rLTBP-2 (10nM) in solution was 
incubated with immobilised perlecan (2.1pmol) or molar equivalent of BSA. Specific binding 
was detected using anti-LTBP-2 antibody (LTBP-2C) (0.1µg/ml). B, Binding curve for the 
interaction of rLTBP-2 with perlecan. Constant concentration of rLTBP-2 in solution (10nM) 
was incubated with increasing amount of perlecan (0-2.1pmol) on the wells, black circles, or 
with molar equivalent of BSA, white circles, which had been coated on the wells. Anti-LTBP-
2 antibody (LTBP-2C) (0.1µg/ml) detection of binding indicates that, the interaction of 
rLTBP-2 with perlecan is proportion to the amount of perlecan present. * indicates statistical 
significance of P≤ 0.05. *, P= 0.0003.  
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sufficient in showing that the interaction between LTBP-2 and perlecan was specific and it 
was not just a non-specific protein-protein interaction. 
 
5.2 The interaction of LTBP-2 with perlecan is via the heparan sulphate side chains 
The findings from previous chapters suggest the interaction of LTBP-2 with perlecan 
was likely to be via its HS-side chains. To verify this possibility, free heparin was added to 
inhibit this interaction. Using a solid phase binding assay, rLTBP-2 in solution was incubated 
with heparin at ten-times the molar concentration of perlecan prior to incubation with 
perlecan-coated wells. A positive control where the interaction of rLTBP-2 with perlecan was 
tested in the absence of added heparin was included in addition to a negative control where a 
molar equivalent of BSA was substituted for perlecan-coated wells. A strong signal was 
observed for the interaction between rLTBP-2 and perlecan (figure 5.2), whereas a 
significant reduction in binding signal was observed when rLTBP-2 was pre-incubated with 
heparin, therefore suggesting free heparin completely blocked the interaction of rLTBP-2 
with perlecan. The presence of heparin did not significantly affect the level of non-specific 
interaction of rLTBP-2 with the BSA-coated wells. If LTBP-2 contained binding regions to 
the protein core component of perlecan, then the presence of free heparin should not have 
completely inhibited the binding of rLTBP-2 with perlecan. Therefore, it was evident that 
LTBP-2 interaction with perlecan is predominantly via the HS-side chains.  
To confirm that LTBP-2 lacks binding affinity for the core protein of perlecan, isolation of 
the core protein was pursued by digesting the GAGs. Initially, methods adopted from 
Hayashi et al., (1992) were used for the preparation of the core protein by digestion with 
heparitinase (section 2.13.6) which cleaves N-sulphated glucosaminidio-L-iduronic acid 
linkages of heparin. After digestion was completed, the enzyme was not denatured, since the 
native structural conformation of perlecan was required for future solid phase binding assays. 
The digested perlecan was compared to undigested perlecan on SDS-PAGE. After Coomassie 
Blue staining of the 10% gel, the undigested perlecan could not be detected on the gel (figure 
5.3). This may have been due to the large size of the HSPG which prevented it from entering 
the polyacrylamide gel. In contrast, the digested perlecan appeared as several bands with high 
molecular weights, which suggested degradation of the core protein. It should be noted that 
an additional band at 66 kDa was also detected and this band was the heparitinase that was 
stained with Coomassie Blue staining. 
  


























Figure 5.2. Perlecan interacts with LTBP-2 via its HS-side chains. Recombinant LTBP-2 
(10nM) in solution or with the addition of free heparin (125nM) were pre-incubated for 15 
minutes prior to incubation with perlecan (1.25pmol) or molar equivalent of BSA on the 
wells. The interaction of rLTBP-2 with perlecan was completely inhibited by free heparin. * 





Figure 5.3. Preparation of the perlecan core protein. Perlecan (12.5µg) was digested with 
(0.042U) of heparitinase. Samples of the undigested (lane 1) and the digested perlecan (lane 







- 83 - 
5.3 The interaction of LTBP-2 with perlecan is cation dependent 
Calcium ions were shown to enhance the interaction between rLTBP-2 and heparin 
(HAC) in section 3.3.4. From this we can speculate that calcium is also required for the 
interaction of LTBP-2 with perlecan. In this study, the calcium dependence of the interaction 
between LTBP-2 and perlecan was investigated. A solid phase binding assay was performed 
to examine the interaction between rLTBP-2 and perlecan in the presence of 2mM calcium 
ions or 5mM EDTA. A strong signal was detected for the interaction of rLTBP-2 and 
perlecan in the presence of 2mM calcium ions, while a low signal was detected for the 
interaction performed in the presence of 5mM EDTA (figure 5.4). The obtained result 
suggested that a metal cation, probably calcium, plays a role in the interaction of LTBP-2 
with perlecan, either directly or indirectly through conformation changes in the LTBP-2 
molecule. 
 
5.4 LTBP-2 interacts with syndecan-4 but not syndecan-2 
To expand the spectrum of HSPGs examined as possible binding ligands of LTBP-2, 
the cell surface HSPG syndecans were investigated for binding to LTBP-2. Possible cell 
adhesion properties have been predicted for fibrillin through its interaction with heparin (Bax 
et al., 2007; Cain et al., 2008). Thus, similar functions may be possible for LTBP-2 through 
interaction with syndecans. The syndecan family consists of four transmembrane HSPG 
proteins syndecan -1 to -4 (Rapraeger, 2000). All members of the syndecan family except 
syndecan-3 have been purified from vascular sources (Kojima et al., 1992; Mertens et al., 
1992). Syndecan-1 is the major syndecan of epithelial cells including vascular endothelium 
(Cizmeci-Smith et al., 1997; Gallo et al., 1996; Kojima et al., 1992). Syndecan-2 is mostly 
present in mesenchymal, neuronal and smooth muscle cells (Cizmeci-Smith et al., 1997; 
Pierce  et al., 1992), while syndecan-3 is the major syndecan of the nervous system 
(Chernousov and Carey, 1993; Hienola et al., 2006). Syndecan-4 is ubiquitously expressed 
but at lower levels than the other syndecans (Tkachenko et al., 2005; Yoneda and Couchman, 
2003). In this study, r-syndecan-2 and -4 were tested for interaction with rLTBP-2 (section 
2.13.1). A solid phase binding assay was used where rLTBP-2 in solution was incubated with 
the syndecan coated on the wells. The result was the detection of a strong specific signal for 
the interaction of rLTBP-2 with r-syndecan-4, using the anti-(LTBP-2) antibody (LTBP-2C) 
compared with the background signal that was detected between rLTBP-2- and BSA-coated 
wells (figure 5.5). In contrast, the antibody detected a weak signal for the interaction 
between rLTBP-2 and r-syndecan-2 (figure 5.5), which was not significant. The data 
obtained from the solid phase assay suggests that rLTBP-2 interacts with r-syndecan-4 but 
not with r-syndecan-2. This result suggests that LTBP-2 does not bind to all HS-side chains.  
- 84 - 
It is possible that heterogeneity in the HS sequences may result in HS having binding 
specificity for LTBP-2. 
The results of the solid phase binding assays identified two potential biological 
ligands for LTBP-2, one a BM HSPG and the other a cell surface HSPG. Both HSPGs 
interact with LTBP-2 though their HS-GAG chains. Overall, LTBP-2 potentially interacts 
with a specific protein-interacting sequence in HS.  
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Figure 5.4. The interaction of perlecan with LTBP-2 is cation dependent. Recombinant 
LTBP-2 (10nM) in three alternative solution including TBS plus calcium ions, TBS only and 
TBS plus EDTAwas incubated with immobilised perlecan (1.1pmol) or molar equivalent of 
BSA. The interaction between LTBP-2 and perlecan in the alternative solutions was detected 
by anti-LTBP-2 antibody (LTBP-2C) (0.1µg/ml). The presence of EDTA completely blocked 
the interaction of rLTBP-2 with HS-side chains of perlecan. * indicates statistical 
















Figure 5.5. LTBP-2 interacts with syndecan-4 but not with syndecan-2. Recombinant LTBP-
2 in solution (10nM) was incubated with r-syndecan -2 and -4 (27pmol) and molar equivalent 
of BSA coated on the wells. Binding was detected with anti-LTBP-2 antibody (LTBP-2C) 
(0.1µg/ml). * indicates statistical significance of P≤ 0.05. *, P= 0.0005.  
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CHAPTER 6 
IMMUNOHISTOCHEMICAL ANALYSIS OF HUMAN FOETAL 
AORTA INDICATES LTBP-2 HAS AREAS OF COLOCALISATION 
WITH PERLECAN 
 
The data in chapter 5 showed that LTBP-2 interacts with HS-side chains of perlecan 
in vitro. However, unlike the in vitro systems where optimal conditions are created to provide 
the best environment for interactions to occur, this is not necessarily true in vivo. Previously, 
it has been shown that LTBP-2 has widespread localisation with fibrillin-microfibrils in 
human foetal aorta (Gibson et al., 1995; Hirani et al., 2007), while perlecan has been 
documented to be the predominant HSPG found in all vascular BM (Murdoch et al., 1994). 
Therefore, LTBP-2 and perlecan are expressed in the same tissue at similar developmental 
stages. It is unclear if LTBP-2 and perlecan are only found in association with fibrillin-
microfibrils and BMs respectively, or if they are found independent of these major structures 
or lie on similar structures. Furthermore, the possibility of an interaction between LTBP-2 
and other components of the matrix, independent of microfibrils, has not fully been explored. 
Therefore, immunohistochemical analysis was undertaken to examine the localisation of 
LTBP-2 and perlecan in developing human thoracic aorta and to determine if they are found 
in close proximity to allow interaction between the two matrix components. The developing 
human aorta was selected as the tissue of choice as it has a high elastic fibre and BM content.  
 
6.1 Localisation of LTBP-2 on microfibrils and perlecan on basement membrane in 
human foetal aorta  
6.1.1 LTBP-2 localises on fibrillin-1-microfibrils in the human foetal aorta 
To investigate the immunolocalisation of LTBP-2 in the aorta, developing human 
aorta from a 20-week-old foetus was obtained under clearance from the Human Ethics 
Committee of University of Adelaide and the Women’s and Children’s Hospital, Adelaide, 
with the informed consent of the patient, mother. The tissue was immediately snap-frozen 
and stored at -80˚C. Cryostat sections of the foetal aorta were prepared (section 2.14) and 
were then immunostained with anti-(LTBP-2) antibody (LTBP-2C) and anti-(fibrillin-1) 
antibody (MAB1919) (appendix C). Specific antibodies to LTBP-2 and fibrillin-1 were used 
firstly to determine the localisation of LTBP-2 and to highlight fibrillin-1-microfibrils in the 
thoracic aorta, and secondly to establish whether all of LTBP-2 found in the aorta localised 
on the fibrillin-microfibrils. Control sections incubated with pre-immune mouse or rabbit IgG  
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were included to indicate non-specific background staining of the polyclonal and the 
monoclonal antibodies respectively. 
To determine any overlap in the distribution patterns of these proteins, stained 
sections were analysed by Leica SP5 spectral scanning confocal microscope, using secondary 
antibodies conjugated to fluorophores Alexa488 and Cy5 (appendix C). These antibodies 
were chosen since the wavelengths used to excite the fluorophores were the furthest apart in 
the emission spectrum allowing distinct visualisation of the stained proteins with minimal 
bleed-through of the fluorescent signal between the two channels used for analysis. 
Confocal microscope analysis of tissue sections stained with anti-(LTBP-2) antibody, 
(LTBP-2C), showed strong staining of LTBP-2 within the medial and intimal layers of the 
developing aorta, whilst LTBP-2 staining was observed to be absent in the adventitia layer of 
the aorta (figure 6.1A). The staining pattern indicated that LTBP-2 is highly expressed only 
in the inner two layers of the thoracic aorta at this stage of development. Examination of the 
control sections incubated with rabbit IgG showed a minimal, generalised cellular staining 
which indicated that non-specific background staining was low (figure 6.1D), and confirmed 
that the staining pattern for LTBP-2 in the aorta was specific. Similar LTBP-2 staining has 
been previously reported in the medial layer of developing human aorta using this anti-
(LTBP-2) antibody (LTBP-2C) (Hirani et al., 2007). In contrast to our findings, Hirani et al., 
(2007) described a lack of LTBP-2 staining in the intimal region. The discrepancy between 
the staining of the intimal layer is perhaps due to the different developmental stages of the 
aorta used in the two studies. Our study looked at expression of LTBP-2 in a 20-week-old 
human foetal aorta, while immunohistochemical studies undertaken by (Hirani et al., 2007) 
examined LTBP-2 expression at 25-36 weeks. 
Staining with fibrillin-1, anti-(fibrillin-1) antibody (MAB1919) produced a 
widespread specific staining in all three intimal, medial and adventitial layers of the aorta 
(figure 6.1B). The specificity of the MAB1919 staining pattern was confirmed by the 
negligible background staining in control sections treated with pre-immune mouse IgG 
(figure 6.1D). Overall, the immuno-staining results indicated that in the developing aorta 
there is an extensive co-distribution of LTBP-2 and fibrillin-1. However, LTBP-2 is not 
present in the adventitial layer.  
 
 
       










Figure 6.1. The distribution of LTBP-2, fibrillin-1, perlecan and laminin in the foetal aorta. Cryostat sections of human foetal aorta (20 weeks) were 
incubated with anti-(LTBP-2) antibody (LTBP-2C) (15µg/ml) (A and C); anti-(Fibrillin-1) antibody (MAB1919) (5µg/ml) (B and C); anti-(perlecan) 
antibody (7A5cc) (1:100 dilution) (E and G); and anti-(EHS Laminin) antibody (Rabbit 47) (1:10 dilution) (F and G). Control sections were incubated with 
matched concentration of rabbit IgG (15µg/ml) and mouse IgG (5µg/ml) (D) and normal rabbit serum (1:10 dilution) and mouse IgG (15µg/ml) (H). 
Primary antibody binding was detected using an appropriate secondary antibody conjugated to florophore Alexa488 or Cy5, prior to analysis on the Leica 
SP5 spectral scanning confocal microscope with a 20×objective. A and B are merged in C, E and F are merged in G. Magnification bars, A-H = 100µm. a, 
adventitia; m, media; and i, intima.   
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To determine whether in the developing aorta LTBP-2 is only found in association 
with fibrillin-microfibrils or if it is found independent of these structures, overlay analysis of 
the dual labelled cryostat sections was carried out. The resulting overlay showed that most of 
LTBP-2 staining in the intimal and the medial layers of the aorta coincided with fibrillin-1 
staining (visualised as yellow areas within figure 6.1C). Therefore, the staining pattern 
confirmed that almost all of the LTBP-2 protein found in the aorta is associated with fibrillin-
1-microfibrils. 
 
6.1.2 Perlecan is predominantly associated with smooth muscle BM in foetal aorta 
  Perlecan is predominantly found in most if not all BM (Bix and Iozzo, 2008; Mohan 
and Spiro, 1991). Thus, it can be assumed that in the developing aorta perlecan will be 
localised on BM. However, it is not known if perlecan may also be found independent of BM 
in this tissue. To determine if perlecan can be found associated with alternative structures 
other than the BM, dual labelling of cryostat sections with anti-(perlecan) antibody (7A5cc), 
and anti-(EHS Laminin, α-chain) antibody, Rabbit 47 (appendix C) was performed (section 
2.14). Laminin is a major BM component (LeBleu et al., 2007), therefore tissue sections 
were stained for laminin α-chain to highlight the BM in the foetal aorta. Control sections 
were incubated with the appropriate mouse IgG and normal rabbit serum to determine the 
level of non-specific background staining.  
When cryostat sections were incubated with anti-(perlecan) antibody (7A5cc) staining 
was detected evenly throughout the medial, and intimal layer of the developing aorta, while 
perlecan staining was largely absent in the adventitia (figure 6.1E). Control sections stained 
with pre-immune mouse IgG showed a negligible signal (figure 6.1H). 
Staining for laminin using anti-(EHS Laminin, α-chain) antibody (Rabbit 47) 
produced a similar pattern to perlecan (figure 6.1F). However, the laminin antibody also 
showed weak non-specific cellular staining detected in the adventitia of foetal aorta sections. 
The cellular staining was considered non-specific as a similar staining pattern was also 
observed for control sections stained with normal rabbit serum (figure 6.1H). The results 
therefore indicate that perlecan and laminin are extensively expressed in the inner two layers 
of the developing aorta.  
  Overlay analysis of dual-labelled cryostat sections with perlecan- and laminin-
specific antibodies, showed perlecan staining considerably overlapped with that of laminin in 
the media, intima and the outer region of the adventitia (visualised as yellow areas within 
figure 6.1G), confirming an extensive colocalisation of perlecan with BM. Interestingly, in 
the intimal region it appeared that some perlecan staining occurs independently of BM 
(figure 6.1G). There also appeared to be some laminin staining independent of perlecan in  
  - 90 - 
the medial layer that is visualised as faint red areas. However, this staining was most likely 
due to non-specific cellular staining by the antibody, as similar staining was also seen in the 
normal rabbit serum treated control section. As anticipated, normal rabbit serum produced a 
higher overall background cellular staining compared to mouse IgG (red staining indicates 
normal rabbit serum in figure 6.1H) in control sections. The higher level of background 
signal observed is due to the presence of impurities in the anti-(EHS Laminin, α-chain) 
antibody (Rabbit 47) and in normal rabbit serum, since they were collected serums from 
rabbit bleeds which had not been affinity purified. Overall, the results indicated that the 
majority of perlecan is found in association with BM in the foetal aorta. 
In summary, although LTBP-2 can be expressed independently of fibrillin-
microfibrils in some tissues, for example the testis (Shipley et al., 2000), when staining the 
developing aorta almost all of the LTBP-2 resides on the fibrillin-microfibrils (figure 6.1C). 
Similarly, the majority of the expressed perlecan in human foetal aorta is found on the BMs 
(figure 6.1G). With the establishment of LTBP-2 and perlecan on distinct structures in the 
foetal aorta, the localisation of microfibrils in relation to BM in the aorta was investigated. 
Determining whether the two matrix components are found close enough in the foetal aorta to 
interact with each other could indicate if LTBP-2 has additional roles in microfibril-basement 
membrane interaction.  
 
6.1.3 Colocalisation of fibrillin-1 with perlecan  
For comparing the distribution patterns of microfibrils and BMs in a 20-week-old 
human foetal aorta, cryostat sections were labelled with dual combinations of anti-(fibrillin-1) 
antibody (Fib-1A) and anti-(perlecan) antibody (7A5cc) (appendix C). Sections incubated 
with the appropriate mouse or rabbit IgG were also included as controls (section 2.14).  
Overlay analysis of cryostat sections stained with specific antibodies to both perlecan 
(figure 6.2A, C, E, & G) and fibrillin-1 (figure 6.2B-C & F-G), showed distinct staining 
patterns for the two antibodies. Generally, each protein appeared to be localised 
independently from the other (figure 6.2C). However, there were patchy areas in the outer 
regions of the medial layer where fibrillin-1 colocalised with perlecan (visualised as yellow 
staining in figure 6.2C). Control sections incubated with rabbit IgG and mouse IgG showed 
negligible background staining (figure 6.2D), confirming the specificity of the staining 
patterns for fibrillin-1 and perlecan in the aorta.  
Higher power examination of the medial layer confirmed the patchy overlapping 
distribution of fibrillin-1 with perlecan (seen as yellow staining, figure 6.2G). A number of 
the areas where fibrillin-1 and perlecan potentially interact have been marked by arrows in 
figure 6.2G and magnified in figure 6.2G e & f. The results indicate that fibrillin-1 and  
 
       
 
       
Figure 6.2. Fibrillin-1 and perlecan have potential areas of colocalisation within the medial layer of human foetal aorta. Cryostat sections (5µm) from 20-week-
foetal aorta were incubated with anti-(perlecan) antibody (7A5cc) (1:100 dilution) (A, C, E and G) and anti-(fibrillin-1) antibody (Fib-1A) (1:10 dilution) (B, C, F 
and G). Primary antibody binding was detected using an appropriate secondary antibody conjugated to flurophore Alexa488 or Cy5, prior to analysis on a Leica 
SP5 spectral scanning confocal microscope with 20×objective (A-G) and 4.04×zoom (E-G). Control sections were incubated with rabbit IgG (15µg/ml) and 
mouse IgG (15µg/ml) (D). A and B are merged in C. E and F are merged in G. In C and G, red staining indicates fibrillin-1, green staining indicates perlecan and 
the patchy areas where fibrillin-1 colocalises with perlecan are seen as yellow regions. The overlapping areas are marked by arrows in G, and are magnified in e 
and f. Magnification bars A-D= 100µm; E-G 25µm and e and f= 5µm.    
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perlecan have a limited co-distribution pattern in the foetal aorta, this perhaps occurring 
where the BM surrounding the smooth muscle cells and elastic fibres are close to each other. 
The results support previous reports of perlecan colocalising with fibrillin-1-microfibrils 
close to BM zones (Tiedemann et al., 2005). Furthermore, our findings and those of 
Tiedemann et al., (2005) identified that in both elastin and elastin-free tissues fibrillin-1 may 
directly link microfibrils to BMs. 
 
6.1.4 Colocalisation of LTBP-2 and perlecan in the foetal aorta  
  Co-localisation of LTBP-2 and perlecan was performed on cryostat sections dual-
labelled with anti-(perlecan) antibody (7A5cc) (figure 6.3A, C, E & G) and anti-(LTBP-2) 
antibody (LTBP-2C) (figure 6.3B, C, F & G) (section 2.14). Analysis of the immuno-stained 
tissue sections showed that LTBP-2 and perlecan generally have uniform and strong staining 
for both molecules detected in the intimal and medial regions (figure 6.3A-C). In addition, 
perlecan also appeared to localise to the blood vessels in the adventitia (figure 6.3A & C). 
Control sections showed negligible background staining (figure 6.3D), indicating that the 
staining for perlecan and LTBP-2 was specific. The overlay analysis of the staining patterns 
for LTBP-2 and perlecan confirmed the mainly independent localisation of perlecan and 
LTBP-2 in the intimal and medial layers (figure 6.3C). Interestingly, there were patchy areas 
in the medial region, particularly towards the outer regions where staining for LTBP-2 
coincided with perlecan staining (seen as yellow areas in figure 6.3C). This pattern was 
similar to that observed for fibrillin-1 and perlecan (section 6.1.3). These areas were therefore 
chosen for examination at higher magnification.  
  Examination at higher magnification of the medial layer revealed scarce areas of 
colocalisation of LTBP-2 and perlecan on the microfibrillar network (figure 6.3G). A 
number of these areas are magnified in figure 6.4G a-d. Elastin autofluorescence has also 
been included to indicate the location of elastic fibres (visualised as blue staining in figure 
6.3G). The confocal analysis of the distribution patterns of LTBP-2 and perlecan therefore 
suggested a potential but limited in vivo interaction between the two proteins.  
  In conclusion, it appears that LTBP-2 has the potential to play a role in the connection 
of microfibrils with BMs through the interaction with perlecan. The potential role of LTBP-2 
as a linker molecule between microfibrils and BMs is further discussed in chapter 8.  
  
 
       
 
       
Figure 6.3. Regions of partial colocalisation of LTBP-2 and perlecan within the medial layer of foetal aorta. Cryostat sections of human foetal aorta (20-week) were incubated with anti-
(perlecan) antibody, 7A5cc, (1:100 dilution) (A,C, E and G) and anti-(LTBP-2) antibody (LTBP-2C) (15µg/ml) (B, C, F, and G). Control sections were incubated with rabbit IgG 
(15µg/ml) and mouse IgG (15µg/ml) (D). Primary antibody binding was detected using an appropriate secondary antibody conjugated to florophore Alexa488 or Cy5, prior to analysis on 
a Leica SP5 spectral scanning confocal microscope with 20×objective (A-G) and 4.04×zoom (E-G). Elastin autofluorescence analysed under distinct channel, seen as blue staining in (G). 
A and B are merged in C. E and F are merged in G. Magnification bars, A-D = 100µm; E-G = 25µm; and a-d = 5µm. a, adventitia; m, media; and i, intima. Perlecan is visualised as green 
staining of BMs, LTBP-2 is visualised as red staining of elastic fibres and areas where BMs and elastic fibres potentially meet are visualised as yellow staining. Arrows indicate the areas 
where LTBP-2 colocalises with perlecan. These regions areas are viewed in higher magnification field in a-d.  
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CHAPTER 7 
IDENTIFICATION OF MATRIX MOLECULAR BINDING PARTNERS 
OF βig-h3 AND LTBP-2 USING AFFINITY BINDING AND 
PROTEOMICS TECHNIQUES 
 
βig-h3 and LTBP-2 are matrix components that are associated with two distinct 
microfibrillar structures of the matrix: collagen VI microfibrils and fibrillin-microfibrils 
respectively (Gibson et al., 1995; Gibson et al., 1997; Hanssen et al., 2003). Previous studies 
have found βig-h3 and LTBP-2 to be present in ECM of most tissues (Escribano et al., 1994; 
Gibson et al., 1997; LeBaron et al., 1995; Moren et al., 1994; Shipley et al., 2000; Skonier et 
al., 1994). Their importance has been demonstrated by their involvement in certain 
phenotypes, for example, in mutations of the human βig-h3 gene (TGFβI) which have been 
the cause of several phenotypically different corneal dystrophies (Klintworth, 2003; Munier 
et al., 1997). Also, there have been reports of involvement of βig-h3 with certain cancers 
including colorectal carcinoma, lung carcinoma, renal cell carcinoma (Kitahara et al., 2001; 
Sasaki et al., 2002; Yamanaka et al., 2008). Furthermore, Shipley et al., (2000) demonstrated 
that knockout of the LTBP-2 gene in mice is embryonic lethal, suggesting that LTBP-2 is an 
important molecule in the development of embryos possibly during implantation. 
Additionally, LTBP-2 has been implicated in the development of degenerative and 
inflammatory pathologies (Bujan et al., 2003).  
Given the recognition of the importance of these matrix proteins, the full extent of the 
physiological functions of βig-h3 and LTBP-2 has not yet been characterised. Therefore, to 
better understand the possible roles of these matrix proteins, binding partners for βig-h3 and 
LTBP-2 need to be identified. With the expression and purification of rLTBP-2 described in 
section 3.1, this chapter firstly describes the expression and purification of rβig-h3 followed 
by subsequent experiments to identify potential binding partners for rβig-h3 and rLTBP-2. 
Some insight has been forthcoming into the potential binding ligands of βig-h3 and 
LTBP-2 from previous studies. Firstly integrin binding motifs of βig-h3 and LTBP-2 have 
been identified (Kim et al., 2000; Saharinen et al., 1999; Skonier et al., 1992). 
Secondly, analysis of tissue extracts has shown βig-h3 and LTBP-2 to be associated with 
collagenVI and fibrillin-microfibrils respectively (Gibson et al., 1995; Gibson et al., 1989; 
Gibson et al., 1997; Hanssen et al., 2003). A number of in vitro binding studies using rβig-h3 
have also identified fibronectin, decorin and biglycan as binding partners of βig-h3 (Billings 
et al., 2002; Reinboth et al., 2006).  
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In vitro solid phase binding assays using rLTBP-2 have identified binding of LTBP-2 
to the N-terminal of fibrillin-1, while no binding was detected for fibrillin-2, MAGP, elastin, 
collagen types I, III, V and VI (Hirani et al., 2007). However, the range of purified matrix 
proteins available to be screened individually by in vitro binding assays for identifying 
additional binding partners of βig-h3 and LTBP-2 represents only a small spectrum of matrix 
proteins with the potential to interact with either βig-h3 and LTBP-2. To more systematically 
identify new binding partners, a different approach was required. 
Previously in our laboratory a yeast-two-hybrid system was tested with βig-h3 as bait. 
However, many false positives were identified due to inappropriate formation of disulphide 
bonds between the bait and the retrieved target protein in the yeast cytoplasm (Hew and 
Gibson, unpublished observations). Therefore an approach using affinity chromatography 
combined with proteomics techniques was tested, using both rβig-h3 and rLTBP-2. Two 
basic techniques, 2-DGE and mass spectrometry were used to identify the binding partners. 
Peptide mass finger-printing is the analytical technique used for bound protein 
identification. In this method, the unknown protein of interest is cleaved into smaller peptides, 
and the masses of the produced peptides are accurately measured by MALDI-TOF-MS. 
These masses are then in silico are matched against protein sequence databases such as in-
house Mascot server, SwissPort, MSDB or NCBI to determine the protein’s identity. The 
results are statistically analysed to find the best match. This approach has great promise for 
improved sensitivity, increased throughput, increased resolution and mass accuracy 
(Bergquist et al., 2002)   
Initially, suitable affinity matrices needed to be made, and an appropriate mixture of 
matrix proteins needed to be prepared. The conditions of the affinity chromatography needed 
to be optimised in order to isolate proteins (from the prepared extract) that specifically bound 
to the affinity matrices. Bound proteins were then to be resolved using SDS-PAGE, or 2-
DGE if sufficient resolution was not achieved by the former method. The identities of each 
protein band would be determined by tryptic digestion and peptide mass finger-printing. 
 
7.1 Expression and purification of recombinant βig-h3  
The expression and purification of full length human rβig-h3 has been described 
previously (Hanssen et al., 2003). Briefly, human βig-h3 cDNA was cloned into pGEMT-
easy vector and clones containing authentic βig-h3 cDNA were selected for subcloning of the 
cDNA into episomal expression vector pCEP-4. The pCEP-4 vector carries an ampicillin 
resistance gene for the selection in bacteria and hygromycin B resistance gene for selection in 
mammalian cells.   
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For purification of human rβig-h3, a his6-tag was introduced close to the N-terminus, 
27 amino acids in the peptide sequence to allow for purification on Ni-sepharose. The 
recombinant expression construct (pCEP/BH18) was transfected into 293-EBNA cells and 
the resultant recombinant βig-h3 protein was purified from the serum-free DMEM medium 
using Ni-sepharose chromatography (section 2.4). The purified recombinant protein when 
analysed by SDS-PAGE and Coomassie Blue staining (section 2.6) appeared to migrate as a 
triplet of bands under reducing conditions, with the major band corresponding to apparent 
molecular mass of 66 kDa, while the minor two bands migrated close together at 71 kDa 
(figure 7.1A, lane1). Tissue βig-h3 migrates at 76-78 kDa in size on gels (Gibson et al., 1996; 
Gibson et al., 1989) but processing also yields a 68-70 kDa isoform (Skonier et al., 1994). 
The major band at 66 kDa and two of the minor bands migrating close to 71 kDa, 
corresponded in size to purified rβig-h3 produced previously (Hanssen et al., 2003). 
In addition to the expected 66 kDa rβig-h3, a smaller protein migrating as a band at 
54 kDa was also purified from the medium (figure 7.1A, lane 1). When the purified protein(s) 
were analysed by immunoblotting (section 2.6), all four bands reacted with anti-(βig-h3) 
antibody (MP78/70) (figure 7.1A, lane 2), thus confirming that all of the bands were βig-h3-
related species and not contaminants. The yield of rβig-h3 was approximately 0.2µg/ml of 
DMEM medium and in total 1.2mg of rβig-h3 was purified.  
 
7.2 Preparation of the affinity column; coupling of rβig-h3 and rLTBP-2 to CNBr-
activated sepharose-4B 
Several factors were considered when selecting an appropriate matrix for affinity 
chromatography. Firstly, the entire protein needed to be considered as a bait protein since 
potential binding sites were not defined. Secondly, the reusability of the coupled column was 
important because purified recombinant proteins were limited in quantity and preparation of a 
fresh column for each experiment would be time consuming and laborious. Thus the bait 
needed to be immobilised covalently to the sepharose support. For these reasons, CNBr-
activated sepharose was chosen as the appropriate support. CNBr-activated sepharose reacts 
readily with primary amines to form a covalent coupling of the bait protein to the agarose 
matrix and to allow multi-point attachment of the protein for good chemical stability. 
Furthermore it immobilises the bait protein in a variety of orientations since the coupling 
occurs at random sites on the protein. 
Due to the potential loss of activity of the bait as a result of repeated contact with the 
denaturant, 6M urea, only small quantities of the rβig-h3 protein e.g.613µg/7.8ml, or rLTBP-
2 e.g. 1mg/7.5ml, were immobilised to CNBr-activated sepharose (200µl). This allowed the 
use of fresh affinity columns for each target protein mixture.  
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For the coupling of rβig-h3 and rLTBP-2 to CNBr-activated sepharose, the purified 
recombinant proteins were first dialysed into a coupling buffer (section 2.15). Dialysis was 
performed at 4°C to minimize degradation of the proteins by proteases. The dialysed 
recombinant proteins were analysed on a 15% polyacrylamide gel to confirm there was no 
substantial loss of proteins during dialysis (section 2.6). The concentrations of the dialysed 
proteins were determined by densitometry against known amounts of standard proteins. 
Analysis of the Coomassie Blue-stained gel of rβig-h3 sample prepared for sepharose 
coupling showed the presence of additional bands which migrated at 128 kDa, 120 kDa, 54- 
kDa, 46 kDa and 42 kDa on 15% SDS-PAGE (figure 7.2A, lane 1). Immuno-reactivity of 
these bands with anti-(βig-h3) antibody (MP78/70) suggested that they appear to be 
degradation and aggregation products of the recombinant protein. Both rβig-h3 and rLTBP-2 
were successfully coupled to the CNBr-activated sepharose, with approximately 3% of rβig-
h3 and 5% of rLTB-2 remaining unbound to the CNBr-activated sepharose after two rounds 
of incubation (section 2.15). This was evident from the faint staining of the recombinant 
proteins detected in the coupling solution after the incubation with CNBr-activated sepharose 
(figure 7.2, lanes 2). Therefore a third incubation with the CNBr-activated sepharose was not 
necessary. The coupled columns were then equilibrated for subsequent affinity 
chromatography.  
 
7.3 Selection of tissue extracts for identification of binding partners for rβig-h3 and 
rLTBP-2  
When selecting a protein mixture to incubate with the prepared affinity columns, it 
was crucial to ensure that the extracted proteins were from a tissue that contained either βig-
h3 or LTBP-2, if not both. It was reasoned that, when the bait protein is present in the tissue, 
then the proteins isolated with the affinity columns were more likely to be valid binding 
partners. One such tissue was bovine nuchal ligament, as both proteins were originally 
characterised from this tissue (Gibson et al., 1995; Gibson et al., 1989; Gibson et al., 1997; 
Hirani et al., 2007). Moreover, successful protein extraction protocols have previously been 
established for bovine nuchal ligament, with the extracted protein populations relatively well 
characterised (Gibson et al., 1989). Furthermore, a number of proteins within bovine nuchal 
ligament have previously been identified as binding partners for βig-h3 or LTBP-2 (Gibson et 
al., 1995; Hanssen et al., 2003; Hirani et al., 2007; Reinboth et al., 2006).   
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Figure 7.1. Purification of rβig-h3. Recombinant βig-h3 (15µl) was resolved by 8% SDS-
PAGE followed by lane 1, Coomassie Blue staining or lane 2, immunoblotting with anti-
(βig-h3) antibody (MP78/70). Recombinant βig-h3 migrated as a triplet with the major band 























Figure 7.2. Determination of the extent of coupling of rβig-h3 or rLTBP-2 to CNBr-activated 
sepharose. A, rβig-h3 and B, rLTBP-2 were incubated with CNBr-activated sepharose and 
unbound materials were analysed by 15% SDS-PAGE and Coomassie Blue staining. 
Recombinant proteins (50µl) present lanes 1, before and lanes 2, after coupling. 
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Bovine nuchal ligament tissue from a foetal calf of 230-day gestation was chosen for 
protein extraction, as there is an increase in the amount of elastic fibre and collagen 
production in the last two months of foetal development (Cleary et al., 1967). The tissue was 
sequentially extracted with 0.1% NP-40 detergent, 1M NaCl and 6M Guanidine 
hydrochloride (GuHCl). Readily soluble proteins such as serum albumin were extracted by 
the initial treatments, saline plus detergent Nonidet P-40 and 1M NaCl, while a different 
population of polypeptides was solubilised by 6M GuHCl (Gibson et al., 1989). Bovine 
nuchal ligament protein mixtures extracted with 1M NaCl (BNLPM-1M NaCl) and 6M 
GuHCl (BNLPM-6M GuHCl) were selected for subsequent affinity binding experiments.  
 
7.4 The use of BNLPM-1M NaCl for identification of novel binding partners  
7.4.1 Selecting a suitable binding buffer  
Initially the solubilised BNLPM-1M NaCl was investigated for potential binding to 
rβig-h3 and rLTBP-2. BNLP-1M NaCl appeared to be more readily soluble in solutions at or 
close to physiological conditions compared with proteins extracted with 6M GuHCl. Before 
the extract was incubated with the coupled rβig-h3 and rLTBP-2 columns, it needed to be 
equilibrated into a suitable buffer. One molar NaCl was a much higher salt concentration 
compared with physiological salt concentration (0.15M), hence this could interfere with 
binding of proteins to the ligands. To ensure binding, it was necessary to perform the 
experiment as close to physiological conditions as possible. Therefore the solubility of the 
BNLPM-1M NaCl was tested in TBS and TBS/0.5M NaCl using SDS-PAGE and Coomassie 
Blue staining (section 2.6). Figure 7.3 illustrates the proteins that remained soluble following 
the different treatments. The BNLPM-1M NaCl was also included for comparison (figure 7.3, 
lane 1). Analysis of the proteins that remained soluble in TBS (figure 7.3, lane 2) and 
proteins that precipitated out of solution in TBS (figure 7.3, lane 3), revealed the presence of 
three protein bands around 40 kDa of similar staining intensity in both the supernatant and 
the precipitate. This suggested a partial precipitation of some BNLPs in TBS. In addition, 
there was relatively strong staining of several protein bands migrating below 35 kDa in the 
precipitated sample (figure 7.3, lane 3) compared to the supernatant (figure 7.3, lane 2). The 
intensity of staining of these precipitated protein bands was similar to that of the same bands 
present in the original 1M NaCl solution (figure 7.3, lane 1), thus confirming the almost 
complete precipitation of these proteins in TBS. Since there was potential for several proteins 
to migrate to the same position during polyacrylamide gel electrophoresis, each band on the 
gel could potentially represent more than one protein and the absence of each band in the 
supernatant could mean the loss of several proteins. Thus TBS was not considered as an 
optimal buffer for the study.   
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The staining of the protein bands in TBS/0.5M NaCl solution was similar to the 
staining detected in BNLPM-1M NaCl, indicating that most if not all of the proteins are 
soluble in the TBS/0.5M NaCl buffer. There were also a number of proteins migrating 
between 45-97 kDa, which appeared in both the supernatant (figure 7.3, lane 4) and the 
precipitate (figure 7.3, lane 5), showing a small degree of precipitation. There appeared to be 
a population of proteins that precipitated out of solution, which were larger than 97 kDa 
(figure 7.3, lane 5). The observed banding pattern of these proteins was different to the 
banding patterns of proteins with similar molecular weights that stayed soluble in solution or 
present in the original 1M NaCl solution. This was due to the analysis of different quantities 
of the precipitated proteins compared with the proteins that remained in the supernatant. 
While out of the total volume of BNLPM (1ml), only a small fraction of the mixture (60µl) 
was analysed by SDS-PAGE for examination of the soluble proteins, precipitated proteins 
from 1ml of BNLPM were used for comparison. Therefore the bands present in the 
precipitated sample which were not present in the supernatant sample or the sample from the 
original solution, represented protein populations with low concentrations, which were 
unable to be detected by Coomassie Blue in the comparison samples tested. Therefore from 
the results it was concluded that there was only minor precipitation of protein bands from 
BNLPM in TBS/0.5M NaCl. Hence, TBS/0.5M NaCl was selected for subsequent affinity 
chromatography experiments.  
 
7.4.2 Incubation of BNLPM with a sepharose column for detection of non-specific 
interactions 
Prior to the incubation of BNLPM with the prepared affinity columns, the level of 
non-specific interaction of the proteins with the sepharose was investigated. For that, 
BNLPM in TBS/0.5M NaCl was incubated with sepharose CL-4B and bound proteins were 
analysed by SDS-PAGE and Coomassie Blue staining, in order to determine the amount of 
non-specific binding of proteins to the sepharose CL-4B (section 2.6). Comparison of the 
BNLPM before and after incubation with sepharose CL-4B showed no major loss of proteins 
(figure 7.4, lane 1& lane 2). However, there were a number of band proteins with molecular 
weights that ranged from 45-200kDa which appeared to be non-specifically binding to 
sepharose CL-4B (figure 7.4, lane 3). The staining intensity of these non-specific binding 
protein bands was either the same or lower compared with that of the same bands remaining 
in solution after incubation (figure 7.4, lane 2). The results therefore suggested that the non-
specific interactions with the sepharose CL-4B were minimal. Moreover, there was no loss of 
specific protein sub-populations due to the non-specific interactions. It would be ideal to have  




Figure 7.3. Solubility of BNLPM-1M NaCl following different treatments.  Lane 1, 
BNLPM-1M NaCl (30µl). Lanes 2 & 3, BNLPM in TBS (60µl). Lanes 4 & 5 BNLPM in 
TBS/0.5M NaCl, supernatant (30µl) and precipitate (1ml). Samples were centrifuged and 
lanes 2 & 4, each supernatant and lanes 3 & 5, each pellet were analysed by 12% SDS-
PAGE and Coomassie Blue staining. 
 
Figure 7.4. BNLPs interacting with sepharose-CL-4B. BNLPM (1mg/ml) in TBS/0.5M NaCl 
was incubated with sepharose CL-4B. Bound and unbound proteins were analysed by SDS-
PAGE on 12% gel and Coomassie Blue stained. Lane 1, mixture prior to incubation (50µl). 
Lane 2, unbound proteins (50µl). Lane 3, bound proteins eluted with 6M urea (500µl). Only 
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no non-specific binding to sepharose, and further reductions may be possible by increasing 
the salt concentration in the buffer. However, by so doing, possible authentic interactions 
with the target proteins could be compromised. Thus the small amount of background 
binding was considered acceptable for subsequent affinity chromatography.  
 
7.5 Identification of potential binding partners for rβig-h3 from the BNLPM- 
1M NaCl 
7.5.1 Analysis of the binding proteins using Coomassie Blue staining 
Novel binding partners for rβig-h3 were investigated using a solubilised BNLPM. 
After incubation of BNLPM with rβig-h3 coupled to CNBr-activated sepharose (rβig-h3-
sepharose) and sepharose CL-4B (sepharose-control), bound proteins were eluted and 
analysed by SDS-PAGE and Coomassie Blue staining (section 2.15 and 2.6). A sample of 
BNLPM prior to incubation with the affinity columns was also included for comparison 
(figure 7.5, lane 1). From examination of the eluted proteins, it appeared that there were 
several more protein bands present in the eluate from the rβig-h3-sepharose (figure 7.5, 
lanes 2), when compared with the eluate from sepharose-control (figure 7.5, lane 3). 
On close inspection of the resolved protein bands, it appeared that there were several 
bands which were common to both the eluates from the rβig-h3-sepharose and sepharose-
control. These proteins migrated at 14 kDa, 14.7 kDa, 45 kDa, and 54 kDa, as well as two 
other bands above 97 kDa on both 15% polyacrylamide gels. All of the above mentioned 
protein bands appeared to be major components of the original extract (figure 7.5, lane 1). 
Greater staining intensity of these protein bands was detected in the eluates from the rβig-h3-
sepharose compared with those from the sepharose-control. Therefore these proteins were 
considered to be possible candidate binding partners for rβig-h3.  
A protein band with an apparent molecular weight of 12.5 kDa was intensely stained 
in the eluates from the sepharose-control (figure 7.5, lane 3), suggesting that the protein 
interacted non-specifically with sepharose. In contrast, there was a moderately strong staining 
of a 15 kDa protein band in the eluate from rβig-h3-sepharose (figure 7.5, lane 2), which 
was also present in the extract. This band was therefore defined as a novel candidate binding 
partner of rβig-h3. A repeat of the experiment further confirmed the specificity of the 
interaction between this particular protein and rβig-h3 protein (data not shown). As good 
practice, upon confirmation of the candidacy of the protein, it was decided to ensure the 
candidate protein was not a βig-h3-related species prior to protein identification by mass 
spectrometry (section 7.5.2). 
A prominent band identified as a candidate binding partner for βig-h3 had the same 
size (66 kDa) as the main band of purified rβig-h3 (figure 7.5, lane 2). In order to determine  
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if this band was βig-h3, eluates were tested for reactivity to specific antibodies to rβig-h3. It 
was possible that βig-h3 had been pulled out from the BNLPM by homeotypic interaction 
with rβig-h3-sepharose or that rβig-h3 had leaked from the sepharose. Another reason for 
testing the eluates for reactivity to rβig-h3-specific antibodies was to identify additional 




Figure 7.5. BNLPs interacting with rβig-h3-sepharose. BNLPM was incubated with rβig-h3-
sepharose and sepharose-control. Bound proteins were analysed by SDS-PAGE on a 15% gel 
and Coomassie Blue stained. Lane 1, BNLPs before incubating with the columns (50µl). 
Lane 2, bound proteins eluted from rβig-h3-sepharose (500µl). Lane 3, bound proteins 
eluted with 6M urea from sepharose-control (500µl). 
 
7.5.2 Detection of βig-h3 in proteins eluted from rβig-h3-sepharose 
The proteins binding to the rβig-h3-sepharose and sepharose-control, plus BNLPM-
1M NaCl were tested for reactivity to anti-(βig-h3) antibody (MP78/70) and anti-(tetra-his) 
antibody by western blot analysis (section 2.6). A number of protein bands (molecular weight 
31 kDa to above 200 kDa) were stained with anti-(βig-h3) antibody (MP78/70) in the sample 
of BNLPM (figure 7.6A, lane 1) and in the eluate from rβig-h3-sepharose (figure 7.6A, lane 
2). The higher molecular weight bands were 1.5-3 times larger in size than the βig-h3 
monomer. Unpublished work by Dr. Hanssen suggested βig-h3 aggregates are present in 
bovine nuchal ligament, thus supporting the idea that these proteins were βig-h3 aggregates. 
There was no Coomassie Blue staining of the candidate 15 kDa band identified in figure 7.5 
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When a sample of BNLPM was immuno-blotted with anti-(tetra-his) antibody, no 
strongly staining bands were detected (figure 7.6B, lane 1), although some minor immuno-
reactive proteins were present. Staining of the eluates from βig-h3-sepharose with anti-(tetra-
his) antibody (figure 7.6B, lane 2), produced staining of similar band proteins previously 
stained with anti-βig-h3 antibody (MP78/70) (figure 7.6A, lane 2). The staining results 
therefore identified the major immuno-reactive bands as rβig-h3, not tissue-extracted βig-h3, 
which was leaching from the column. It was therefore deduced that regular replacement of 
the column would be required due to the significant loss of the coupled protein with each 
experiment. As expected, there was no staining detected in the sepharose-control (figure 
7.6B, lane 3). Overall, the majority of the proteins in the eluates from βig-h3-sepharose were 
rβig-h3, which had been coupled to the sepharose. Therefore, the findings indicated that rβig-
h3 was not completely linking to the sepharose.  
 
 
Figure 7.6. Identification of rβig-h3 in the eluted protein fractions. Proteins bound to rβig-
h3-sepharose and sepharose-control were eluted with 6M urea and eluates were analysed by 
15% SDS-PAGE and immunoblotting with A, anti-(βig-h3) antibody (MP78/70) or B, anti-
(tetra-his) antibody, specific for rβig-h3.  Lane 1, BNLPM before incubation with the 
columns (60µl). Lane 2, proteins binding to rβig-h3-sepharose (125µl). Lane 3, proteins 
binding to sepharose-control (125µl). 
 
Immunoblotting analysis of the eluates from βig-h3-sepharose identified the majority 
of the candidate bands as βig-h3 species or aggregates of βig-h3, except for the protein band 
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mass spectrometry. The mass spectrometric analysis was performed at Protein Core Facility 
at the Hanson Institute by Dr. Ian R. Milne using tryptic digestion. The mass spectrometry 
analysis identified the band as a human keratin contaminant in the sample. Keratin-like 
proteins are one of the most common contaminations found during a protein identification 
process by mass spectrometry. Keratin proteins can come from virtually anywhere, from the 
air, dandruff from the hair and skin, and those already present in the extract. The keratin 
protein can have a molecular weight ranging from 20 kDa to 70 kDa, but the size may vary 
depending on the point of the experiment at which it was introduced. Keratin contamination 
affects identification of potential protein bands depending on the keratin: protein ratio of the 
excised band. Even with stringent conditions of cleanliness complete avoidance is hardly 
possible. Steps were introduced to minimize future contamination, including washing of all 
containers with 0.1M NaOH prior to use, keeping contact of the samples and gels with air to 
the minimum by making sure lids were always on the test tubes and containers during all 
steps of the experiment, and ensuring face masks were worn when inspecting and analysing 
the stained gels. 
 
7.5.3 Detection of the potential binding proteins for rβig-h3 using silver staining 
The results in section 7.5.2 demonstrated that most of the intensely-stained bands in 
the eluate from the βig-h3-sepharose were identified as rβig-h3 derivatives. The BNLPM 
contains many proteins at various concentrations that may interact with rβig-h3 with varying 
affinities. These factors may affect the chance of detecting an interaction with rβig-h3 since 
only minute amounts of the ligand may be present in the eluates. Therefore, rare interacting 
molecules may not be detected by Coomassie Blue staining after separation by SDS-PAGE. 
In order to visualise a wider spectrum of proteins binding to rβig-h3, a more sensitive method 
of detection was considered. One such technique was silver staining. Silver staining has a 
sensitivity of 0.3-10ng/band (Switzer et al., 1979), compared with Coomassie Blue R-250 
which has a sensitivity of 50-100ng/band. Initially the modified silver staining protocol from 
Cheng et al., (1994) was adapted to detect proteins eluted from rβig-h3-sepharose (section 
2.7). However, this method resulted in almost instantaneous development of the protein 
bands and the background gel, making it difficult to distinguish individual protein bands 
separated in the polyacrylamide wells. The high sensitivity of this silver staining method did 
not allow comparison to be made between the samples (data not shown). However, there was 
a significant increase in the overall number of bands detected on the gel compared to 
Coomassie Blue staining. Modifications were therefore made to reduce the background 
staining and to permit more control over the rate of staining. The first modification was the 
addition of a washing step after silver nitrate incubation, for up to 10 minutes, instead of a  
  - 106 - 
quick rinse. This washing step after incubating the polyacrylamide gel with silver nitrate did 
not however improve the contrast between the protein bands and the background as it washed 
away the silver nitrate from the gel and hence no staining was detected (results not shown). 
The second modification included diluting the developing solution. It was found that 
development of protein bands using a diluted developing agent slightly reduced the overall 
background staining, but not to required levels (results not shown). Also, this did not improve 
the rate of protein band development versus background development. Addition of a washing 
step after incubating the polyacrylamide gel with silver nitrate did not help as it washed away 
the silver nitrate from the gel and hence no staining was detected.  
Due to the above problems, a second method for silver staining was adapted from 
Gromova, (2006) (see section 2.7). Initial modifications were made to the protocol to suit the 
thin polyacrylamide gels used for the separation of the proteins. A quick rinse of 10 seconds 
with distilled water replaced the 3×5min and 2×1min washes after sensitising the gel with 
sodium thiosulphate, and after incubation of the gel with silver nitrate respectively. The result 
was minimal background staining and greater control over the staining intensity of the 
developing protein bands. This method was used for all subsequent silver staining. Figure 
7.7 illustrates the pattern of proteins bound to the rβig-h3-sepharose and sepharose-control. 
Numerous protein bands were detected in the eluates from both rβig-h3-sepharose (figure 7.7, 
lane 1) and sepharose-control (figure 7.7, lane 2) by silver staining when compared to 
Coomassie Blue staining previously described (figure 7.5, lane 2 & lane 3). Therefore as 
expected, a larger spectrum of proteins potentially interacting with the rβig-h3 was revealed 
due to this higher sensitivity. 
Bands present in the eluates from both rβig-h3-sepharose and sepharose-control were 
disregarded. However, a substantial number of protein bands remained that were candidate 
binding partners of βig-h3. However, we were interested in focusing on one or two stained 
bands which represented major new binding partners for rβig-h3 in BNLPM rather than 
previously identified binding partners. Therefore, measures were taken in order to identify 
more specific binding partners for rβig-h3 using silver staining. 
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Figure 7.7. Detection of BNLPs binding to rβig-h3-sepharsose using silver staining. Bound 
proteins were eluted with 6M urea and subsequently analysed by 15% SDS-PAGE and silver 
staining. Lane 1, eluted proteins from rβig-h3-sepharose (200µl). Lane 2, proteins eluted 
from sepharose-control (200µl). This stain improved the sensitivity for detection of proteins, 
exposing more protein bands that appear to interact with rβig-h3. 
 
7.5.4 Isolation of potential binding partners of βig-h3 using immobilised-Metal Affinity 
chromatography 
The rβig-h3 contains a Ni-binding his6-tag and thus Ni-sepharose chromatography can 
potentially be used to pull out rβig-h3 together with proteins that are bound specifically to it. 
An advantage of using Ni-sepharose is that the bait protein binds to the Ni-sepharose by its 
his-tag compared with the randomly cross-linking of rβig-h3 to the CNBr-activated sepharose. 
Therefore the use of Ni-sepharose allows the entire rβig-h3 molecule to be available to bind 
its ligands. This may maximise the identification of specific binding partners. 
In section 7.4.1 TBS/0.5M NaCl was considered as an optimal buffer for BNLPM for 
subsequent affinity binding to rβig-h3-sepharose. However, it is possible that the presence of 
0.5M NaCl may interfere with binding of rβig-h3 to some ligands. Consequently, binding 
studies were carried out under physiological conditions. However, two factors needed to be 
considered before carrying out the experiment. Firstly, as previously shown in section 7.4.1, 
there is a complete loss of the lower molecular weight proteins when BNLPM-1M NaCl is 
dialysed into TBS. Loss of these proteins due to precipitation potentially meant loss of 
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unidentified proteins with the potential to interact with βig-h3. Thus loss of a small portion of 
these proteins would still leave many other interactions to be identified under physiological 
conditions. To prevent the precipitation of rβig-h3 in TBS, it was necessary to bind rβig-h3 to 
Ni-sepharose prior to incubation with the BNLPM in a physiological buffer (TBS). In 
addition, Ni-sepharose was used as a control (section 2.16). 
Bound proteins were eluted with 500mM imidazole, resolved by SDS-PAGE and 
detected by silver staining. A number of intensely stained bands, such as those migrating at 
26 kDa, 42 kDa, 46 kDa, 54 kDa, 66 kDa, 97 kDa, 120 kDa, 128 kDa and 200 kDa, were 
detected in the eluate from the rβig-h3-Ni-sepharose (figure 7.8A, lane 1) which was not as 
strongly stained in the Ni-sepharose-control (figure 7.8A, lane 2). However, there also 
appeared to be more non-specific interaction of proteins with the Ni-sepharose-control, 
compared to previous sepharose-control. Most of the non-specifically interacting proteins 
were of very high molecular weight for one protein band migrating at 46 kDa. To identify 
rβig-h3 protein and its isoforms verses the mixture of candidate binding partners, the eluates 
from both rβig-h3-Ni-sepharose and Ni-sepharose-control were immunoblotted with anti-
(tetra-his) antibody and anti-(βig-h3) antibodies (MP78/70) and Rabbit 45 (section 2.6). A 
sample of purified rβig-h3 was also included for positive identification of rβig-h3. Two 
specific antibodies to βig-h3 were used as they recognised different epitopes. The Rabbit 45 
is made to a peptide in fasciclin-1 domain of βig-h3, while (MP78/70) recognises mainly 




and non-covalent interactions of betaamples from the Ni-sepharose-control (figure 7.8B, 
lane 2). Therefore, the results indicated that tissue βig-h3 does not bind non-specifically to 
Ni-sepharose. Anti-(tetra-his) antibody staining of the purified rβig-h3 sample showed 
staining of a major band at 66 kDa and the triplet band at 56 kDa (figure 7.8B, lane 3). It 
should be noted that due to the difference in quantity of rβig-h3 present in the eluate from 
rβig-h3-Ni-sepharose and the purified sample, it was not possible to confirm the identity of 
the other identified band proteins in figure 7.8B lane 1. Similarly anti-(βig-h3) antibody 
(MP78/70) identified the prominent bands at 42k-66 kDa, 120 kDa, 128 kDa and 200 kDa, 
but not the bands at 26 kDa and 97 kDa as βigh-3 in the rβig-h3-Ni-sepharose eluate (figure 
7.8C lane 1). There was no staining detected in the eluted samples from the Ni-sepharose-
control (figure 7.8C, lane 2).  The immuno-reactivity of a 97 kDa band protein in the purified rβig-h3 sample 
(figure 7.8C, lane3), suggested that the similar sized protein band observed by silver staining 
could potentially be related to rβig-h3. Anti-(βig-h3) antibody Rabbit 45 staining of the  
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fractionated samples by SDS-PAGE identified similar bands migrating at 42-66 kDa, 128 
kDa and 200 kDa in the eluate from rβig-h3-Ni-sepharose (figure 7.8D, lane 1). There was 
no staining detected in the eluted sample from the Ni-sepharose-control when tested with the 
anti-(βig-h3) antibody, Rabbit 45 (figure 7.8C lane 2). Furthermore, band proteins stained 
with anti-(βig-h3) antibody (MP78/70) in the sample of purified rβig-h3, also showed 
reactivity to anti-(βig-h3) antibody, Rabbit-45 (figure 7.8D, lane 3). Overall from these 
results it was concluded that the majority of the prominent bands detected in the silver 
stained eluate from rβig-h3 coupled to Ni-sepharose were βig-h3. The exception was the 
silver-stained band with molecular weight of 26 kDa, in the eluate from βig-h3-Ni-sepharose 
which did not immuno-react with either of the antibodies and therefore, may be a potential 
binding partner of βig-h3. To confirm the protein band as a unique candidate binding partner 
for βig-h3, the BNLPM was also tested for immuno-reactivity to anti-(tetra-his) antibody, and 
anti-βig-h3 antibodies (MP78/70) and Rabbit 45). No reactivity of the candidate protein band 
to anti-(tetra-his) antibody and anti-βig-h3 antibody (MP78/70) was detected (data not 
shown). However, the candidate protein showed reactivity to anti-βig-h3 antibody, Rabbit 45 
suggesting the possibility that the candidate band may be related to βig-h3 (figure 7.8D, lane 
4). In addition the major βig-h3 species at 66 kDa was detected as a doublet in the BNLPM 
compared to the βig-h3 coupled and eluted from Ni-sepharose. 
From the collected data no certain candidate binding partners were identified as it was 
concluded that rβig-h3 interfered with gel analysis of potential binding partners. Therefore, 
this alternative approach of nickel affinity chromatography under physiological conditions 
did not appear to improve the detectability of protein interactions with rβig-h3. 
From the results of sections 7.5.1-7.5.3, it was apparent that a lot more proteins in the 
BNLPM were bound to rβig-h3-sepharose than to sepharose-control. Some of these proteins 
may be authentic binding ligands of βig-h3. However, identification of a few specific βig-h3 
ligands was not achieved using the methods described above, nor was it possible to narrow 
down and select with confidence the potential candidate binding partners amongst the rest of 
the eluted proteins. To reduce problems in the system, different aspects of the system had to 
be tested. Given that a substantial number of BNLPs were binding to the affinity columns, 
BNLPM was tested to determine if the BNLPs were sticky in nature. For this, the approach 
taken was changing of the bait protein, to see whether the same degree of non-specific 
interaction between BNLPs and a different bait protein still occurred. Therefore, rLTBP-2 
was chosen as an alternative bait protein for separation of potential binding ligands from 








Figure 7.8. Affinity chromatography on columns of rβig-h3 bound to Ni-sepharose. BNLPM was incubated with rβig-h3 (30µg) coupled to Ni-sepharose 
or Ni-sepharose-control. Bound proteins were eluted with 500mM imidazole and eluates (50µl) were analysed by SDS-PAGE on a 15% gel, followed by A, 
silver staining, or immunoblotting with B, anti-(tetra-his) antibody, or anti-(βig-h3) antibody; C, MP78/70 and D, Rabbit 45. Lane 1, rβig-h3 plus BNLPs 
eluted from Ni-sepharose (50µl). Lane 2, BNLPs eluted from Ni-sepharose-control (50µl). Lane 3, purified rβig-h3 (0.6µg). Lane 4, BNLPM extract 
(20µl). The majority of the unique bands identified were rβig-h3 that bound to Ni-sepharose. Arrows in A indicate molecular weights of some of the eluted 
proteins from the Ni-sepharose.  
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7.6 Identification of binding partners for rLTBP-2 from BNLPM using silver staining 
  The interaction of rLTBP-2 with BNLPMs was investigated to identify novel binding 
ligands for LTBP-2, and to observe how the banding pattern of proteins eluted from rLTBP-
2-sepharose compared with that for rβig-h3. A BSA-coupled sepharose was added as a 
control to identify non-specific protein-protein interactions that might be occurring in the 
affinity chromatography system. Analysis of proteins eluting from rLTBP-2-sepharose and 
BSA-sepharose-control following incubation with BNLPM in TBS/0.5M NaCl, showed more 
protein bands in the eluate from rLTBP-2-sepharose (figure 7.9A, lane 1) compared to the 
eluate from BSA-sepharose-control (figure 7.9A, lane 2). Comparison of the eluates from 
rLTBP-2-sepharose with gels from previous experiments using rβig-h3-sepharose (figure 7.7, 
lane 1) showed that both have very similar banding patterns, therefore suggesting that the 
isolated proteins binding non-specifically. When the silver stained eluate from the sepharose-
control (figure 7.7 lane 2) and BSA-sepharose-control (figure 7.9A lane 2) were compared, 
it appeared that there were more band proteins present in the eluate from sepharose-control, 
although it appeared that there was an overall increased quantity of proteins present in the 
eluate from BSA-sepharose-control. This was evident from the stronger staining of the band 
ation</KEYWORD><KEYWORD>*Heart 
Catheterization</KEYWORD><KEYWORD>*Pulmonary Valve 
Stenosis</KEYWORD></KEYWORDS><UR-control represent a wider spectrum of non-
specifically interacting proteins making sepharose-control a more appropriate control for 
identification of non-specifically interacting proteins.     The detection of a large number of BNLPs in the eluate from rLTBP-2-sepharose 
reflects the previous observations made for eluates from rβig-h3-sepharose, i.e. that the large 
number of proteins isolated from BNLPM by rβig-h3-sepharose and rLTBP-2-sepharose 
could be due to the adhesive property of the BNLPs. Thus, usage of an alternative protein 
mixture may perhaps be more successful for identification of potential binding partners with 
βig-h3-sepharose and LTBP-2-sepharose. 
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Figure 7.9. Identification of matrix proteins potentially interacting with LTBP-2. Matrix 
protein mixtures; A, BNLPM or B, BM-rich matrigel mixture (1mg/ml) were incubated with 
rLTBP-2-sepharose and BSA-sepharose-control. Bound proteins were eluted with 6M urea 
and eluates were analysed by 15% SDS-PAGE and silver staining. Lanes 1, proteins bound 
to rLTBP-2-sepharose (200µl). Lanes 2, bound proteins to BSA-sepharose-control (200µl).  
 
7.7 Isolation of binding partners for rLTBP-2 from a basement membrane-rich mixture  
  Since the distribution of LTBP-2 in all tissues is not yet defined, and LTBP-2 
expression has been reported in BM-rich tissues such as placenta (Moren et al., 1994), there 
is a possibility that LTBP-2 may have some association with BM. Therefore, it was decided 
to search for binding partners for LTBP-2 amongst BM components. If isolation of binding 
ligands for LTBP-2 was successful, searching for βig-h3 binding partners in a BM mixture 
would then be considered, since βig-h3 expression has previously been reported in the BM of 
proximal tubules of kidney (Park, 2004). The commercially available BM preparation, 
matrigel (BD Biosciences, San Jose, CA) was used for the experiments. Matrigel BM mix is 
a solubilised BM preparation extracted from the EHS mouse sarcoma, a tumour rich in these 
components. Its major component is laminin, followed by collagen IV, HSPG and nidogen. It 
also contains TGF-β and other growth factors which occur naturally in the EHS tumours. 
  After the incubation of matrigel at 1mg/ml in TBS with rLTBP-2-sepharose and BSA-
sepharose-control, eluates were analysed by SDS-PAGE and silver staining (section 2.15, 2.6 
and 2.7). Several protein bands appeared to be interacting non-specifically with both rLTBP-
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the results of incubating rLTBP-2-sepharose with matrigel were very similar to that of 
incubating rLTBP-2-sepharose with BNLPM, in that a large number of proteins from both 
mixtures bound non-specifically to rLTBP-2. Therefore, it appeared that, similar to BNLPs, 
the BM proteins contain strong adhesive properties. In addition, it can be concluded from the 
combined results that LTBP-2 also has extensive adhesive properties that contribute to its 
non-specific interaction with BNLPs and proteins found in matrigel. Similar adhesive 
characteristics also appear to exist for βig-h3, although alternative tissue extracts or protein 
mixtures need to be tested to confirm this observation. 
  From the results of the affinity chromatography thus far, it was evident that the 
general adhesive characteristics of matrix proteins including βig-h3 and LTBP-2 were major 
problems for the isolation of binding partners from various extracts at or close to 
physiological conditions. With this in mind, modifications to the affinity chromatography 
system were necessary and hence considered in an attempt to reduce the non-specific protein-
protein interactions of rβig-h3 and rLTBP-2. 
 
7.8 Affinity chromatography improvements for isolation of binding ligands for βig-h3 
and LTBP-2 from BNLPM  
7.8.1 Dilution of BNLPM 
  To reduce non-specific binding, alterations to the affinity chromatography system 
were considered for identifying binding partners for rβig-h3 and rLTBP-2. BNLPM was 
chosen over matrigel since BNLPs interacted non-specifically with sepharose-control and 
BSA-sepharose-control to a lesser extent than the proteins in the matrigel mixture. 
Initially, the concentration of BNLPs incubated with the columns was decreased to 
investigate its effect on the specificity of the interaction with rβig-h3 and rLTBP-2. 
Previously a total of 1mg/ml of solubilised BNLPM in TBS/0.5M NaCl was incubated with 
each column. Since the mixture contains a diverse population of proteins, the concentration 
of the individual proteins will be quite low compared to concentration of the bait protein. 
Thus it was predicted that excess bait protein would be available to interact non-specifically 
at a lower affinity with various proteins instead of specifically with its high affinity binding 
partners. These non-specific binding proteins may also have precipitated on the column 
contributing to the high level of background observed in previous experiments. It was 
considered that dilution of the BNLPM may result in an increased chance of specific protein-
protein interactions occurring during the incubation period. 
A 1/10 dilution of BNLPM (100µg/ml), was incubated with rβig-h3-sepharose, 
rLTBP-2-sepharose and sepharose-control. Silver staining of the eluted proteins from the 
columns indicated that more BNLPs bound to rβig-h3-sepharose (figure 7.10, lane 1) and  
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rLTBP-2-sepharose (figure 7.10, lane 2) compared to the sepharose-control (figure 7.10, 
lane 3). The protein patterns from rβig-h3-sepharose and rLTBP-2-sepharose appeared to be 
similar, though the intensity of the staining of the bands was greater in the eluate from the 
rLTBP-2-sepharose. The reduction in the concentration of the extract did not appear to 
increase the specificity of the interaction between rβig-h3 and rLTBP-2 with the BNLPs. The 
dilution of the BNLPM also appeared to make no significant difference to the pattern of 
bands in the non-specific binding to the sepharose-control column, compared to the undiluted 
extract (figure 7.7, lane 2). However, a general increase in the staining intensity of the 
protein bands was noted, suggesting dilution of the BNLPM actually increased the 
background binding.  
 
7.8.2 Reducing the size of the ‘bait’ protein columns 
The size of the rβig-h3-sepharose, rLTBP-2-sepharose, BSA-sepharose-control and 
sepharose-control columns (40µl) was reduced 5-fold with respect to the amount of BNLPM. 
Silver staining of the eluted proteins from the smaller columns revealed a different pattern of 
bands with a total of only four bands identified in the eluates from all four columns. These 
were rβig-h3-sepharose (figure 7.11, lane 1), rLTBP-2-sepharose (figure 7.11, lane 2) and 
BSA-sepharose-control (figure 7.11, lane 3). No protein bands were detected in the 
sepharose-control (figure 7.11 lane 4). These results showed that decreasing the amount of 
bait protein, by reducing size of the columns, did not increase the interaction with specific 
binding partners in the BNLPM. 
  Despite altering the concentration of the BNLPM, or the size of protein-sepharose 
columns and the use of different protein mixtures (BNLPM, matrigel), a large number of 
proteins in the mixtures continued to bind to both the rβig-h3-sepharose and rLTBP-2-
sepharose. This suggested that most interactions were of a non-specific nature. Due to our 
continuing inability to reduce the non-specific interaction of the proteins in tissue extracts 
with the recombinant proteins, a different approach needed to be considered. Better controls 
were needed for distinguishing the proteins binding specifically to the bait-sepharose 
columns compared with those that bound non-specifically. Hence, the eluates from rβig-h3-
sepharose and rLTBP-2-sepharose were chosen to act as controls for the other since most 
proteins appeared to be non-specifically binding to both rβig-h3 and rLTBP-2. Identification 
of proteins that bind uniquely to only one of the two bait proteins would suggest a specific 
interaction.  
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Figure 7.10. Effect of decreased concentration of BNLPM on isolating binding ligands for 
rβig-h3 and rLTBP-2. BNLPM at 100µg/ml was incubated with rβig-h3-sepharose and 
sepharose-control. Bound proteins were eluted with 6M urea and eluates were analysed by 
15% SDS-PAGE and silver staining. Lane 1, rβig-h3-sepharose (200µl). Lane 2, rLTBP-2-
sepharose (200µl). Lane 3, sepharose-control. The pattern of proteins eluted from rβig-h3 
and sepharose column appeared to be very similar. 
 
Figure 7.11. Effect of reducing the size of the sepharose affinity columns on non-specific 
background binding. The amount of rβig-h3-sepharose and rLTBP-2-sepharose incubated 
with BNLPM was reduced from 200µl to 40µl. Bound proteins were analysed by 15% SDS-
PAGE and silver staining. Lane 1, rβig-h3-sepharose (200µl). Lane 2, rLTBP-2-sepharose 
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7.9 Separation of proteins eluted from rβig-h3- and rLTBP-2-sepharose by 2-D Gel 
Electrophoresis (2-DGE) 
7.9.1 Silver staining detection of proteins separated by 2-DGE  
The large number of proteins that bound to rβig-h3 and rLTBP-2 made it difficult to 
identify specific binding partners, especially when the eluates from both rβig-h3-sepharose 
and rLTBP-2-sepharose gave very similar banding patterns. Considering that the proteins are 
associated with different structures within the tissue it was unlikely that they shared a large 
number of binding partners. Therefore the results thus far indicated that the adhesive natures 
of βig-h3 and LTBP-2 contributed to the similar banding patterns seen when the eluates from 
both columns were separated on a polyacrylamide gel. There were potential differences in the 
proteins that bound to the two sepharose columns; however, they may have been masked by 
insufficient separation of the eluted proteins by SDS-PAGE. It was considered that further 
separation of the proteins might aid in identification of distinct binding partners of rβig-h3 
and/or rLTBP-2. For additional separation, affinity-purified proteins were analysed by 2-
dimensional gel electrophoresis (2-DGE) (section 2.17). Two-DGE is a widely used 
separation technique in which proteins are separated according to isoelectric point by 
isoelectric focusing in the first dimension, and according to molecular weight by SDS-PAGE 
in the second dimension (O'Farrell, 1975). 2-DGE has a high capacity for resolution of 
complex mixtures of protein, permitting visualisation and analysis of hundreds of protein 
spots (Tannu and Hemby, 2006). 
BNLPM was applied to both the rβig-h3-sepharose and rLTBP-2-sepharose and 
bound proteins were eluted and the total protein concentrations were determined using the 
Bradford assay (section 2.15). A sample of the eluate, (5.5µg) was made up in standard 
solubilisation buffer (section 2.17) which was a modification of O’Farrell’s lysis buffer 
(O'Farrell, 1975). These modifications included change of the total urea concentration from 
9.5M urea to 6M, substituting 5% β-mercaptoethanol for 50mM dithiothreitol and 2% (w/v) 
NP-40 for 4% CHAPS (as recommended by Bio-Rad Laboratories, Hercules, CA). This was 
then followed by passive loading of the sample on to the 7cm IPG strip pH 3-10. Proteins 
were separated by isoelectric focusing using a slow ramping preset program (section 2.17). 
After completion of the isoelectric focusing, the IPG strip was then treated sequentially with 
dithiothreitol and iodoacetamide equilibration buffers (appendix B) and electrophoresed on a 
10% polyacrylamide gel (section 2.6). The protein spot patterns of eluates from rβig-h3-
sepharose and rLTBP-2-sepharose, were visualised by silver staining (section 2.7) (figure 
7.12). Compared to the protein spots detected on the gel of the eluate from rβig-h3-sepharose 







                 
 
Figure 7.12. 2-DGE analysis of BNLPs bound to rβig-h3 and rLTBP-2. Eluates from rβig-h3-sepharose and rLTBP-2-sepharose were separated in the first 
dimension by isoelectric focusing on a pH 3-10 IPG strip, followed by 10% SDS-PAGE separation and silver staining. A, Proteins bound to rβig-h3-
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rLTBP-2-sepharose (figure 7.12B). There were a number of spots that seemed specific to the 
individual bait proteins which were marked by arrows in figure 7.12, but it was difficult to 
confirm their candidacy due to inequality of loading between the two gels. The reduced 
amount of protein present on the SDS-PAGE of the sample from the rLTBP-2-sepharose may 
have been caused by insufficient sample entering the IPG strip or by the loss of proteins 
during dialysis prior to application to the strip. In addition to the difference in the amount of 
total protein present on the gels, there were horizontal steaks associated with some protein 
spots which were more apparent in the gel of the sample eluted from the rLTBP-2-sepharose. 
The horizontal streaking associated with protein spots indicated incomplete focusing of the 
protein spots. This might have been caused by samples having incomplete solubilisation prior 
to application or by the presence of ionic impurities in the sample. In contrast to the LTBP-2 
gel, there was a prominent vertical streak observed close to pH 7 in the sample eluted from 
rβig-h3-sepharose. The vertical streak was probably due to high salt in the mixture, perhaps 
due to inefficient removal of salts by dialysis. Furthermore, as described by (Gorg et al., 
1988), vertical streaking is related to the second dimension, and may be caused by 
insufficient equilibration prior to SDS-PAGE (Gorg et al 1988). In summary, an increase in 
solubility of the proteins in the samples was required to improve the entry of the proteins into 
the IPG strip, as well as improving the focusing of the proteins in the strip by altering the 
isoelectric focusing run. These are further discussed section 7.9.2. 
 
7.9.2 Improving the resolution of 2-DGE 
From the evidence in section 7.9.1, the separation of the BNLPs eluting from rβig-h3-
sepharose and rLTBP-2-sepharose needed to be optimised for comparison and identification 
of specific ligands with adequate certainty. Firstly, the total protein concentrations of both 
samples needed to be equal to compare the samples properly. Therefore, extra care was taken 
during preparation of the sample for isoelectric focusing, i.e. during dialysis of the samples 
into 6M urea and during rehydration of the IPG strip, to minimize protein loss. Furthermore, 
to further improve the entry of the proteins into the IPG strip during passive rehydration, and 
to improve their focusing on the strip, the solubility of the eluates could be improved by 
dialysis into enhanced solubilisation solution. This was designed to increase both the uptake 
of the proteins by the strip and the protein resolution by allowing complete dis-aggregation, 
denaturation, and reduction of proteins due to disruption of all protein-protein interactions 
(Herbert, 1999; Rabilloud, 1996). A typical solubilisation solution contains 1) a chaotropic 
agent such as urea and/or thiourea for denaturation of proteins (Galvani et al., 2001; 
Rabilloud et al., 1997), 2) detergents for forming stable solubilised complexes with exposed 
hydrophobic residues during focusing, 3) reducing agents for reduction of disulphide bonds  
  - 119 - 
to ensure complete protein solubilisation, and 4) carrier ampholytes to keep the separated 
proteins in a charged state (Lalwani et al., 2005). Compared to the original solubilising 
solution, the enhanced solubilising solution contains the additional non-detergents 
sulfobetaine 3-10, and the chaotropic agent thiourea and replaces of dithiothreitol with the 
reducing agent tributylphosphine. A urea-thiourea mixture has been reported to improve the 
solubility and resolution of proteins on IPG strip compared with urea alone. Also 
tributylphosphine is known to be a more selective and efficient reducing agent than 
dithiothreitol, as it retains its reducing power at acidic pH 5 and at pH levels above 7.5 
(Herbert et al., 1998). The addition of the zwitterionic surfactant, sulfobetaine 3-10 has been 
reported to improve protein solubility at or near its isoelectric point (Esteve-Romero et al., 
1996).  
Secondly, the isoelectric focusing resolution needed to be improved for differentiation 
of the fainter proteins spots. Therefore, several aspects of the isoelectric focusing were 
altered in an attempt at improving the focusing of the protein mixture. One of the isoelectric 
focusing alterations that were considered was the time of the conditioning step. This step was 
increased from 15 minutes to 3 hours to allow more time for the salts and other contaminants 
to be removed prior to focusing the proteins. Salts increase the ionic strength of the solution 
and thus produce a high current which is not desired when high voltages need to be reached 
during the isoelectric focusing (Vincourt et al., 2006). An additional clean up step to further 
remove salt from the samples was considered, but additional steps needed to be kept to a 
minimum to limit losses of the protein sample. 
To observe whether salts and contaminants were the reason for insufficient focusing 
of the proteins, a sample of eluate from rβig-h3-sepharose (5.5µg) was loaded on to a IPG pH 
3-10 strip through passive rehydration and was isoelectric-focused with a 3 hrs conditioning 
step and several changes of the electrode filter paper electrode strips. Silver staining of the 2-
D pattern, showed reduction in the vertical smearing (figure 7.13A) previously present. 
However, there also appeared to be a marked reduction in the total amount of protein 
resolved on the gel. Thus it was difficult to establish how the prolonged voltage step aided in 
the focusing of the proteins. There did appear to be a slight change in one of the prominent 
spots migrating at 47 kDa. This spot seemed to focus as three spots, instead of one as 
previously, but this result may have been caused by protein carbamylation. Protein 
carbamylation changes a protein’s isoelectric point and is caused by reaction with isocyanate, 
a urea degradation product. However, the proteins migrating at 37 kDa have consistently 
clustered very close together, therefore these protein spots might be normal modifications of 






                 
 
Figure 7.13. The effect of a prolonged conditioning step or different solubilisation solution on isoelectric focusing of proteins. Proteins bound to rβig-h3-
sepharose (5.5µg) were separated by 2-DGE under different conditions and silver stained for analysis. In A, the conditioning step was for 3 hours during 
the isoelectric focusing run, while in B, bound protein was dialysed into multiple surfactant solubilisation solution prior to passive rehydration. Fewer 
proteins were observed on the gels.  
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To investigate whether enhanced solubilisation solution improved the uploading of 
the proteins onto the strip and their focusing, the eluted proteins from rβig-h3-sepharose 
(5.5µg) were dialysed into a multiple surfactant solubilisation solution, loaded passively onto 
the IPG strip and analysed by for 2-DGE. Silver staining of the 2-D gel revealed once again 
reduced amounts of total proteins present on the gel (figure 7.13B), when compared with the 
original conditions used. The protein spots that were detectable on the gel did not appear 
better focused. They looked blurred and had vertical smears still associated with a number of 
the spots. The results therefore indicated that under our standard conditions the use of 
multiple surfactant solubilisation solution did not improve the focusing of the proteins on the 
IPG strip during isoelectric focusing. Similar findings were reported by Lee, (2009) where 
direct correlation between the effects of buffers with changes in protein solubilisation was 
investigated. Lee, (2009) reported that neither the replacement of dithiothreitol with 
tributylphosphine nor the addition of detergent improved the solubility and resolution of the 
protein sample tested. In contrast, solubilisation of proteins with buffer containing 1.5% 
dithiothreitol and 4% CHAPS increased spot numbers, density and resolution (Lee, 2009). 
Therefore it appeared that the original solubilisation solution and the initial focusing program 
were more appropriate for use for isoelectric focusing.  
From the results it was concluded that one of the contributing factors to the lack of 
identification of specific binding ligands for βig-h3 and LTBP-2 was poor reproducibility of 
protein spot patterns. This perhaps was caused by the lack of consistent uptake of the protein 
sample into the IPG strip. Therefore an alternative approach which included cup loading was 
considered to improve sample loading. Cup loading is an alternative approach to passive 
rehydration and it is commonly used to improve resolution when separating basic proteins 
(Görg et al., 2000). For this, samples were actively loaded using a cup onto a pre-hydrated 
IPG strip and separated by 2-DGE (sections 2.17). The resulting spot pattern however, 
showed no improvements in the amount or resolution of proteins entering the gel (data not 
shown). 
Optimal conditions for solubility and resolution of protein samples vary somewhat 
with the type of sample under examination. Thus far, the problems of insufficient sample 
entering the gel and incomplete focusing of spots were unable to be eliminated by various 
modifications of the 2-DGE method. It was considered that, working with such low 
concentrations of protein in association with complicated sample preparation may be 
affecting the total protein that is resolved on the gel. Because of such low amounts of 
proteins being available for analysis, silver staining appeared to be of limited value for 
identifying protein spots from artefacts on the gels. Therefore, increasing the sensitivity of 
the staining would overcome the lack of detection of scarce protein spots and allow for  
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adequate comparison between the eluates from the rβig-h3-sepharose and rLTBP-2-sepharose. 
The detection of minute amounts of proteins may even compensate for the insufficient 
focusing of the proteins on the IPG strip. Another contributing factor to the inability of 
positive identification of unique protein spots was the variability seen within two gels after 2-
DGE, making it difficult to match protein spots in the two gels. The variability associated 
with 2-DGE, including sample preparation and sample separation, was approximately 20-
30% from gel-to-gel. Therefore better methods needed to be considered in order to eliminate 
gel-to-gel variation.  
 
7.9.3 Detection of proteins separated by 2-DGE using 2-D-DIGE technology 
7.9.3.1 Labelling of the proteins with CyDye DIGE Fluor minimal dye 
The silver stained 2-DGE protein spot patterns were difficult to analyse, compare and 
contrast. This was mostly due to inconsistent concentration of sample protein entering the 
IPG strip due to loss of protein during sample preparation. Additionally, there was gel-to-gel 
variation which also contributed to the difficulty in trying to distinguish real differences 
between unique proteins and non-specifically binding proteins that bound to rβig-h3-
sepharose and rLTBP-2-sepharose. Hence 2-D SDS-PAGE using fluorescence 2-D difference 
gel electrophoresis (2-D-DIGE) technology was employed for detection of minute amounts 
of protein being analysed and to improve comparability between eluates from rβig-h3-
sepharose and rLTBP-2-sepharose. The advantage of this technology is that it allows the 
analysis of both samples on the one gel, eliminating gel to gel variation. 
2-D DIGE uses molecular weight- and isoelectric point-matched, spectrally resolvable 
cyanine dyes (Unlu et al., 1997) to label two or three protein samples prior to 2-DGE. It is 
the use of different dyes to separately label BNLPs eluted from rβig-h3-sepharose and 
rLTBP-2-sepharose that allows for co-separation of the samples in a single 2-D 
polyacrylamide gel. Firstly, CyDye DIGE fluor minimal dyes, Cy3 and Cy5 were used for 
labelling of the bound proteins. The sensitivity of CyDye DIGE dyes Cy3 and Cy5 is 0.025ng 
compared with silver staining which has a sensitivity of 1ng (Marouga et al., 2005). The 
labelling reaction was designed to ensure labelling of approximately 1-2% of the lysine 
residues of the protein sample (Marouga et al., 2005; Tannu and Hemby, 2006). Therefore, 
for comparison of protein spot pattern between proteins bound to rβig-h3-sepharose and 
rLTBP-2-sepharose, 5µg of eluates from both sepharose columns were labelled with CyDye 
DIGE fluor minimal dyes Cy3 and Cy5 respectively. 
After the CyDye-labelled proteins had been fractionated by 2-DGE, the gels were 
scanned and analysed by a Typhoon Trio+ variable mode imager (GE Healthcare, Uppsala, 
Sweden). The resulting spot patterns for the eluates from rβig-h3-sepharose (figure 7.14A &  
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C) and rLTBP-2-sepharose (figure 7.14B & C) appeared to be very similar and the 
inconsistency between the concentrations of the two eluates appeared to have been eliminated. 
However, there appeared to be fewer protein spots detected when samples were labelled with 
the CyDye DIGE fluor minimal dyes than when previously stained with silver. This 
suggested that the labelling reaction was not efficient. Furthermore, the labelled proteins 
were not focused sufficiently, as they all appeared to be migrating as a block in the second 
dimension. In addition, instead of protein spots horizontal smears dominated the gel, which 
further suggested that the isoelectric focusing step was not optimised. In spite of these 
problems, the overlay of the two staining patterns revealed several protein spots that appeared 
to be unique to rβig-h3-sepharose or rLTBP-2-sepharose which were marked by arrows in 
figure 7.14C. To confirm the authenticity of the unique spots, the experiment was repeated. 
Figure 7.15 illustrates the spot pattern achieved for each of the fractionated samples. In this 
experiment the labelling reaction appeared to be more successful as there were more total 
protein spots present, most of which appeared to have localised in the centre of the gel close 
to neutral pH (figure 7.15). No obvious unique protein spots were identified by comparing 
the separated BNLPs eluted from the rβig-h3-sepharose (figure 7.15A & C) with rLTBP-2-
sepharose (figure 7.15B & C). However, from the overlay analysis of the spot patterns, 
several protein spots were identified as possible unique binding partners for both rβig-h3 and 
rLTBP-2 (figure 7.15C). The unique protein spots identified previously were no longer 
detectable, perhaps due to better labelling of the proteins in the samples, thus indicating that 
they were not true unique protein spots. However, they were neither sufficiently convincing 
nor abundant to be taken for protein identification. 
From the results of CyDye DIGE fluor minimal dye labelling of the eluates, it 
appeared that there was inconsistency with the labelling of the protein samples under analysis. 
Consistency was necessary for labelling of the protein samples and subsequent binding ligand 
identification. Since each CyDye DIGE fluor minimal dye labels only a small percentage of 
the total protein present in the sample (Marouga et al., 2005), the next approach was to use 
CyDye DIGE fluor saturation dyes for labelling. CyDye DIGE fluor saturation dye labelling, 
labels the majority of the total proteins present in the samples, which improves the sensitivity 








               
 
Figure 7.14. Comparison of the bound proteins to rβig-h3 and rLTBP-2 using 2-D-DIGE technology. CyDye DIGE fluor minimal dye labelling of the 
eluates from A, rβig-h3-sepharose (5µg) and B, rLTBP-2-sepharose (5µg), prior to 2-DGE. A and B are superimposed in C. Arrows indicate the specific 
spots for each protein. Proteins specifically binding to rβig-h3 are visualised as green spots, while red spots are proteins binding specifically to rLTBP-2. 








               
 
 
Figure 7.15. Repeat of CyDye DIGE fluor minimal labelling of bound proteins to rβig-h3 and rLTBP-2. A sample of the eluates from A, rβig-h3-sepharose 
(5µg) and B, rLTBP-2-sepharose (5µg) were labelled with Cy3 and Cy5 respectively, prior to 2-DGE. A and B are superimposed in C. Arrows indicate 
specific spots to each protein. There were more proteins spots present on the gel compared with initial CyDye DIGE fluor minimal labelling of bound 
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7.9.3.2 Labelling of the proteins with CyDye DIGE fluor saturation dyes 
The CyDye DIGE fluor saturation dyes label all reduced cysteine thiols of proteins, 
and are even more sensitive than minimal dyes in detecting amounts as low as 15pg 
(Marouga et al., 2005). It was hoped that this system would increase the number of protein 
spots detected and the intensity of the detected protein spots. In previous experiments, only 
the abundant proteins were detected and these appeared to be present in eluates from both 
rβig-h3-sepharose and rLTBP-2-sepharose. Visualsing the larger spectrum of proteins present 
in the samples would increase the chance of identifying authentic candidate partners. 
Similar to CyDye DIGE fluor minimal dye labelling, 5µg of bound proteins eluted 
from rβig-h3-sepharose and rLTBP-2-sepharose were labelled with Cy3 and Cy5 respectively. 
After labelling of the bound proteins, they were combined and were loaded on the IPG strip 
through passive rehydration (section 2.17). Upon completing the fractionation of the labelled 
proteins by size, the gel was scanned and analysed once again by a Typhoon Trio+ variable 
mode imager (GE Healthcare, Uppsala, Sweden). The resulting image was a black gel with 
no traces of labelled protein spots and a dye front at the bottom of the polyacrylamide gel 
(data not shown). The results indicated that the labelling reaction was unsuccessful, and no 
proteins were labelled despite following the manufacturer’s instructions (see section 2.17). 
The experiment was repeated, this time paying extra attention to the pH of the sample prior to 
commencing labelling, since it is essential for the protein samples to be at pH 8.0 for efficient 
labelling with CyDye DIGE fluor saturation dyes. Analysis of the gel using Typhoon Trio+ 
again revealed no labelled spots, suggesting unsuccessful labelling of the proteins with 
CyDye DIGE fluor saturation dyes. Several possible factors may have contributed to the 
unsuccessful CyDye DIGE fluor saturation dye labelling of the bound proteins, including the 
loss of BNLPs during sample preparation for labelling and fractionation by 2-DGE. 
Furthermore, even though care was taken to ensure an optimised condition for successful 
labelling, the conditions may have still been sub-optimal for labelling, perhaps due to 
contaminants being carried over or perhaps due to over-estimation of the amount of proteins 
in the eluates. 
Identification of the novel binding ligands for βig-h3 and LTBP-2 from protein 
mixtures proved to be difficult using affinity chromatography and proteomics techniques. 
The non-specific interaction of proteins with the affinity columns and low concentration of 
eluates remained major problems despite various modifications. The small quantities of 
purified recombinant proteins available for column preparation were also a limiting factor for 
this project, and preparation of affinity columns with more ‘bait’ proteins should be 
considered for similar experiments in the future. The amount of ‘bait’ protein available was 
one of several limiting factors in the isolation of novel binding partners of rβig-h3 and  
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rLTBP-2 using affinity chromatography. Details of these and possible alternatives for future 
experiments are outlined and discussed in section 8.2.2.   
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CHAPTER 8 
DISCUSSION AND FUTURE DIRECTIONS 
 
8.1 Discussion 
LTBP-2 belongs to the fibrillin/LTBPs superfamily of ECM proteins. The members 
of this superfamily share similar protein composition and structure. The full extent of LTBP-
2 functions within the ECM is still unclear. The involvement of LTBP-2 in elastic fibre 
assembly has been suggested following tissue extraction and immunohistochemical analysis 
of bovine nuchal ligament, where LTBP-2 was identified as an associated component of 
fibrillin-microfibrils (Gibson et al., 1995). In Dr. Gibson’s laboratory, to further characterise 
the function of LTBP-2 in the structure and assembly of elastic fibres, the identification of 
LTBP-2 interactions with associated components of fibrillin-microfibrils has been ongoing. 
Binding and immunohistochemical studies have been used previously to demonstrate the 
interaction between LTBP-2 and fibrillin-1 (Hirani et al., 2007). No direct interaction with 
other elastic fibre-associated proteins, namely fibrillin-2, tropoelastin, MAGP-1, -2, dermatan 
sulphate-PGs, decorin and biglycan, was identified (Hirani et al., 2007). 
In recent years the interaction of fibrillin-1 with unidentified HSPGs has been 
reported to have an essential influence on the assembly of microfibrils and elastic fibres 
(Cain et al., 2005; Cain et al., 2008; Ritty et al., 2003a; Tiedemann et al., 2001). In elastic 
tissues HSPGs are found mainly on cell surfaces for example, syndecans and glypican or in 
BM for example, perlecan. This suggested the importance of HSPG and instigated the 
investigation of possible HSPG interactions with LTBP-2.  
To commence with, conjugated heparin was used to represent HSPG in the solid 
phase binding studies with LTBP-2. One of the reasons for this use was the limited 
availability of rHSPG. Recombinant HSPG of interest were either not available (perlecan) or 
were very expensive in small quantities (syndecans). Tissue extraction of HSPGs is possible, 
but it is difficult and it usually results in low yields of impure product. On the other hand, 
heparin was readily available commercially in large quantities. The most important factor 
however, is the structural similarity that is shared between heparin and HS which allowed 
heparin to be suitable for the binding studies (table 1.1). Solid phase binding assay was the 
method of choice for determining direct interactions between LTBP-2 and heparin. Other 
methods such as co-culture systems in conjunction with immunofluorescence staining can be 
used to identify interactions between two matrix proteins. However, colocalisation does not  
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necessarily indicate that there is a direct interaction between the proteins, as was found for 
fibronectin and LTBP-1 (Chen et al., 2007).  
Solid phase binding studies revealed that full length rLTBP-2 contains a moderately 
strong binding affinity for heparin (section 3.3.5). To ensure the interaction was not merely 
charge-related, it was important to test the interaction of LTBP-2 with C-6-S, another highly 
sulphated GAG, which is found in the matrix attached to other PG. Sulphate groups are 
attached to a number of hydroxyl or amino groups on GAG and they contribute considerably 
to the GAG polyanionic properties (Zhang et al., 2005). The inability of C-6-S to block the 
interaction between LTBP-2 and heparin suggests that the heparin-binding region(s) in 
LTBP-2 are specific for heparan sulphate (section 3.3.3). Similar results were found by 
Tiedemann  et al., (2001), where inhibition assays were used to demonstrate the lack of 
binding inhibition between heparin and fibrillin-1 with chondroitin -4-sulphate, C-6-S or 
dermatan sulphate, thus confirming the specificity of heparin binding to fibrillin-1. 
Furthermore, (Kozel et al., 2004) demonstrated that HS, but not chondroitin sulphate was 
able to decrease the deposition of tropoelastin into fibres in an in vitro model. 
The interaction of LTBP-2 with heparin was found to be largely cation (calcium) 
dependent, similar to the interaction of heparin with other relevant ECM proteins, for 
example, fibrillins (Jensen et al., 2001; Kielty and Shuttleworth, 1993; Reinhardt et al., 
1997a; Reinhardt et al., 1997b) and fibulins (Yanagisawa et al., 2002). Depletion of calcium 
ions prevented the binding of LTBP-2 to heparin (section 3.3.4), although the mechanism by 
which the binding was affected is not clear. Two possible ways in which the binding of 
LTBP-2 to heparin may have been affected are (a) directly, if one of the many cbEGF-like 
domains present in LTBP-2 calcium was involved in the binding site itself perhaps on or (b) 
indirectly, where removal of calcium ions may alter the structural conformation of the 
cbEGF-like domains on LTBP-2, consequently disrupting the heparin binding site. Similar 
enhancement of binding to heparin in the presence of calcium ions has been previously 
demonstrated for other relevant molecules, for example MAGP-1 to fibrillin-1 (Jensen et al., 
2001). Furthermore, (Yanagisawa et al., 2002) demonstrated that the binding of fibulin-5 to 
tropoelastin is inhibited in the presence of 10mM EDTA. In general, it appears that calcium 
chelation with 5mM EDTA or 5mM EGTA does not permanently affect the integrity or the 
function of proteins. Indeed, Kielty and Shuttleworth (1993), demonstrated that the effects of 
calcium chelation can be rapidly reversed when isolated fibrillin-microfibrils were incubated 
with 5mM EDTA or 5mM EGTA prior to incubation with calcium (5mM CaCl2). However, 
the effects of 25mM EDTA or 25mM EGTA were not completely reversed by subsequent 
incubation with calcium (25mM CaCl2). Disrupted regions within individual microfibrils 
were still observed in these treated microfibrils (Kielty and Shuttleworth 1993).  
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To aid further functional analysis of LTBP-2, it was planned to identify the location 
of the heparin binding sites on LTBP-2. Recombinant central and carboxy-terminal fragments 
of LTBP-2 were tested for heparin binding. The C-terminal fragment of LTBP-2 lacked 
heparin binding. Since LTBP-2 interacts with fibrillin-1 through its carboxyl region (Hirani 
et al., 2007), the absence of a binding site for heparin in this region implies that LTBP-2 
interaction with heparin/HSPGs is unlikely to directly interfere with LTBP-2 binding to 
fibrillin-1-microfibrils. A relatively low-affinity binding site was identified in the central 
region of LTBP-2. The difference in the strength of heparin binding to the full length LTBP-2, 
compared with the central region of this molecule, suggested additional heparin binding site(s) 
may be present in the amino-terminal region of LTBP-2. Subsequent binding studies from 
our laboratory have revealed three heparin binding-sites in the N-terminal region of LTBP-2 
(J Adams and M Gibson). 
Thus far five heparin binding sites have been identified on fibrillin-1 (Cain et al., 
2005; Cain et al., 2008; Tiedemann et al., 2001).There are two in the N-terminal region and 
one in the C-terminal region, which are considered to regulate linear assembly of microfibrils, 
perhaps by acting as a template for the newly-secreted fibrillin-1 or for alignment and 
concentration of fibrillins-1 (Cain et al., 2008). Earlier cell culture experiments had shown 
that exogenous heparin disrupts microfibril deposition, but has no effect on the secretion of 
these macromolecules (Tiedemann et al., 2001). Interestingly, heparin was found to inhibit 
the binding of MAGP-1 to the N-terminal region of fibrillin-1, but was found not to affect the 
head to tail binding of fibrillin-1 (Ritty et al., 2003a). Thus N-terminal HS binding is likely to 
be a critical determinant of fibrillin-1 polymerisation during microfibril assembly and of 
MAGP-1 binding during elastic fibre assembly (Cain et al., 2005). The heparin binding site 
at the C-terminal region of fibrillin-1 overlaps with the tropoelastin binding site on fibrillin-1, 
and binding assays have been used to demonstrate that heparin inhibits the interaction of 
tropoelastin with fibrillin-1 C-terminal regions (Cain et al., 2008). Tropoelastin has another 
binding site in the central region of fibrillin-1 (Rock et al., 2004). Competitive binding 
between heparin and tropoelastin for the fibrillin-1 central region has also been demonstrated. 
Therefore, HS attachment to fibrillin-1 at sites overlapping with tropoelastin has been 
suggested to regulate the deposition of elastin onto the microfibrils (Cain et al., 2005; Cain et 
al., 2008). A heparin binding site in central region of fibrillin-1 has also been shown to bind 
perlecan (Tiedemann et al., 2005). This interaction is proposed to be involved in anchorage 
of microfibrils to BM (Tiedemann et al., 2005). With the identification of multiple heparin 
binding sites on fibrillin-1, it can be speculated that heparin/HS binding ability of LTBP-2 
may modulate the binding of HSPGs with various sites on fibrillin-1 (see below).   
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To investigate the implications of LTBP-2 interaction with heparin for microfibril and 
elastic fibre assembly, the immunolocalisation of LTBP-2 in elastic tissues was examined 
(Chapter 6). In the human foetal aorta, the majority of LTBP-2 was revealed to be associated 
with elastic fibres in the medial layer and not with elastin-free microfibrils in the adventitia. 
These findings suggest that LTBP-2 interaction with fibrillin-1 is not essential for the 
assembly of microfibrils. Therefore, it appears that LTBP-2 is more important for elastic 
fibrillogenesis, rather than microfibrillogenesis, and the interaction of LTBP-2 with HSPG is 
more likely to involved in this process.  
It can be speculated that the interaction between LTBP-2 and heparin may be 
involved in the deposition of elastin on fibrillin-1 microfibrils. A recent study has implicated 
LTBP-2 in promoting elastin deposition on fibrillin-1-containing microfibrils during elastic 
fibre assembly (Hirai et al., 2007). Hirai et al., (2007) demonstrated that the fibulin-5-
targeting role of the LTBP-2 is mediated by the interaction of N-terminal region of LTBP-2 
with fibulin-5, a protein well documented for its involvement with deposition of elastin on 
microfibrils during elastic fibre assembly (Freeman et al., 2005). It is possible that, during 
targeting of the fibulin-5/elastin complex to fibrillin-1 microfibrils, LTBP-2 binding to HS-
side chains of HSPG displaces it from fibrillin-1-microfibrils allowing deposition of the 
elastin. This speculation is supported by the inhibition studies showing that heparin binding 
to fibrillin-1 prevents tropoelastin from binding to fibrillin-1 (Cain et al., 2008). Therefore, 
LTBP-2 binding HSPGs may regulate elastic deposition on microfibrils during elastic fibre 
assembly.  
An alternative way that the HSPGs binding to LTBP-2 may play a role in elastic fibre 
assembly is through regulating the interaction of LTBP-2 with fibulin-5. HS-chains of 
HSPGs binding to LTBP-2 may instigate conformational changes to the LTBP-2 protein 
structure. This may in turn have either a positive or a negative influence on LTBP-2 binding 
with fibulin-5, depending on whether it enhances or inhibits the interaction.  
There is strong evidence that fibrillin-microfibrils intersect with BM in various tissues 
(Sakai  et al., 1986; Tiedemann et al., 2005). In human tissues, studies have shown the 
colocalisation of perlecan with fibrillin-1-microfibrils (Tiedemann et al., 2005). In addition, 
in vitro binding studies have shown that fibrillin-1 interacts with high affinity to domain V of 
perlecan core protein and with relatively low affinity with the HS-chains attached to domain I 
of the protein core (Tiedemann et al., 2005). This raises the question whether there are other 
associated components of fibrillin-microfibrils, which have the potential to serve as “linker” 
molecules, between microfibrils and BM. One such molecule could be LTBP-2. 
On the molecular level we have shown that LTBP-2 interacts with the HS-side chains 
of perlecan (section 5.1). The presence of exogenous heparin was found to greatly inhibit the  
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interaction between LTBP-2 and perlecan, indicating the prominent binding was to the HS-
chains. However, protein-protein interaction between LTBP-2 and the protein core 
component of perlecan cannot be completely ruled out, and further experiments investigating 
the binding interaction with the perlecan protein core are needed. At the tissue level, LTBP-2 
and perlecan have been found to partially colocalise in the medial layer of the foetal aorta 
(section 6.1.4). The identified interaction between LTBP-2 and perlecan suggests a potential 
role of LTBP-2 in connecting microfibrils to BMs. Previously, (Tiedemann et al., 2001) 
demonstrated by double immunofluorescence and immunogold labelling that fibrillin-1 and 
perlecan were colocalised in close vicinity with various dermal and ocular BM. In the present 
study it is of interest that perlecan was found to colocalise with fibrillin-1 in the medial layer 
of the developing foetal aorta, in areas where microfibrils and BM are in close contact. The 
distribution patterns of fibrillin-1 and perlecan in the foetal aorta were found to be similar to 
that of LTBP-2 and perlecan. This similar pattern of overlap suggests that LTBP-2 may play 
a part in the interaction of fibrillin-1-microfibrils and perlecan in the aorta. The role of 
LTBP-2 could be to stabilise the interaction between fibrillin-1 and the core protein of 
perlecan by interacting with the HS-chains of perlecan. The interaction of fibrillin-1 with 
perlecan in the foetal aorta still remains to be confirmed as does the interaction of LTBP-2 
with perlecan in this tissue. In order to confirm these interactions in vivo, electron 
microscopy analysis of these regions is required. Post-embedded electron microscopy 
staining of tissue samples was attempted to identify the structures associated with LTBP-2, 
fibrillin-1 and perlecan in the developing aorta. However, analysis of the sections was 
uninformative due to lack of staining. This may be due to the large size of the gold particles 
not being able to penetrate the tissue after embedding. To overcome this problem, pre-
imbedding staining of fresh samples needs to be considered. Further studies on the role of 
LTBP-2 in microfibril-BM interactions are suggested in section 8.2.1. 
It has been reported that knockout of mouse ltbp-2 results in embryonic lethality 
between E-3.5 and E-6.5 (Shipley et al., 2000). In the study it was reported that the 
expression of ltbp-2 mRNA is detected at E-3.5, is switched off by E-6.5 and reinitiates again 
at E-13.5. The absence of elastic fibres or fibrillin microfibrils in a developing embryo at E-
3.5 indicates any role of LTBP-2 in early mouse development must be independent of these 
structures. Such novel functions of LTBP-2 have yet to be investigated. 
During early embryogenesis, the only ECM structure to exist is BM surrounding the 
developing blastocoelic cavity, and perlecan is present within this structure (Arikawa-
Hirasawa et al., 1999; Costell et al., 1999). The BM plays a critical role during early stages 
of the developing embryo (Miner and Yurchenco, 2004). Disruption in initial stages of BM 
development can have severe consequences for the state of the embryo, usually causing  
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embryonic lethality (Miner and Yurchenco, 2004). For instance, knockout of the laminin γ1 
subunit, the most expressed laminin subunit of the first BM in the embryo, causes lethality 
during the same period reported for LTBP-2 null lethality (E-5) (Miner et al., 2004; Smyth et 
al., 1999). The death of the embryo is due to the absence of BM (Smyth et al., 1999). We can 
speculate that LTBP-2 associates with the BM by interacting with perlecan, and thus it plays 
a role in early embryo development which is independent from elastic fibres. The possibility 
that the interaction of LTBP-2 with perlecan is necessary for proper development of the 
embryo deserves further investigation.  
In addition to the interaction with perlecan, we have established that LTBP-2 interacts 
with the cell surface HSPG syndecan-4 but not with another member of the syndecan family, 
syndecan-2, hence suggesting LTBP-2 may possess novel cell interaction. A previous study 
has demonstrated that LTBP-2 supports melanoma cell adhesion and migration (Vehvilainen 
et al., 2003), which appears to be dependent on α3β1 and α6β1 integrins, and that soluble 
heparin was able to inhibit this adhesion to LTBP-2. Syndecan-4 could therefore be a natural 
modulator of LTBP-2 interactions.  
Cell adhesion is a central, regulated cascade of events during development (Gumbiner, 
1996). The interaction of cells with the ECM contributes to modifications in cell proliferation, 
morphogenesis and survival and HSPGs allow this interaction to occur (Wilcox-Adelman et 
al., 2002). During embryo development syndecan-4 is mainly expressed in the embryonic 
ectoderm of the post-implantation embryo (Sutherland et al. 1991). It is possible that LTBP-2 
interacting with syndecans-4-expressing cells may be involved in some of these cell 
processes during development, after implantation of the embryo. Further analysis of the 
interaction of LTBP-2 with syndecan-4, identifying syndecan-expressing cells and 
establishing the distribution patterns in developing embryos may produce rewarding data. 
In addition to the solid phase binding studies we were interested in employing an 
alternative approach for isolating binding partners for LTBP-2 and also matrix protein βig-h3 
from tissue extracts or other protein mixtures using affinity chromatography. The advantage 
of this method was that it was not limited to the availability of purified candidate proteins. In 
addition to the LTBP-2 work, identifying βig-h3 interaction with associated components of 
collagen type-VI microfibrils has been ongoing in Dr. Gibson’s laboratory. Furthermore, 
isolating binding ligands of βig-h3 independent of collagen-VI microfibrils will provide 
insight into the possible novel function of this molecule in the matrix. During attempts to 
identify binding ligands for LTBP-2 and βig-h3, it was found that the highly adhesive nature 
of the two proteins contributed to non-specific interactions with the BNLPs, making it 
difficult to identify specific partners for these proteins by SDS-PAGE. Modifications to the  
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affinity chromatography system were carried out to improve detectability of specific 
interactions of proteins with the rβig-h3- and rLTBP-2 attached to sepharose columns.  
The presence of large numbers of proteins present in the eluted fractions from the 
columns made separation by SDS-PAGE alone an inadequate method. Thus 2-DGE was 
necessary for sufficient separation of the proteins. Two-Dimensional Gel Electrophoresis is a 
powerful technology for the study of a highly diverse protein sample. In general, 2,000 
protein spots can be visualised on a gel depending on the staining technique, the pI range of 
the first dimension and the size of the 2-DGE (Tannu and Hemby, 2006).  
The separation of the bait-column eluates by 2-DGE and subsequent silver staining 
did little to help identify candidate binding partners of rβig-h3 and rLTBP-2. This was due to 
several contributing factors, including the inconsistency of the amount of proteins entering 
the gels, most likely due to loss of proteins during sample preparation, and the use of small 
amounts of material. Some loss of protein during sample preparation is inevitable, but 
commencing with amounts as low as 5µg makes any loss significant. It should be noted that 
there are specific limitations to 2-DGE which depend on the characteristics of the proteins to 
be visualised. For instance, many hydrophobic proteins or extreme acidic or basic proteins 
are not able to enter the IPG strip used for first dimensional separation (Van den Bergh et al., 
2003). The detection of low numbers of protein spots on a gel made confirming possible 
candidate binding partners difficult. Even though silver staining is a highly sensitive method 
for protein staining (Steinberg et al., 2000), it can easily over-develop and speckled 
background staining also occurs (unpublished observation). In order to visualise less 
abundant proteins without compromising visualisation of more abundant proteins, 2-DGE in 
conjunction with CyDye DIGE fluor minimal and saturation dyes was considered. CyDye 
DIGE fluor minimal and saturation dyes and 2-DGE are proven tools for identification of 
ligands since in combination they provide sensitivity and allow analysis of multiple samples 
on one polyacrylamide gel. 
  CyDye DIGE fluor minimal and saturation dyes are much more sensitive than 
Coomassie Blue staining and are quantitative, unlike silver staining. However, there was a 
lack of reproducibility in the labelling of the proteins with the CyDye DIGE fluor minimal 
dyes, even though labelling of the proteins was achieved. To overcome this difficulty, CyDye 
DIGE fluor saturation dyes were used to label up to 5µg of total protein and generate 2-D 
images with 1,500 protein spots (Kondo et al., 2003). However, we were again unable to 
optimise the conditions for the labelling of proteins with CyDye DIGE fluor saturation dyes, 
and this was the main factor in the lack of adequate protein labelling which contributed to 
low numbers of proteins detectable on the gels.  
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Even though a suitable separating method and sensitive detection techniques were 
developed, higher initial concentrations of protein samples appeared to be the key to 
overcoming the above problem. The rationale for this is a) less manipulation is needed for 
sample preparation, for example various sample concentration steps will be eliminated, and b) 
several experiments can be carried out from the same column eluates and thus reproducibility 
will be improved. The higher concentrations will thus improve detection of possible 
candidate binding partners for rβig-h3 and rLTBP-2. 
 
8.2 Future Directions 
8.2.1 Experiments for the comprehensive understanding of LTBP-2 interactions with HSPG 
The recognition of heparin binding sites on fibrillin-1 has shed new light on its 
interaction with other ECM structures and the complexity of microfibril assembly (Cain et al., 
2005; Tiedemann et al., 2001; Tiedemann et al., 2005). More recently, LTBP-4 interaction 
with heparan sulphate has been shown to play a role in TGF-β storage and cell adhesion 
(Kantola et al., 2008). In this thesis, the interaction of LTBP-2 with heparin/HSPGs including 
perlecan and syndecan-4 has been demonstrated. However, more studies are needed for 
confirmation of the functional role of these binding interactions with LTBP-2. Defining the 
affinities of the LTBP-2 interactions with perlecan and syndecan-4 in vitro will indicate the 
strength of the interaction, and whether it is likely to be transient or more permanent. Results 
obtained in section 5.2 indicated the interaction between LTBP-2 and perlecan is through its 
HS-side chains. To determine if perlecan interacts only via its GAG-side chains, solid phase 
binding assay using perlecan core protein will determine if there are additional LTBP-2 
binding sites on perlecan.  
To understand the physiological significance of the identified interactions, 
determination of the range of tissues where LTBP-2 colocalises with perlecan or syndecan-4 
is required using immunohistochemisty. The use of this technique may also confirm any 
identified  in vitro interaction to be biologically relevant. Both LTBP-2 and perlecan are 
expressed in tissues such as the aorta, lung, and kidney and these are possible tissues for 
further investigation. Colocalisation of LTBP-2 with HSPGs perlecan and/or syndecan-4 
during different stages of normal mouse embryonic development is another area of interest 
for understanding the possible functions of LTBP-2 in embryo development. Perlecan plays a 
role in the adaptive modification of the uterine micro-environment to receive and implant the 
embryo (San Martin et al., 2004). The role of LTBP-2 in this process needs further 
characterisation using immunohistochemistry techniques to look at the distribution patterns 
of the pre-implanted embryo and the uterine tissue. Furthermore, since syndecan-4 is mainly 
expressed in both the embryo and the uterine tissue after the embryo is implanted (San  
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Martin et al., 2004), distribution patterns of LTBP-2 and syndecan-4 in embryos and uterine 
tissues after implantation are worthy of investigation. 
 
8.2.2 Possible alternatives for the identification of binding partners for βig-h3 and LTBP-2 
  Determining protein-protein interaction is an important component in assigning 
function and understanding the biological relevance of βig-h3 and LTBP-2 within a 
physiological context. The actual detection of protein interaction is complicated by the fact 
that proteins themselves are chemically distinct entities with differing charges, numerous 
secondary and tertiary structural folds, and may include a wide variety of parameters, for 
instance concentration of protein, ionic strength, and dissociation constants, all of which can 
influence molecular interactions (Howell et al., 2006; Kantola et al., 2008). Hence, selection 
of the most appropriate experimental techniques is important to ensure that the interaction is 
detected.   
  Several methods can be used to study protein-protein interactions. Affinity 
chromatography was the first method of choice for detection of specific protein interaction 
with rβig-h3 and rLTBP-2 which were coupled to sepharose. The method was chosen 
because affinity chromatography has been used very successfully to identify specifically 
interacting proteins (Howell et al., 2006). Many efforts were made to identify specific 
partners from BNLPMs for rβig-h3 and rLTBP-2 attached to sepharose. The high background 
binding made the direct identification of potential interactions difficult using this method. 
Further alterations (to the method) may be made to improve the identification of specific 
binding partners for rβig-h3 and rLTBP-2 using this method. One of the alterations may be 
performing binding studies between rβig-h3-sepharose or rLTBP-2-sepharose in the presence 
of a mild detergent such as Nonidet P-40, Lubrol PX, octylglucoside, CHAPS, tween-20 or 
triton X-100, to aid in minimizing non-specific interactions of hydrophobic domains of 
proteins with βig-h3 and LTBP-2 coupled to sepharose. Alternatively, testing alternative 
eluting buffers for the elution of bound proteins may improve the isolation of candidate 
binding partners of βig-h3 and LTBP-2. Rather than using a strong denaturant (6M urea) for 
elution of all of the bound proteins, a gradient of denaturants can be used for the gradual 
elution of proteins interacting with different affinities from the columns. Alternatively, 
fractionation of the BNLPM using gel filtration chromatography prior to incubation with 
rβig-h3-sepharose and rLTBP-2-separose would be another appropriate approach for 
reducing the background binding problem.  
  In addition to alterations of binding conditions, increasing the size of the coupled 
columns used in affinity chromatography, by coupling more rβig-h3 and rLTBP-2 to CNBr- 
activated sepharose, may have improved the analysis of the proteins binding to rβig-h3- 
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sepharose and rLTBP-2-sepharose. An increase in the size of the affinity columns should 
correlate with an increase in the amount of proteins eluted from the columns. Thus analysis 
of the bound proteins using Coomassie Blue staining would have been possible with minimal 
handling of the samples. However, an increase in the size of the columns also risks an 
increase in the amount of non-specific interaction with the columns. In 2-DGE, starting with 
a higher concentration of protein sample would mean that there would be a greater chance of 
retaining rarer proteins during sample preparation and thus more of these proteins would be 
visibly represented on the gel.  
  Another procedure similar in principle to the affinity columns used for interaction 
studies is affinity blotting. With affinity blotting, BNLPs eluted from rβig-h3 sepharose and 
rLTBP-2 sepharose can be fractionated by either SDS-PAGE or 2-DGE and transferred to 
nitrocellulose membrane. Specific interactors can then be identified by their ability to bind 
the probe (rβig-h3 or rLTBP-2). The appropriate probes can subsequently be detected either 
with antibodies specific to each protein or by anti-(tetra-his) antibody specific for the his6-tag 
of the recombinant proteins. Affinity blotting was used previously to identify the specific 
interaction of MAGP-1 with the α3 (VI) chain of pepsin type VI collagen (Finnis and Gibson, 
1997). Considerations in affinity blotting include the recovery of the biological activity of the 
proteins after separation under denaturing conditions and the activity of the probes added to 
the membrane. 
  Other methods such as co-immunoprecipitation (CoIP) can be used for detection of 
potential ligands of βig-h3 and LTBP-2. CoIP uses bait-specific antibody to co-precipitate the 
bait protein along with any target protein for identification of specific interactors, for 
example of βig-h3 and LTBP-2. The CoIP method has the advantage of identifying less 
tightly bound targets due to the specificity of the antibody for antigen. This allows interaction 
experiments to be carried out under less stringent conditions, more closely mimicking in vivo 
conditions. For example, successful identification of LTBP-2 interaction with fibulin-5 from 
cultured media of bovine aortic smooth muscle cells using CoIP has been recently reported 
Hirai et al., (2006). A disadvantage of this method is that it is not suitable for low abundance 
proteins (Howell et al., 2006). 
  The most common biochemical technique used to identify protein-protein interactions 
include affinity purification procedures. Either using antibodies to endogenous proteins or 
using exogenous expression of tagged recombinant protein baits. Mass spectrometry has 
become established as method of choice for identifying purified proteins because of its high 
sensitivity. However, the majority of these proteins usually represent contaminants, including 
proteins that bind non-specifically to the affinity matrix (Boulon et al., 2010). Thus, despite 
many technical improvements made in recent years, the unambiguous discrimination between  
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genuine protein interaction partners, either stable or transient and co-purifying contaminants 
remains one of the major challenges in the field. Most researchers have sought to identify 
specific protein interactors by reducing or eliminating the background of non-specific 
proteins through either biochemical or data analysis strategies (Boulon et al., 2010). In this 
project eliminating non-specific interactors was attempted at the biochemical level however, 
our groups have eliminated background binding through data analysis strategies. 
  Recently, affinity capture liquid chromatography tandem mass spectrometry has been 
used by others successfully to identify ECM molecular interactions (Cain et al., 2009). A 
range of purified recombinant human elastic fibre molecules containing four his6-tags were 
incubated with cells in culture or with the solubilised matrix. This was followed by 
purification of protein complexes formed with the recombinant proteins using a HisTrap FF 
column. Mass spectrometry analysis of the eluates from the affinity column revealed that 
abundant proteins were purified though this protocol. Amongst the proteins binding 
specifically to the bait proteins, keratin contaminants were also present and were estimated to 
have a protein-protein association probability of greater than 40% (Cain et al., 2009). These 
proteins were therefore removed from further analysis. It appears that the presence of non-
specific contaminants is inevitable. An alternate to the attempts of eliminating non-specific 
binding of proteins to the affinity columns, is discarding them from future analysis similar to 
the works of Cain et al., (2009). 
  In addition, the combination of quantitative mass spectrometry and differential 
labelling of proteins with heavy isotopes, especially with stable isotope labelling with amino 
acids in cell culture (SILAC) (Ong et al., 2002; Ong and Mann, 2006) can also help to 
distinguish between specific and non-specific binding proteins in an affinity experiment. 
Differentiation between specific and non-specific binding of proteins is achieved through the 
inclusion of an integral negative control. The presence of a negative control allows for direct 
comparison between the relative levels of each protein present in the control and 
experimental samples. SILAC thus objectively identifies proteins that can bind non-
specifically to the affinity matrix or the fusion tag protein and highhights by comparison 
proteins that bind specifically to the bait protein (Vermeulen et al., 2008). For instance, HeLa 
cells expressing a tagged protein were metabolically labelled by culturing in heavy media 
containing 13C-isotopes of arginine and lysine, while the parental HeLa cells were grown in 
light media containing the 12C-isotopes of arginine and lysine. Whole cell extracts were then 
prepared and pre-cleared on sepharose beads. The pre-cleared extracts were mixed in equal 
amounts prior to affinity purification of the tagged protein. This was followed by elution of 
the protein from the beads and size fractionation by SDS-PAGE for digestion and liquid 
chromatography tandem mass spectrometric analysis. The advantage of SILAC is that it  
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identifies components of protein complexes purified under lower stringency conditions, 
which preserves more specific interactions (Trinkle-Mulcahy et al., 2008).  
  Overall, we have characterised LTBP-2 as a heparin/HSPG binding molecule. In vitro 
binding assays demonstrated LTBP-2 binds basement membrane HSPG perlecan and 
transmembrane cell-signalling HSPG syndecan-4. These findings suggest LTBP-2 has a more 
complex function in elastic fibre assembly, than previously anticipated. As described in 
section 1.1.2 tropoelastin aggregates on cell surfaces and it remains attached to cell surface 
heparan sulphate, prior to its release onto preformed microfibrils. Since unknown HSPGs 
play a critical role in elastic fibre assembly, it may be that LTBP-2 binding to heparan 
sulphate enhances displacement of the fibulin-5/elastin complex from the cell surface HSPGs. 
In addition, the binding of LTBP-2 to GAG-side chains of HSPGs may be involved in the 
detachment of elastin from fibulin-5 during its deposition on fibrillin-microfibril scaffold. 
Syndecan-4 is a strong candidate for a HSPG involved in the above mechanisms. The 
interaction of LTBP-2 with syndecan-4 may also be important for other processes. Generally, 
LTBP-2 is known as an antiadhesive molecule with poor interaction with integrin receptors. 
However, the findings presented within this thesis suggest that syndecan-4 may be a novel 
mediator of LTBP-2-cell signalling. In addition, it would be interesting to investigate whether 
LTBP-2 binding to syndecan-4 influences heparin sulphate-dependent growth factor 
signalling e.g, fibroblast growth factor-2, which requires the formation of a ternary complex 
with its high affinity receptors (FGFR1-FGFR4) and HSPGs to initiate its signalling cascade 
(Eswarakumar et al., 2005; Jaye et al., 1992). Identification of novel binding partners for 
LTBP-2 has helped in understanding the function of this intriguing matrix molecule. Further 
studies into revealing the full spectrum of LTBP-2-binding proteins is an exciting area of 
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APPENDIX A 
 
Primer sequences used for cloning of recombinant LTBP-2NT(H) and LTBP-2C(H). Prime 
sequences are written 5’-3’. Primer sequences are based upon Genbank
TM published 
sequences, accession numbers and base numbers where the primers bind are included. 
 




HindIII +LTBP-2 NT 
Forward  
CAC CAA GCT TCC AAA GGG ACC CCG T
  
492-506 NM_000428 
LTBP-2 NT Reverse+ 
HindIII 
GGC CAA GCT TAG AGT  CAC CCT TGT C  2749-2763  NM_000428 
LTBP-2 Central Forward 
 
CTG AAA GCT TGG ACT CTC AGG CTG 
GCC AGG 
2758-2776 NM_000428 






GTTTTCCCAGTCACGAC    
M13R 
 
CAGGAAACAGCTATGAC    
HLTBPF3 
 
CAG CCC CCT GGG TGA CTC CT 
 
2141-2148 NM_000428 
LTBP-R2  TCA CAG AGC GCG GCC CCA CAT AC 
 
4450-4472 NM_000428 
    





10×PCR reaction buffer (Stratagene, La Jolla, 
CA) 




1% Triton X-100 
1mg/ml nuclease-free BSA 
 
6× load buffer for DNA gels 
5mL Glycerol 
2mL 50× TAE buffer (see below) 
2mL Bromophenol Blue (saturated) (see below) 
Adjust volume to 10mL using ddH2O, aliquot and 
store at -20˚C 
 
50× TAE 
2M Tris-HCl  
57.1mL Glacial acetic acid 
0.1M Na2EDTA.2H2O 




0.5g bacto yeast extract 
10mM NaCl 
2.5mM KCl 
Dissolve in 100mL ddH2O, autoclave and cool to 
room temperature. Add 20mM Mg
2+ (1mL of 2M 
Mg
2+ stock containing 1M MgCl2 and 1M MgSO4) 
and 20mM glucose. Filter through 0.2µm filter to 




10g Bacto-tryptone (BD Biosciences, Sparks, MD) 
5g Bacto-yeast extract (BD Biosciences, Sparks, 
MD) 
86mM NaCl 
Dissolve in 1L ddH2O, adjust pH to 7.5 with 
NaOH and autoclave to sterilize. For LB plates, 
include 15g bacto-agar (BD, Sparks, MD) prior to 
autoclaving. 
Allow solutions to cool to 55˚C prior to adding 
amplicillin. 
 
Dulbecco’s Modification of Eagles Medium 
(DMEM) 
13.05g/1L Powdered DMEM 
3.7g/1L NaHCO3 
pH 7.2 





















Filter through 0.45µm filter 
 
0.1M NiSO4 (nickel sulphate) 
0.1M NiSO4.6H2O 
Dissolve in ddH2O and filter through a 0.2µm filter. 
 
10mM Imidazole Buffer 




500mM Imidazole Buffer 
1×Phosphate buffer 
500mM Imidazole 
pH 7.4-7.6  
 




Add ddH2O to 100mls, filter through 0.2µm filter 
 
1M NaOH Solution 
4g NaOH 
Dissolve in 100mLs of ddH2O, filter through 0.2µm 
filter  
 





Dissolve in ddH2O, adjust pH 7.4 
 
Freezing solution A 
50% (v/v) Foetal Calf Serum 
50% (v/v) DMEM 
 
Freezing solution B 
15% (v/v) Dimethyl sulphoxide (DMSO) 
85% (v/v) DMEM 
Dilute DMSO into DMEM then filter sterilize the 
solution through 0.2µm. 
 
Stock 30% Acrylamide Solution  
4.22M (30%) acrylamide  
52mM (0.8%) Bis-acrylamide (N-
N,Methylenebisaceylamide)  
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Dissolve in ddH2O, filter using whatman paper, 
store in a dark bottle at 4˚C 
 
Separating Gel 
25mL separating gel buffer 
 x mL Stock 30% acrylamide solution (amount 
depends on the strength of the separating gel) 
10mg Ammonium persulphate  
22.5µL TEMED (Sigma-Aldrich, St. Louis, MO) 
Dissolve in ddH2O to total volume of 50mL, the 
ammonium persulphate and TEMED should only 
be added just before gels are to be set 
 
3% Stacking Gel 
12.5mL Stacking Gel Buffer  
2.5mL Stock acrylamide solution  
18.8mg Ammonium Peroxide 
11µL TEMED 
Dissolve in ddH2O to total volume of 25mL, the 
ammonium persulphate and TEMED should be 
added just before gels are to be set     
 
Protein sample Loading Buffer 
10mL Glycerol (add last) 
25mL Stacking gel buffer (see above) 
2M Urea 
20mL of 10% (w/v) SDS solution 
20mg phenylmethylsulphonyl fluoride (PMSF)  
(dissolve in of ethanol added dropwise) (Sigma-
aldrich, St Louis, MO) 
5mL Bromophenol Blue (saturated) (see below) 
Dissolve in 100mL ddH2O until dissolved, aliquot 
and store at -20˚C. 
 
Saturated Bromophenol Blue 
0.1g Bromophenol Blue 







Dissolve in ddH2O, do not pH 
 
Coomassie Brillian Blue R-250 
Dye content of coomassie Blue should be ∼50% 
 
0.3% (w/v) Coomassie brilliant Blue R-250 
45% (v/v) Methanol  
9% (v/v) Acetic Acid  
Dissolve in ddH2O, stir solution well, filter using  
Whatman paper before use. 
 
40% Methanol/ acetic acid solution 
40% (v/v) Methanol 
7% (v/v) Acetic Acid 
Dissolve in ddH2O 
 
 
7.5% Methanol/ acetic acid solution 
7.5% (v/v) Methanol 
7% (v/v) Acetic Acid 







Tris Buffered Saline (TBS) 
20mM Tris 
0.13M NaCl 
0.0005% (w/v) Thimerosal 
Dissolve in ddH2O, adjust pH to 7.4 with HCl and 
autoclave if sterile solution required 
 
Blocking solution for western blots 
10% (w/v) non-fat skim milk in TBS 
3% (w/v) BSA in TBS for anti-(his tag) antibodies 
 
Antibody solution for western blots 
2% (w/v) non-fat milk in TBS 
3% (w/v) BSA in TBS for anti-(his tag) antibodies 
 
Tris/ Tween-20/ Triton X-100 
20mM Tris 
500mM NaCl 
0.05% (v/v) Tween-20 
0.2% (v/v) Triton X-100 
0.005% Thimerosal 
Dissolve Tris, NaCl, and thimerosal in ddH2O and 








Developing solution for revealing western blots 
10mL Substrate Buffer 
100µL BCIP (see below) 
100µL NBT (see below) 
mix and use immediately 
 
5-Bromo-4Chloro-3-indolyl-phosphate (BCIP) 
(Diagnostic Chemicals Ltd, Charlottetown, PEI)  
25mg BCIP 
0.5ml H2O 
0.5ml N, N-Dimethylformamide (DMF) 
 
Nitro Blue Tetrazolium (NBT) 




0.7ml N, N-Dimethylformamide (DMF) 
 
H2SO4/Sodium Tetreborate 
0.0125M Tetraborate in conc. H2SO4. 








pH 4  










0.2% Bio-Lyte 3/10 ampholytes 
0.0002% Bromophenol Blue 
 
Dithiothreitol Equilibration Buffer 
6M Urea 
2% (v/v) SDS 
0.05M Tris pH8.8 
20% (v/v) Glycerol 
2% (w/v) Dithiothreitol 
 
Iodoacetamide Equilibration Buffer 
6M Urea 
2% (v/v) SDS 
0.05M Tris pH8.8 
20% (v/v) Glycerol 







pH 8.5 for minimal labelling  
pH 8.0 for saturation labelling  
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APPENDIX C 
 
Antibody concentrations for various experiments conducted are listed in the table below. 
Concentrations for each antibody are indicated as working dilutions from stock antibody 
solution ane are specified for western blots, solid phase assays and tissue section 
immunofluorescence. 
 














1:1000 1:1000-1:2000   

























  1:10 
Perlecan  7A5CC Mouse 
Monoclonal 








  1:10 
βig-h3  MP78/70 Polyclonal  1:500     
βig-h3  Rabbit-45 Polyclonal  1:5000     




































  1:25  

















  1:25  
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